[
    {
        "chunk_id": "rr6007_chunk_0",
        "document_id": "rr6007",
        "text": "Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html. \nImmunization of Health-Care Personnel\nRecommendations of the Advisory Committee on \nImmunization Practices (ACIP)\nMMWR Logo - MMWR Morbidity and Mortality Weekly Report\nRecommendations and Reports / Vol. 60 / No. 7\t\nNovember 25, 2011 \nHHS/CDC Logo - U.S. Department of Health and\n Human Services (HHS)\r\n\r\nCenters for Disease Control and Prevention (CDC)\r\nThe cover photograph depicts an adult female health-care professi\nRecommendations and Reports\nOn the cover: An adult female health-care professional receiving an intramuscular vaccination into her left shoulder muscle from a nurse.\nDisclosure of Relationship\nCDC, our planners, and our content experts wish to disclose that",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_1",
        "document_id": "rr6007",
        "text": "Disclosure of Relationship\nCDC, our planners, and our content experts wish to disclose that \nthey have no financial interests or other relationships with the \nmanufacturers of commercial products, suppliers of commercial \nservices, or commercial supporters. This report will not include \nany discussion of the unlabeled use of a product or a product under \ninvestigational use with the exception of the following situations:\n1. For varicella postexposure prophylaxis for persons without \nevidence of immunity who have contraindications for \nvaccination and who are at risk for severe disease and \ncomplications, the product currently used in the United States, \nVariZIG (Cangene Corporation, Winnipeg, Canada), is \navailable under an Investigational New Drug Application \nExpanded Access Protocol.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_2",
        "document_id": "rr6007",
        "text": "available under an Investigational New Drug Application \nExpanded Access Protocol.\n2. The interval between administration of Td and Tdap might be \n<5 years as indicated in package insert.\n3. One Tdap product, Adacel (sanofi pasteur, Toronto, Canada), \nis labeled for use in persons aged 11\u201364 years. The other Tdap \nproduct, Boostrix (GlaxoSmithKline Biologicals, Rixensart, \nBelgium), is labeled for use in persons aged \u226510 years. Until \nACIP reviews the current recommendations on use of Tdap in \npersons aged \u226565 years, either Tdap product may be used in \npersons aged \u226565 years.\n4. Meningococcal conjugate vaccines are licensed only as a single \ndose. The 2-dose series of meningococcal conjugate vaccine is \nrecommended for persons with certain medical risk factors, and",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_3",
        "document_id": "rr6007",
        "text": "recommended for persons with certain medical risk factors, and \nthe booster dose of meningococcal conjugate vaccine is \nrecommended for persons who remain at increased risk for a \nprolonged period.\nCONTENTS\nIntroduction.............................................................................................................2\nMethods....................................................................................................................2\nDiseases for Which Vaccination Is Recommended....................................3\nDiseases for Which Vaccination Might Be Indicated in Certain \nCircumstances................................................................................................... 25",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_4",
        "document_id": "rr6007",
        "text": "Other Vaccines Recommended for Adults................................................. 28\nAcknowledgments............................................................................................. 29\nReferences............................................................................................................. 29\nThe MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), \nU.S. Department of Health and Human Services, Atlanta, GA 30333.\nSuggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR 2011;60(No. SS-#):[inclusive page numbers].\nCenters for Disease Control and Prevention\nThomas R. Frieden, MD, MPH, Director",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_5",
        "document_id": "rr6007",
        "text": "Centers for Disease Control and Prevention\nThomas R. Frieden, MD, MPH, Director\nHarold W. Jaffe, MD, MA, Associate Director for Science\nJames W. Stephens, PhD, Director, Office of Science Quality\nStephen B. Thacker, MD, MSc, Deputy Director for Surveillance, Epidemiology, and Laboratory Services\nStephanie Zaza, MD, MPH, Director, Epidemiology and Analysis Program Office\nMMWR Editorial and Production Staff\nRonald L. Moolenaar, MD, MPH, Editor, MMWR Series\nChristine G. Casey, MD, Deputy Editor, MMWR Series\nTeresa F. Rutledge, Managing Editor, MMWR Series\nDavid C. Johnson, Lead Technical Writer-Editor\nJeffrey D. Sokolow, MA, Project Editor\nMartha F. Boyd, Lead Visual Information Specialist\nMaureen A. Leahy, Julia C. Martinroe, \nStephen R. Spriggs, Terraye M. Starr",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_6",
        "document_id": "rr6007",
        "text": "Maureen A. Leahy, Julia C. Martinroe, \nStephen R. Spriggs, Terraye M. Starr\nVisual Information Specialists\nQuang M. Doan, MBA, Phyllis H. King\nInformation Technology Specialists\nMMWR Editorial Board\nWilliam L. Roper, MD, MPH, Chapel Hill, NC, Chairman\nVirginia A. Caine, MD, Indianapolis, IN\nMatthew L. Boulton, MD, MPH, Ann Arbor, MI\nJonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA\nDavid W. Fleming, MD, Seattle, WA\nWilliam E. Halperin, MD, DrPH, MPH, Newark, NJ\nKing K. Holmes, MD, PhD, Seattle, WA\nDeborah Holtzman, PhD, Atlanta, GA\nTimothy F. Jones, MD, Nashville, TN\nDennis G. Maki, MD, Madison, WI\nPatricia Quinlisk, MD, MPH, Des Moines, IA\nPatrick L. Remington, MD, MPH, Madison, WI\nBarbara K. Rimer, DrPH, Chapel Hill, NC\nJohn V. Rullan, MD, MPH, San Juan, PR",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_7",
        "document_id": "rr6007",
        "text": "Barbara K. Rimer, DrPH, Chapel Hill, NC\nJohn V. Rullan, MD, MPH, San Juan, PR\nWilliam Schaffner, MD, Nashville, TN\nAnne Schuchat, MD, Atlanta, GA\nDixie E. Snider, MD, MPH, Atlanta, GA\nJohn W. Ward, MD, Atlanta, GA\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n1\nImmunization of Health-Care Personnel\nRecommendations of the Advisory Committee on Immunization Practices \n(ACIP)\nPrepared by\nAbigail Shefer, MD1\nWilliam Atkinson, MD1\nCarole Friedman, DO1*\nDavid T. Kuhar, MD2\nGina Mootrey, DO1\nStephanie R. Bialek, MD1\nAmanda Cohn, MD1\nAnthony Fiore, MD3 \nLisa Grohskopf, MD1\nJennifer L. Liang, DVM1\nSuchita A. Lorick, DO1\nMona Marin, MD1\nEric Mintz, MD2\nTrudy V. Murphy, MD4\nAnna Newton, MPH2\nAmy Parker Fiebelkorn, MSN, MPH1\nJane Seward, MBBS1\nGregory Wallace, MD1",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_8",
        "document_id": "rr6007",
        "text": "Anna Newton, MPH2\nAmy Parker Fiebelkorn, MSN, MPH1\nJane Seward, MBBS1\nGregory Wallace, MD1\n1National Center for Immunization and Respiratory Diseases\n2National Center for Emerging and Zoonotic Infectious Diseases\n3Center for Global Health\n4National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention\n*Deceased.\nSummary\nThis report updates the previously published summary of recommendations for vaccinating health-care personnel (HCP) in \nthe United States (CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization \nPractices [ACIP] and the Hospital Infection Control Practices Advisory Committee [HICPAC]. MMWR 1997;46[No. RR-18]).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_9",
        "document_id": "rr6007",
        "text": "This report was reviewed by and includes input from the Healthcare (formerly Hospital) Infection Control Practices Advisory \nCommittee. These updated recommendations can assist hospital administrators, infection-control practitioners, employee health \nclinicians, and HCP in optimizing infection prevention and control programs. The recommendations for vaccinating HCP are \npresented by disease in two categories: 1) those diseases for which vaccination or documentation of immunity is recommended because \nof risks to HCP in their work settings for acquiring disease or transmitting to patients and 2) those for which vaccination might \nbe indicated in certain circumstances. Background information for each vaccine-preventable disease and specific recommendations",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_10",
        "document_id": "rr6007",
        "text": "for use of each vaccine are presented. Certain infection-control measures that relate to vaccination also are included in this report. \nIn addition, ACIP recommendations for the remaining vaccines that are recommended for certain or all adults are summarized, \nas are considerations for catch-up and travel vaccinations and for work restrictions. This report summarizes all current ACIP \nrecommendations for vaccination of HCP and does not contain any new recommendations or policies.\nThe material in this report originated in the National Center for \nImmunization and Respiratory Diseases, Anne Schuchat, MD, \nDirector.\nCorresponding preparer: Abigail Shefer, MD, National Center for \nImmunization and Respiratory Diseases, 1600 Clifton Rd., MS A-19,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_11",
        "document_id": "rr6007",
        "text": "Immunization and Respiratory Diseases, 1600 Clifton Rd., MS A-19, \nAtlanta, GA 30333. Telephone: 404-639-8233; Fax: 404-417-0791; \nE-mail: ams7@cdc.gov.\nThe recommendations provided in this report apply, \nbut are not limited, to HCP in acute-care hospitals; long-\nterm\u2013care facilities (e.g., nursing homes and skilled nursing \nfacilities); physician\u2019s offices; rehabilitation centers; urgent \ncare centers, and outpatient clinics as well as to persons who \nprovide home health care and emergency medical services.\nRecommendations and Reports\n2\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nIntroduction\nThis report updates the previously published summary \nof recommendations of the Advisory Committee on \nImmunization Practices (ACIP) and the Healthcare (formerly",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_12",
        "document_id": "rr6007",
        "text": "Immunization Practices (ACIP) and the Healthcare (formerly \nHospital) Infection Control Practices Advisory Committee \n(HICPAC) for vaccinating health-care personnel (HCP) in \nthe United States (1). The report, which was reviewed by \nand includes input from HICPAC, summarizes all current \nACIP recommendations for vaccination of HCP and does \nnot contain any new recommendations or policies that have \nnot been published previously. These recommendations can \nassist hospital administrators, infection-control practitioners, \nemployee health clinicians, and HCP in optimizing infection \nprevention and control programs.\nHCP are defined as all paid and unpaid persons working \nin health-care settings who have the potential for exposure \nto patients and/or to infectious materials, including body",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_13",
        "document_id": "rr6007",
        "text": "to patients and/or to infectious materials, including body \nsubstances, contaminated medical supplies and equipment, \ncontaminated environmental surfaces, or contaminated air. \nHCP might include (but are not limited to) physicians, \nnurses, nursing assistants, therapists, technicians, emergency \nmedical service personnel, dental personnel, pharmacists, \nlaboratory personnel, autopsy personnel, students and trainees, \ncontractual staff not employed by the health-care facility, and \npersons (e.g., clerical, dietary, housekeeping, laundry, security, \nmaintenance, administrative, billing, and volunteers) not \ndirectly involved in patient care but potentially exposed to \ninfectious agents that can be transmitted to and from HCP \nand patients (2).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_14",
        "document_id": "rr6007",
        "text": "infectious agents that can be transmitted to and from HCP \nand patients (2).\nBecause of their contact with patients or infective material \nfrom patients, many HCP are at risk for exposure to (and possible \ntransmission of) vaccine-preventable diseases. Employers and \nHCP have a shared responsibility to prevent occupationally \nacquired infections and avoid causing harm to patients by taking \nreasonable precautions to prevent transmission of vaccine-\npreventable diseases. Vaccination programs are therefore an \nessential part of infection prevention and control for HCP. \nOptimal use of recommended vaccines helps maintain immunity \nand safeguard HCP from infection, thereby helping protect \npatients from becoming infected; pertinent ACIP statements",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_15",
        "document_id": "rr6007",
        "text": "patients from becoming infected; pertinent ACIP statements \non various individual vaccines and diseases have been published \n(Table 1). Nationwide, ongoing implementation of these vaccine \nrecommendations through well-managed vaccination programs \ncould substantially reduce both the number of susceptible HCP \nin any setting in which they interact with patients and their risks \nfor transmitting vaccine-preventable diseases to patients, other \nHCP, and other contacts (3).\nHICPAC and CDC have recommended that secure, \npreferably computerized, systems should be used to manage \nvaccination records for HCP so records can be retrieved easily \nas needed (3). Each record should reflect immunity status \nfor indicated vaccine-preventable diseases (i.e., documented",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_16",
        "document_id": "rr6007",
        "text": "for indicated vaccine-preventable diseases (i.e., documented \ndisease, vaccination history, or serology results) as well as \nvaccinations administered during employment and any \ndocumented episodes of adverse events after vaccination (4). \nFor each vaccine, the record should include date of vaccine \nadministration (including for those vaccines that might have \nbeen received prior to employment), vaccine manufacturer \nand lot number, edition and distribution date of the language-\nappropriate Vaccine Information Statement (VIS) provided \nto the vaccinee at the time of vaccination, and the name, \naddress, and title of the person administering the vaccine \n(4). Accurate vaccination records can help to rapidly identify \nsusceptible HCP (i.e., those with no history of vaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_17",
        "document_id": "rr6007",
        "text": "susceptible HCP (i.e., those with no history of vaccination \nor lack of documentation of immunity) during an outbreak \nsituation and can help reduce costs and disruptions to health-\ncare operations (5\u20137). HCP should be provided a copy of \ntheir vaccination records and encouraged to keep it with their \npersonal health records so they can readily be made available \nto future employers.\nHICPAC has encouraged any facility or organization that \nprovides direct patient care to formulate a comprehensive \nvaccination policy for all HCP (3). The American Hospital \nAssociation has endorsed the concept of vaccination programs \nfor both hospital personnel and patients (8). To ensure that all \nHCP are up to date with respect to recommended vaccines,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_18",
        "document_id": "rr6007",
        "text": "HCP are up to date with respect to recommended vaccines, \nfacilities should review HCP vaccination and immunity status \nat the time of hire and on a regular basis (i.e., at least annually) \nwith consideration of offering needed vaccines, if necessary, in \nconjunction with routine annual disease-prevention measures \n(e.g., influenza vaccination or tuberculin testing). These \nrecommendations (Tables 2 and 3) should be considered \nduring policy development. Several states and health-care \nfacilities have established requirements relating to assessment \nof vaccination status and/or administration of one or more \nvaccines for HCP (9,10). Disease-specific outbreak control \nmeasures are described in this report and elsewhere (3,11,12). \nAll HCP should adhere to all other recommended infection-",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_19",
        "document_id": "rr6007",
        "text": "All HCP should adhere to all other recommended infection-\ncontrol guidelines, whether or not they are individually \ndetermined to have immunity to a vaccine-preventable disease.\nMethods\nIn 2008, the ACIP Immunization of Health-Care Personnel \nWork Group (the Work Group) was formed as a subgroup of \nthe ACIP Adult Immunization Work Group to update the \npreviously published recommendations for immunization \nof HCP. The Work Group comprised professionals from \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n3\nacademic medicine (pediatrics, family medicine, internal \nmedicine, occupational and environmental medicine, and \ninfectious disease); federal and state public health professionals; \nand liaisons from the Society for Healthcare Epidemiology",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_20",
        "document_id": "rr6007",
        "text": "and liaisons from the Society for Healthcare Epidemiology \nof America and HICPAC. The Work Group met monthly, \ndeveloped an outline for the report, worked closely with subject \nmatter experts at CDC (who developed, revised, and updated \nsections of the report), and provided subsequent critical review \nof the draft documents. The approach of the Work Group was \nto summarize previously published ACIP recommendations \nand not to make new recommendations or policies; a \ncomprehensive list of publications containing the various \nvaccine-specific recommendations is provided (Table 1). In \nFebruary 2011, the updated report was presented to ACIP, \nwhich voted to approve it.\nThe recommendations for vaccination of HCP are presented \nbelow by disease in two categories: 1) those diseases for",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_21",
        "document_id": "rr6007",
        "text": "below by disease in two categories: 1) those diseases for \nwhich routine vaccination or documentation of immunity is \nrecommended for HCP because of risks to HCP in their work \nsettings and, should HCP become infected, to the patients they \nserve and 2) those diseases for which vaccination of HCP might \nbe indicated in certain circumstances. Vaccines recommended \nin the first category are hepatitis B, seasonal influenza, measles, \nmumps, and rubella, pertussis, and varicella vaccines. Vaccines \nin the second category are meningococcal, typhoid, and polio \nvaccines. Except for influenza, all of the diseases prevented by \nthese vaccines are notifiable at the national level (13). Main \nchanges from the 1997 ACIP recommendations have been \nsummarized (Box).\nDiseases for Which Vaccination Is",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_22",
        "document_id": "rr6007",
        "text": "summarized (Box).\nDiseases for Which Vaccination Is \nRecommended\nOn the basis of documented nosocomial transmission, \nHCP are considered to be at substantial risk for acquiring \nor transmitting hepatitis B, influenza, measles, mumps, \nrubella, pertussis, and varicella. Current recommendations for \nvaccination are provided below. \nHepatitis B\nBackground\nEpidemiology and Risk Factors\nHepatitis B is an infection caused by the hepatitis B virus \n(HBV), which is transmitted through percutaneous (i.e., \nbreaks in the skin) or mucosal (i.e., direct contact with \nmucous membranes) exposure to infectious blood or body \nfluids. The virus is highly infectious; for nonimmune persons, \ndisease transmission from a needlestick exposure is up to",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_23",
        "document_id": "rr6007",
        "text": "disease transmission from a needlestick exposure is up to \n100 times more likely for exposure to hepatitis B e antigen \n(HBeAg)\u2013positive blood than to HIV-positive blood (14). \nHBV infection is a well recognized occupational risk for U.S. \nHCP and globally. The risk for HBV is associated with degree \nof contact with blood in the work place and with the hepatitis B \ne-antigen status of the source persons (15). The virus is also \nenvironmentally stable, remaining infectious on environmental \nsurfaces for at least 7 days (16).\nIn 2009 in the United States, 3,371 cases of acute HBV \ninfection were reported nationally, and an estimated 38,000 \nnew cases of HBV infection occurred after accounting for \nunderreporting and underdiagnosis (17). Of 4,519 persons",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_24",
        "document_id": "rr6007",
        "text": "underreporting and underdiagnosis (17). Of 4,519 persons \nreported with acute HBV infection in 2007, approximately \n40% were hospitalized and 1.5% died (18). HBV can lead \nto chronic infection, which can result in cirrhosis of the liver, \nliver failure, liver cancer, and death. An estimated 800,000\u20131.4 \nmillion persons in the United States are living with chronic \nHBV infection; these persons serve as the main reservoir for \ncontinued HBV transmission (19).\nVaccines to prevent hepatitis B became available in the \nUnited States in 1981; a decade later, a national strategy to \neliminate HBV infection was implemented, and the routine \nvaccination of children was recommended (20). During 1990\u2013\n2009, the rate of new HBV infections declined approximately",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_25",
        "document_id": "rr6007",
        "text": "2009, the rate of new HBV infections declined approximately \n84%, from 8.5 to 1.1 cases per 100,000 population (17); the \ndecline was greatest (98%) among persons aged <19 years, for \nwhom recommendations for routine infant and adolescent \nvaccination have been applied. Although hepatitis B vaccine \ncoverage is high in infants, children, and adolescents (91.8% \nin infants aged 19\u201335 months and 91.6% in adolescents aged \n13\u201317 years) (21,22), coverage remains lower (41.8% in 2009) \nfor certain adult populations, including those with behavioral \nrisks for HBV infection (e.g., men who have sex with men and \npersons who use injection drugs) (23).\nHepatitis B in Health-Care Settings \nDuring 1982, when hepatitis B vaccine was first recommended",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_26",
        "document_id": "rr6007",
        "text": "Hepatitis B in Health-Care Settings \nDuring 1982, when hepatitis B vaccine was first recommended \nfor HCP, an estimated 10,000 infections occurred among \npersons employed in a medical or dental field. By 2004, \nthe number of HBV infections among HCP had decreased \nto an estimated 304 infections, largely resulting from the \nimplementation of routine preexposure vaccination and \nimproved infection-control precautions (24\u201326).\nThe risk for acquiring HBV infection from occupational \nexposures is dependent on the frequency of percutaneous and \nmucosal exposures to blood or body fluids (e.g., semen, saliva, \nand wound exudates) containing HBV, particularly fluids \ncontaining HBeAg (a marker for high HBV replication and \nviral load) (27\u201331). The risk is higher during the professional",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_27",
        "document_id": "rr6007",
        "text": "viral load) (27\u201331). The risk is higher during the professional \nRecommendations and Reports\n4\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\ntraining period and can vary throughout a person\u2019s career (1). \nDepending on the tasks performed, health-care or public \nsafety personnel might be at risk for HBV exposure; in \naddition, personnel providing care and assistance to persons \nin outpatient settings and those residing in long-term\u2013care \nfacilities (e.g., assisted living) might be at risk for acquiring or \nfacilitating transmission of HBV infection when they perform \nprocedures that expose them to blood (e.g., assisted blood-\nglucose monitoring and wound care) (32\u201334).\nA Federal Standard issued in December 1991 under \nthe Occupational Safety and Health Act mandates that",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_28",
        "document_id": "rr6007",
        "text": "the Occupational Safety and Health Act mandates that \nhepatitis B vaccine be made available at the employer\u2019s expense \nto all health-care personnel who are exposed occupationally \nto blood or other potentially infectious materials (35). The \nFederal Standard defines occupational exposure as reasonably \nanticipated skin, eye, mucous membrane, or parenteral \ncontact with blood or other potentially infectious materials \nthat might result from the performance of an employee\u2019s \nduties (35). Occupational Safety and Health Administration \nBOX. Summary of main changes* from 1997 Advisory Committee on Immunization Practices/Hospital (now Healthcare) Infection Control \nPractices Advisory Committee recommendations for immunization of health-care personnel (HCP)\nHepatitis B",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_29",
        "document_id": "rr6007",
        "text": "Hepatitis B\n\u2022 HCP and trainees in certain populations at high risk for chronic hepatitis B (e.g., those born in countries with high and \nintermediate endemicity) should be tested for HBsAg and anti-HBc/anti-HBs to determine infection status.\nInfluenza\n\u2022 Emphasis that all HCP, not just those with direct patient care duties, should receive an annual influenza vaccination\n\u2022 Comprehensive programs to increase vaccine coverage among HCP are needed; influenza vaccination rates among HCP \nwithin facilities should be measured and reported regularly.\nMeasles, mumps, and rubella (MMR)\n\u2022 History of disease is no longer considered adequate presumptive evidence of measles or mumps immunity for HCP;",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_30",
        "document_id": "rr6007",
        "text": "laboratory confirmation of disease was added as acceptable presumptive evidence of immunity. History of disease has \nnever been considered adequate evidence of immunity for rubella.\n\u2022 The footnotes have been changed regarding the recommendations for personnel born before 1957 in routine and \noutbreak contexts. Specifically, guidance is provided for 2 doses of MMR for measles and mumps protection and 1 dose \nof MMR for rubella protection.\nPertussis\n\u2022 HCP, regardless of age, should receive a single dose of Tdap as soon as feasible if they have not previously received Tdap.\n\u2022 The minimal interval was removed, and Tdap can now be administered regardless of interval since the last tetanus or \ndiphtheria-containing vaccine.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_31",
        "document_id": "rr6007",
        "text": "diphtheria-containing vaccine.\n\u2022 Hospitals and ambulatory-care facilities should provide Tdap for HCP and use approaches that maximize vaccination rates.\nVaricella\nCriteria for evidence of immunity to varicella were established. For HCP they include\n\u2022 written documentation with 2 doses of vaccine,\n\u2022 laboratory evidence of immunity or laboratory confirmation of disease,\n\u2022 diagnosis of history of varicella disease by health-care provider, or diagnosis of history of herpes zoster by health-care \nprovider.\nMeningococcal\n\u2022 HCP with anatomic or functional asplenia or persistent complement component deficiencies should now receive a \n2-dose series of meningococcal conjugate vaccine. HCP with HIV infection who are vaccinated should also receive a 2 \ndose series.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_32",
        "document_id": "rr6007",
        "text": "dose series.\n\u2022 Those HCP who remain in groups at high risk are recommended to be revaccinated every 5 years.\nAbbreviations: HBsAg = Hepatitis B surface antigen; anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; Tdap = tetanus toxoid, \nreduced diptheria toxoid and acellular pertussis vaccine; HIV = human immunodeficiency virus.\n*\tUpdated recommendations made since publication of the 1997 summary of recommendations (CDC Immunization of health-care workers: recommendations \nof the Advisory Committee on Immunization Practices [ACIP] and the Hospital Infection Control Practices Advisory Committee [HICPAC]. MMWR \n1997;46[No. RR-18]). \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n5",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_33",
        "document_id": "rr6007",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n5\n(OSHA) vaccination practice requirements (e.g., preexposure \nand postexposure antibody testing) are based on current ACIP \nrecommendations. OSHA regulations might have accelerated \nthe use of hepatitis B vaccine in HCP (36).\nData from a national, cross-sectional survey demonstrated \nthat during 2002\u20132003, an estimated 75% of HCP had \nreceived the 3-dose hepatitis B vaccination series (37). Since \n2002, rates of 1-dose and 3-dose vaccination coverage have \nremained stable. Data obtained through the National Health \nInterview Survey (NHIS) in 2009 demonstrated a \u22651-dose \ncoverage rate of 75%\u201377% and a \u22653-dose rate of 67%\u201368% \namong HCP aged 18\u201349 years (23). Similarly, data obtained",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_34",
        "document_id": "rr6007",
        "text": "among HCP aged 18\u201349 years (23). Similarly, data obtained \nthrough the National Immunization Survey\u2013Adult (NIS-\nAdult) in 2007 demonstrated a \u22653-dose coverage of 62% \namong HCP aged 18\u201364 years (38). The Healthy People \n2020 goal (objective no. IID-15.3) of a hepatitis B vaccination \ncoverage rate of 90% among HCP (39) has not been achieved.\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nVaccine Effectiveness\nThe 3-dose vaccine series administered intramuscularly at \n0, 1, and 6 months produces a protective antibody response \nin approximately 30%\u201355% of healthy adults aged \u226440 years \nafter the first dose, 75% after the second dose, and >90% \nafter the third dose (40\u201342). After age 40 years, <90% of \npersons vaccinated with 3 doses have a protective antibody",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_35",
        "document_id": "rr6007",
        "text": "persons vaccinated with 3 doses have a protective antibody \nresponse, and by age 60 years, protective levels of antibody \ndevelop in approximately 75% of vaccinated persons (43). \nSmoking, obesity, genetic factors, and immune suppression \nalso are associated with diminished immune response to \nhepatitis B vaccination (43\u201346).\nDuration of Immunity\nProtection against symptomatic and chronic HBV infection \nhas been documented to persist for \u226522 years in vaccine \nresponders (47). Immunocompetent persons who achieve \nhepatitis B surface antibody (anti-HBs) concentrations of \n\u226510 mIU/mL after preexposure vaccination have protection \nagainst both acute disease and chronic infection. Anti-HBs \nlevels decline over time. Regardless, responders continue to",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_36",
        "document_id": "rr6007",
        "text": "levels decline over time. Regardless, responders continue to \nbe protected, and the majority of responders will show an \nanamnestic response to vaccine challenge (47\u201351). Declines \nmight be somewhat faster among persons vaccinated as infants \nrather than as older children, adolescents, or adults and among \nthose administered recombinant vaccine instead of plasma \nvaccine (which has not been commercially available in the \nUnited States since the late 1980s). Although immunogenicity is \nlower among immunocompromised persons, those who achieve \nand maintain a protective antibody response before exposure \nto HBV have a high level of protection from infection (52).\nAmong persons who do not respond to a primary 3-dose \nvaccine series (i.e., those in whom anti-HBs concentrations",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_37",
        "document_id": "rr6007",
        "text": "vaccine series (i.e., those in whom anti-HBs concentrations \nof \u226510 mIU/mL were not achieved), 25%\u201350% respond to \nan additional vaccine dose, and 44%\u2013100% respond to a \n3-dose revaccination series using standard or high dosage vac\u00ad\ncine (43,53\u201358). Persons who have measurable but low (i.e., \n1\u20139 mIU/mL) levels of anti-HBs after the initial series have \nbetter response to revaccination than persons who have no anti-\nHBs (49,53,54). Persons who do not have protective levels of \nanti-HBs 1\u20132 months after revaccination either are infected with \nHBV or can be considered primary nonresponders; for the latter \ngroup, genetic factors might be associated with nonresponse to \nhepatitis B vaccination (54,58,59). ACIP does not recommend \nmore than two vaccine series in nonresponders (52).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_38",
        "document_id": "rr6007",
        "text": "more than two vaccine series in nonresponders (52).\nVaccine Safety \nHepatitis B vaccines have been demonstrated to be safe \nwhen administered to infants, children, adolescents, and adults \n(52,60,61). Although rare cases of arthritis or alopecia have \nbeen associated temporally with hepatitis B vaccination, recent \ndata do not support a causal relationship between hepatitis B \nvaccine and either arthritis or alopecia (61\u201363). During 1982\u2013\n2004, an estimated 70 million adolescents and adults and 50 \nmillion infants and children in the United States received \u22651 \ndose of hepatitis B vaccine (52). The most frequently reported \nside effects in persons receiving hepatitis B vaccine are pain \nat the injection site (3%\u201329%) and temperature of >99.9\u00b0F",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_39",
        "document_id": "rr6007",
        "text": "at the injection site (3%\u201329%) and temperature of >99.9\u00b0F \n(>37.7\u00b0C) (1%\u20136%) (64\u201367). However, in placebo-controlled \nstudies, these side effects were reported no more frequently \namong persons receiving hepatitis B vaccine than among \npersons receiving placebo (40,41,64\u201367). Revaccination is not \nassociated with an increase in adverse events.\nHepatitis B vaccination is contraindicated for persons with a \nhistory of hypersensitivity to yeast or any vaccine component \n(4,64\u201366). Persons with a history of serious adverse events (e.g., \nanaphylaxis) after receipt of hepatitis B vaccine should not \nreceive additional doses. As with other vaccines, vaccination of \npersons with moderate or severe acute illness, with or without \nfever, should be deferred until illness resolves (4). Vaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_40",
        "document_id": "rr6007",
        "text": "fever, should be deferred until illness resolves (4). Vaccination \nis not contraindicated in persons with a history of multiple \nsclerosis, Guillain-Barr\u00e9 Syndrome, autoimmune disease \n(e.g., systemic lupus erythematosis and rheumatoid arthritis), \nor other chronic diseases. Pregnancy is not a contraindication \nto vaccination; limited data suggest that developing fetuses \nare not at risk for adverse events when hepatitis B vaccine is \nadministered to pregnant women (4,68). Available vaccines \ncontain noninfectious hepatitis B surface antigen (HBsAg) \nand do not pose any risk for infection to the fetus. \nRecommendations and Reports\n6\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nRecommendations\nTwo single-antigen hepatitis B vaccines, Recombivax HB",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_41",
        "document_id": "rr6007",
        "text": "Recommendations\nTwo single-antigen hepatitis B vaccines, Recombivax HB \n(Merck & Co., Inc., Whitehouse Station, New Jersey) and \nEngerix-B (GlaxoSmithKline Biologicals, Rixensart, Belgium) \nand one combination hepatitis A and hepatitis B vaccine, \nTwinrix (GlaxoSmithKline Biologicals), are available in the \nUnited States. Primary vaccination consists of \u22653 intramuscular \ndoses of hepatitis B vaccine or of the combined hepatitis A and \nhepatitis B vaccine. The hepatitis vaccine series does not need \nto be restarted if the second or third dose is delayed. Detailed \nvaccination recommendations are available in previously \npublished guidelines (52). Vaccine schedules are available at \nhttp://www.cdc.gov/vaccines/recs/schedules/adult-schedule.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_42",
        "document_id": "rr6007",
        "text": "http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.\nhtm#HCWs. In adults, hepatitis B vaccine always should be \nadministered into the deltoid muscle. Longer needles (up to \n1.5 inches in length) might be required for obese adults (4).\nPreexposure \nUnvaccinated and Incompletely Vaccinated HCP \nand Trainees: Pre- and Postvaccination Serologic Testing\n\u2022 Prevaccination serologic testing for previous infection is \nnot indicated for the majority of persons being vaccinated \nbecause of occupational risk unless the hospital or health-\ncare organization considers such testing cost-effective \n(3,52,69\u201372). However, such testing is indicated for HCP \nand is cost-effective in certain high-risk populations (see \nHCP and Trainees at Additional Risk), regardless of \nvaccination status (71,73).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_43",
        "document_id": "rr6007",
        "text": "HCP and Trainees at Additional Risk), regardless of \nvaccination status (71,73).\n\u2022 All unvaccinated persons whose work- and training-related \nactivities involve reasonably anticipated risk for exposure \nto blood or other infectious body fluids (e.g., HCP, long-\nterm\u2013care facility staff, and public safety workers) should \nbe vaccinated with the complete, \u22653-dose hepatitis B \nvaccine series.\n\u2022 Persons with an incomplete series are not considered \nprotected and should complete the \u22653-dose series.\n\u2022 Because higher risk has been reported during the \nprofessional training period, the vaccination series should \nbe completed before trainees have contact with blood; \nvaccination should be offered in schools of medicine, \ndentistry, nursing, laboratory technology, and other allied",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_44",
        "document_id": "rr6007",
        "text": "dentistry, nursing, laboratory technology, and other allied \nhealth professions.\n\u2022 To determine the need for revaccination and to guide \npostexposure prophylaxis, postvaccination serologic testing \nshould be performed for all HCP at high risk for \noccupational percutaneous or mucosal exposure to blood \nor body fluids. Postvaccination serologic testing is \nperformed 1\u20132 months after administration of the last \ndose of the vaccine series using a method that allows \ndetection of the protective concentration of anti-HBs \n(\u226510 mIU/mL). Persons determined to have anti-HBs \nconcentrations of \u226510 mIU/mL after receipt of the primary \nvaccine series are considered immune, and the result \nshould be documented. Immunocompetent persons have \nlong-term protection and do not need further periodic",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_45",
        "document_id": "rr6007",
        "text": "long-term protection and do not need further periodic \ntesting to assess anti-HBs levels. Postvaccination testing \nfor persons at low risk for mucosal or percutaneous \nexposure to blood or body fluids (e.g., public safety \nworkers and HCP without direct patient contact) likely \nis not cost effective (52); however, persons who do not \nundergo postvaccination testing should be counseled to \nseek immediate testing if exposed.\n\u2022 Persons determined to have anti-HBs concentrations of <10 \nmIU/mL soon after receipt of the primary vaccine series \nshould be revaccinated. For these persons, administration \nof a second complete 3-dose series on an appropriate \nschedule, followed by anti-HBs testing 1\u20132 months after \nthe third dose, usually is more practical than conducting",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_46",
        "document_id": "rr6007",
        "text": "the third dose, usually is more practical than conducting \nserologic testing after each additional dose of vaccine.\n\u2022 Persons who do not have a protective concentration of \nanti-HBs (\u226510 mIU/mL) after revaccination (i.e., after \nreceiving a total of 6 doses) should be tested for HBsAg \nand anti-HBc to determine infection status. Those \ndetermined not to be infected but who have anti-HBs <10 \nmIU/mL (nonresponders) should be considered susceptible \nto HBV infection and should be counseled about \nprecautions to prevent HBV infection and the need to \nobtain hepatitis B immune globulin (HBIG) postexposure \nprophylaxis for any known or likely exposure to HBsAg-\npositive blood (72). Persons determined to be infected \n(anti-HBc-positive) and positive for HBsAg should be",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_47",
        "document_id": "rr6007",
        "text": "(anti-HBc-positive) and positive for HBsAg should be \nprovided counseling regarding how to prevent HBV \ntransmission to others and referred for further evaluation \n(e.g., HBV viral load testing), care, treatment, and other \nservices, as appropriate (69\u201371). Persons who are HBsAg-\npositive and who perform exposure-prone procedures \nshould seek counsel from a review panel comprised of \nexperts with a balanced perspective (e.g., HCPs\u2019 personal \nphysicians and infectious disease specialists) regarding the \nprocedures that they can perform safely. They should not \nbe excluded from work (69). Persons who were infected \nin the past (anti-HBc-positive but negative for HBsAg) \nrequire no vaccination or treatment.\nPostexposure \nThe need for postexposure prophylaxis should be evaluated",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_48",
        "document_id": "rr6007",
        "text": "Postexposure \nThe need for postexposure prophylaxis should be evaluated \nimmediately after HCP experience any percutaneous, ocular, \nmucous-membrane or nonintact skin exposure to blood \nor body fluid in the workplace. Decisions to administer \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n7\npostexposure prophylaxis should be based on the HBsAg status \nof the source and the vaccination history and vaccine-response \nstatus of the exposed HCP (Table 4) (72).\nUnvaccinated and Incompletely Vaccinated HCP \nand Trainees\n\u2022 Unvaccinated or incompletely vaccinated persons who \nexperience a workplace exposure from persons known to \nbe HBsAg-positive should receive 1 dose of hepatitis B \nimmune globulin HBIG (i.e., passive vaccination) as soon",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_49",
        "document_id": "rr6007",
        "text": "immune globulin HBIG (i.e., passive vaccination) as soon \nas possible after exposure (preferably within 24 hours). \nThe effectiveness of HBIG when administered >7 days \nafter percutaneous or permucosal exposures is unknown \n(Table 4).\n\u2022 Hepatitis B vaccine should be administered in the deltoid \nmuscle as soon as possible after exposure; HBIG should \nbe administered at the same time at another injection site. \nThe 3-dose hepatitis B vaccine series should be completed \nfor previously unvaccinated and incompletely vaccinated \npersons who have needlestick or other percutaneous \nexposures, regardless of the HBsAg status of the source \nand whether the status of the source is known. To \ndocument protective levels of anti-HBs (\u226510mIU/mL), \npostvaccination testing of persons who received HBIG for",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_50",
        "document_id": "rr6007",
        "text": "postvaccination testing of persons who received HBIG for \npostexposure prophylaxis should be performed after anti-\nHBs from HBIG is no longer detectable (4\u20136 months after \nadministration). \nVaccinated HCP and Trainees\n\u2022 Vaccinated HCP with documented immunity (anti-HBs \nconcentrations of \u226510 mIU/mL) require no postexposure \nprophylaxis, serologic testing, or additional vaccination.\n\u2022 Vaccinated HCP with documented nonresponse to a \n3-dose vaccine series should receive 1 dose of HBIG and \na second 3-dose vaccine series if the source is HBsAg-\npositive or known to be at high risk for carrying hepatitis. \nIf the source is known or determined to be HBsAg- \nnegative, these previously nonresponding HCP should \ncomplete the revaccination series and undergo",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_51",
        "document_id": "rr6007",
        "text": "negative, these previously nonresponding HCP should \ncomplete the revaccination series and undergo \npostvaccination testing to ensure that their response status \nis documented (Table 4). Postvaccination testing of \npersons who received HBIG for PEP should be performed \nafter anti-HBs from HBIG is no longer detectable (4\u20136 \nmonths after administration). \n\u2022 Vaccinated HCP with documented nonresponse to two \n3-dose vaccine series should receive 2 doses of HBIG, 1 \nmonth apart if the source is HBsAg-positive or known to \nbe at high risk for carrying hepatitis; no additional \nvaccination is necessary. If the source is known or \ndetermined to be HBsAg-negative, these previously \nnonresponding HCP need no additional testing or \ntreatment (Table 4).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_52",
        "document_id": "rr6007",
        "text": "nonresponding HCP need no additional testing or \ntreatment (Table 4).\n\u2022 Vaccinated HCP with no documentation of postvaccination \nserologic response who are exposed to an HBsAg-positive \nsource should have serum obtained for anti-HBs testing \nimmediately. Those determined to have protective levels \nof antibody (anti-HBs \u226510 mIU/mL) require no additional \ntreatment; those with concentrations <10 mIU/mL should \nreceive 1 dose of HBIG, along with a booster dose of \nhepatitis B vaccine. To document protective levels of anti-\nHBs (\u226510mIU/mL), postvaccination testing of persons \nwho received HBIG for postexposure prophylaxis should \nbe performed after anti-HBs from HBIG is no longer \ndetectable (4\u20136 months after administration).\n\u2022 Vaccinated HCP with no documentation of postvaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_53",
        "document_id": "rr6007",
        "text": "\u2022 Vaccinated HCP with no documentation of postvaccination \nserologic response who are exposed to a source with \nunknown infection status should be tested for anti-HBs. \nThose determined to have protective levels of antibody \nrequire no additional treatment; those with concentrations \n<10 mIU/mL should receive a booster dose of hepatitis B \nvaccine and serologic testing 1\u20132 months later.\n\u2022 Vaccinated HCP with no documentation of postvaccination \nserologic response who are exposed to a source known to \nbe HBsAg-negative require no testing or treatment (Table 4).\nHCP and Trainees at Additional Risk \n\u2022 Regardless of vaccination history, HCP and trainees in \ncertain high-risk populations, including those born in \ngeographic regions with high HBsAg prevalence (\u22658%) and",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_54",
        "document_id": "rr6007",
        "text": "geographic regions with high HBsAg prevalence (\u22658%) and \nintermediate (2%\u20137%) prevalence (71), unvaccinated U.S-\nborn HCP whose parents were born in regions of high \nHBsAg prevalence, HIV-positive HCP, HCP who have \ndisclosed having engaged or currently engaging in high-risk \nsubstance abuse or sexual behaviors, and HCP who require \nimmunosuppressive therapy or who are on hemodialysis \nshould be tested for HBsAg and anti-HBc/anti-HBs to \ndetermine infection status. For those who are unvaccinated, \nblood should be drawn for testing before the first dose of \nvaccine is administered, and vaccination should be \nadministered during the same health-care visit. Persons \ntesting negative for hepatitis B infection or immunity should \nbe managed in the same manner as other uninfected HCP.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_55",
        "document_id": "rr6007",
        "text": "be managed in the same manner as other uninfected HCP. \nPersons determined to be HBsAg-positive should be \nprovided counseling regarding how to prevent HBV \ntransmission to others and referred for further evaluation \n(e.g., HBV viral load testing), care, treatment, and other \nservices as appropriate (69\u201371). Persons who are HBsAg-\npositive and who perform exposure-prone procedures \nshould seek counsel from a review panel comprised of \nexperts with a balanced perspective (e.g., personal physicians \nRecommendations and Reports\n8\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nof HCP and infectious disease specialists) regarding the \nprocedures that they can perform safely. They should not \nbe excluded from work (69). Additional information",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_56",
        "document_id": "rr6007",
        "text": "be excluded from work (69). Additional information \nregarding prevaccination testing for HCP with other \nhepatitis B risk factors and for pregnant women has been \npublished previously (52,71). HCP receiving hemodialysis \nshould be provided annual anti-HBs testing and should be \nadministered a booster dose of vaccine when anti-HBs levels \ndecline to <10 mIU/mL (52).\n\u2022 For other immunocompromised HCP (e.g., HIV-infected \npersons, hematopoietic stem-cell transplant recipients, and \npersons receiving chemotherapy), the frequency of \npostvaccination testing and the need for booster doses has \nnot been determined (52). \nOther Considerations\n\u2022 Occupational health programs and others responsible for \ninfection prevention and control should identify all staff",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_57",
        "document_id": "rr6007",
        "text": "infection prevention and control should identify all staff \nwhose work-related activities involve exposure to blood or \nother potentially infectious body fluids in a health-care, \nlaboratory, public safety, or institutional setting (including \nemployees, students, contractors, attending clinicians, \nemergency medical technicians, paramedics, and volunteers); \nprovide education to staff to encourage vaccination; and \nimplement active follow-up, with reminders to track \ncompletion of the vaccine series and postvaccination testing \namong persons receiving vaccination (72). \n\u2022 In partnership with state and local health authorities, \nhousehold, sex, or needle-sharing contacts of HBsAg-\npositive HCP and trainees should be identified, tested,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_58",
        "document_id": "rr6007",
        "text": "positive HCP and trainees should be identified, tested, \nvaccinated (if indicated), and provided with counseling and \nreferral for needed services, when appropriate. \nInfluenza\nBackground\nEpidemiology and Risk Factors\nInfluenza causes an estimated average of >200,000 \nhospitalizations and 3,000\u201349,000 deaths annually in the \nUnited States (74\u201376). The majority of influenza-related \nsevere illnesses and deaths occur among persons with chronic \nmedical conditions, infants and young children, seniors, and \npregnant women (74\u201378). Reducing the risk for influenza \namong persons at higher risk for complications is a major focus \nof influenza prevention strategies (77).\nInfluenza Transmission in Health-Care Settings\nHCP are exposed to patients with influenza in the workplace",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_59",
        "document_id": "rr6007",
        "text": "HCP are exposed to patients with influenza in the workplace \nand are thus at risk of occupationally acquired influenza and of \ntransmitting influenza to patients and other HCP. In a cross-\nsectional survey of hospital house staff (physicians in training), \n37% reported influenza-like illness during September\u2013April, \nand 9% reported more than one respiratory illness. Length of \nillness varied (range: 1\u201310 days; mean: 7 days), as did days of \nwork missed (range: 0\u201310 days; mean: 0.7 days) (79). Infected \nHCP who continue to work while ill might transmit influenza \nto patients, many of whom are at increased risk for severe \noutcomes from influenza. HCP are therefore recommended \nfor routine annual influenza vaccination (77).\nFew randomized trials of the effect that influenza vaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_60",
        "document_id": "rr6007",
        "text": "Few randomized trials of the effect that influenza vaccination \nhas on illness in HCP have been conducted. In one randomized \ntrial of 427 HCP, influenza vaccination of HCP failed to \ndecrease episodes of respiratory infection or duration of illness \nbut was associated with a 28% decrease in absenteeism (from \n1.4 days to 1.0 day) attributable to respiratory infections (80). \nNo laboratory confirmation of influenza was obtained in this \nstudy. In another randomized trial among HCP, vaccination \nwas associated with a significantly lower rate of serological \nevidence of influenza infection, with a vaccine efficacy rate of \n88% for influenza A and 89% for influenza B (p<0.05) (81); \nhowever, no significant differences were noted in days of febrile \nrespiratory illness or absenteeism.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_61",
        "document_id": "rr6007",
        "text": "respiratory illness or absenteeism.\nInfluenza can cause outbreaks of severe respiratory illness \namong hospitalized persons and long-term-care residents (82\u2013\n90). Influenza outbreaks in hospitals (86\u201388) and long-term\u2013\ncare facilities (91) have been associated with low vaccination \nrates among HCP. One nonrandomized study demonstrated \nan increase in HCW vaccination rates and decrease in \nnosocomially acquired, laboratory-confirmed influenza in a \nhospital after a mobile cart\u2013based HCP vaccination program \nwas introduced (86). Several randomized controlled studies of \nthe impact of HCP vaccination on morbidity and mortality \nin long-term care facilities have been performed (92\u201395). \nThese studies have demonstrated substantial decreases in all-",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_62",
        "document_id": "rr6007",
        "text": "These studies have demonstrated substantial decreases in all-\ncause mortality (92\u201395) and influenza-like illness (92,94,95). \nHowever, studies which examine and demonstrate efficacy in \npreventing more specific outcomes (e.g., laboratory-confirmed \ninfluenza illness and mortality) are lacking. Recent systematic \nreviews suggest that vaccination of HCP in settings in which \npatients also were vaccinated provided significant reductions \nin deaths among elderly patients from all causes and deaths \nfrom pneumonia, but also note that additional randomized \ncontrolled trials are warranted (96,97), as are examination of \nmore specific outcomes.\nPreventing influenza among HCP who might serve as sources \nof influenza virus transmission provides additional protection",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_63",
        "document_id": "rr6007",
        "text": "of influenza virus transmission provides additional protection \nto patients at risk for influenza complications. Vaccination \nof HCP can specifically benefit patients who cannot receive \nvaccination (e.g., infants aged <6 months or those with severe \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n9\nallergic reactions to prior influenza vaccination), patients \nwho respond poorly to vaccination (e.g., persons aged \u226585 \nyears and immune-compromised persons), and persons for \nwhom antiviral treatment is not available (e.g., persons with \nmedical contraindications). Although annual vaccination has \nlong been recommended for HCP and is a high priority for \nreducing morbidity associated with influenza in health-care",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_64",
        "document_id": "rr6007",
        "text": "reducing morbidity associated with influenza in health-care \nsettings (98\u2013100), national survey data have demonstrated \nthat the vaccination coverage level during the 2008\u201309 season \nwas 52.9% (101).\nConsiderations Regarding Influenza Vaccination \nof HCP\nBarriers to HCP aceptance of influenza vaccination have \nincluded fear of vaccine side effects (particularly influenza-\nlike symptoms), insufficient time or inconvenience, perceived \nineffectiveness of the vaccine, perceived low likelihood of \ncontracting influenza, avoidance of medications, and fear of \nneedles (79,102\u2013109). Factors demonstrated to increase vaccine \nacceptance include a desire for self-protection, previous receipt \nof influenza vaccine, a desire to protect patients, and perceived",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_65",
        "document_id": "rr6007",
        "text": "of influenza vaccine, a desire to protect patients, and perceived \neffectiveness of vaccine (79,105,106,109\u2013112). Strategies \nthat have demonstrated improvement in HCP vaccination \nrates have included campaigns to emphasize the benefits of \nHCP vaccination for staff and patients, vaccination of senior \nmedical staff or opinion leaders, removing administrative \nbarriers (e.g., costs), providing vaccine in locations and at \ntimes easily accessible by HCP, and monitoring and reporting \nHCP influenza vaccination rates (99,113\u2013120). Intranasally \nadministered live attenuated influenza vaccine (LAIV) is an \noption for healthy, nonpregnant adults aged <50 years who \ndislike needles.\nThe practice of obtaining signed declinations from HCP \noffered influenza vaccination has been adopted by some",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_66",
        "document_id": "rr6007",
        "text": "offered influenza vaccination has been adopted by some \ninstitutions but has not yet been demonstrated to exceed \ncoverage rates of >70%\u201380% (99,115,121\u2013123). Institutions \nthat require declination statements from HCP who refuse \ninfluenza vaccination should educate and counsel these HCP \nabout benefits of the vaccine.\nEach health-care facility should develop a comprehensive \ninfluenza vaccination strategy that includes targeted education \nabout the disease, including disease risk among HCP and \npatients, and about the vaccine. In addition, the program \nshould establish easily accessible vaccination sites and inform \nHCP about their locations and schedule. Facilities that \nemploy HCP should provide influenza vaccine at no cost to",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_67",
        "document_id": "rr6007",
        "text": "employ HCP should provide influenza vaccine at no cost to \npersonnel (124). The most effective combination of approaches \nfor achieving high influenza vaccination coverage among \nHCP likely varies by institution. Hospitals and health-care \norganizations in the United States traditionally have employed \nan immunization strategy that includes one or more of the \nfollowing components: education about influenza, easy access \nto vaccine, incentives to encourage immunization, organized \ncampaigns, institution of declination policies, and legislative \nand regulatory efforts (e.g., vaccination requirements) (99, \n115, 121\u2013126).\nBeginning January 1, 2007, the Joint Commission on \nAccreditation of Health-Care Organizations required",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_68",
        "document_id": "rr6007",
        "text": "Accreditation of Health-Care Organizations required \naccredited organizations to offer influenza vaccinations to staff, \nincluding volunteers and licensed independent practitioners \nand to report coverage levels among HCP (127). Standards \nare available for measuring vaccination coverage among \nHCP as a measure of program performance within a health-\ncare setting (128). Beginning January 2013, the Centers for \nMedicaid Services will require acute care hospitals to report \nHCP influenza vaccine as part of its hospital inpatient quality \nreporting program.*\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nEffectiveness of influenza vaccines varies from year to year \nand depends on the age and health status of the person getting",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_69",
        "document_id": "rr6007",
        "text": "and depends on the age and health status of the person getting \nthe vaccine and the similarity or \u201cmatch\u201d between the viruses \nor virus in the vaccine and those in circulation. Vaccine strains \nare selected for inclusion in the influenza vaccine every year \nbased on international surveillance and scientists\u2019 estimations \nabout which types and strains of viruses will circulate in a \ngiven year. Annual vaccination is recommended because the \npredominant circulating influenza viruses typically change \nfrom season to season and, because immunity declines over \ntime postvaccination (77).\nIn placebo-controlled studies among adults, the most \nfrequent side effect of vaccination was soreness at the \nvaccination site (affecting 10%\u201364% of patients) that lasted",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_70",
        "document_id": "rr6007",
        "text": "vaccination site (affecting 10%\u201364% of patients) that lasted \n<2 days (129,130). These injection-site reactions typically were \nmild and rarely interfered with the recipient\u2019s ability to conduct \nusual daily activities. The main contraindication to influenza \nvaccination is a history of anaphylactic hypersensitivity to egg \nor other components of the vaccine. A history of Guillain-\nBarr\u00e9 Syndrome within 6 weeks following a previous dose of \ninfluenza vaccine is considered to be a precaution for use of \ninfluenza vaccines (77).\n*\tUS Department of Health and Human Services. Medicare program; hospital \ninpatient prospective payment systems for acute care hospitals and the long-\nterm care hospital prospective payment system and FY2012 rates; hospitals\u2019",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_71",
        "document_id": "rr6007",
        "text": "term care hospital prospective payment system and FY2012 rates; hospitals\u2019 \nFTE resident caps for graduate medical education payment; final rules. Federal \nRegister 2011;76:51631\u20133.\nRecommendations and Reports\n10\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nRecommendations\nVaccination \nAnnual influenza vaccination is recommended for all persons \naged \u22656 months who have no medical contraindication; \ntherefore, vaccination of all HCP who have no contraindications \nis recommended. The influenza vaccine is evaluated annually \nwith one or more vaccine strains updated almost every year. \nIn addition, antibody titers decline during the year after \nvaccination. Thus, annual vaccination with the current \nseason\u2019s formulation is recommended. Annual vaccination is",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_72",
        "document_id": "rr6007",
        "text": "season\u2019s formulation is recommended. Annual vaccination is \nappropriate and safe to begin as early in the season as vaccine \nis available. HCP should be among the groups considered for \nprioritized receipt of influenza vaccines when vaccine supply \nis limited.\nTwo types of influenza vaccines are available. LAIV is \nadministered intranasally and is licensed for use in healthy \nnonpregnant persons aged 2\u201349 years. The trivalent inactivated \nvaccine (TIV) is administered as an intramuscular injection \nand can be given to any person aged \u22656 months. Both vaccine \ntypes contain vaccine virus strains that are selected to stimulate \na protective immune response against the wild-type viruses \nthat are thought to be most likely in circulation during the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_73",
        "document_id": "rr6007",
        "text": "that are thought to be most likely in circulation during the \nupcoming season. Use of LAIV for HCP who care for patients \nhoused in protective inpatient environments has been a \ntheoretic concern, but transmission of LAIV in health-care \nsettings has not been reported. LAIV can be used for HCP \nwho work in any setting, except those who care for severely \nimmunocompromised hospitalized persons who require care \nin a protective environment. HCP who themselves have a \ncondition that confers high risk for influenza complications, \nwho are pregnant, or who are aged \u226550 years should not receive \nLAIV and should be administered TIV instead. An inactivated \ntrivalent vaccine containing 60 mcg of hemagglutinin antigen \nper influenza vaccine virus strain (Fluzone High-Dose [sanofi",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_74",
        "document_id": "rr6007",
        "text": "per influenza vaccine virus strain (Fluzone High-Dose [sanofi \npasteur]) is an alternative inactivated vaccine for persons aged \n\u226565 years. Persons aged \u226565 years may be administered any \nof the standard-dose TIV preparations or Fluzone High-Dose \n(77). The majority of TIV preparations are administered \nintramuscularly. An intradermally administered TIV was \nlicensed in May 2011 and is an alternative to other TIV \npreparations for persons aged 18\u201364 years (131).\nUse of Antiviral Drugs for Treating Exposed Persons \nand Controlling Outbreaks\nUse of antiviral drugs for chemoprophylaxis or treatment of \ninfluenza is an adjunct to (but not a substitute for) vaccination. \nOseltamivir or zanamivir are recommended currently for \nchemoprophylaxis or treatment of influenza (132,133). TIV",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_75",
        "document_id": "rr6007",
        "text": "chemoprophylaxis or treatment of influenza (132,133). TIV \ncan be administered to exposed, unvaccinated HCP at the \nsame time as chemoprophylaxis, but LAIV should be avoided \nbecause the antiviral medication will prevent viral replication \nneeded to stimulate a vaccine response (77). Antivirals are \nused often among patients during outbreaks in closed settings \nsuch as long-term\u2013care facilities but also can be administered \nto unvaccinated HCP during outbreaks, when an exposure \nto a person with influenza occurs, or after exposure when \nvaccination is not thought to be protective against the strain \nto which a vaccinated HCP was exposed. Chemoprophylaxis \nconsists of 1 dose (of either antiviral drug) daily for 10 days, \nand treatment consists of 1 dose twice daily for 5 days. In",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_76",
        "document_id": "rr6007",
        "text": "and treatment consists of 1 dose twice daily for 5 days. In \nmany instances of HCP exposure, watchful waiting and early \ninitiation of treatment if symptoms appear is preferred rather \nthan use of antiviral chemoprophylaxis immediately after \nexposure. The intensity and duration of the exposure and the \nunderlying health status of the exposed worker are important \nfactors in clinical judgments about whether to provide \nchemoprophylaxis. If chemoprophylaxis is used, the provider \nshould base choice of the agent on whether the circulating \nstrain or strains of influenza have demonstrated resistance to \nparticular antivirals.\nProgram Evaluation\n\u2022 Health-care administrators should include influenza \nvaccination coverage among HCP as a measure of quality \nof care (124).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_77",
        "document_id": "rr6007",
        "text": "vaccination coverage among HCP as a measure of quality \nof care (124).\n\u2022 Influenza vaccination rates among HCP within facilities \nshould be regularly measured and reported, and ward-, \nunit-, and specialty-specific coverage rates should be \nprovided to staff and administration (124). Such \ninformation might be useful to promote compliance with \nvaccination policies.\nMeasles\nBackground\nEpidemiology and Risk Factors \nMeasles is a highly contagious rash illness that is transmitted by \nrespiratory droplets and airborne spread. Severe complications, \nwhich might result in death, include pneumonia and \nencephalitis. Before the national measles vaccination program \nwas implemented in 1963, almost every person acquired \nmeasles before adulthood; an estimated 3\u20134 million persons",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_78",
        "document_id": "rr6007",
        "text": "measles before adulthood; an estimated 3\u20134 million persons \nin the United States acquired measles each year (134). \nApproximately 500,000 persons were reported to have had \nmeasles annually, of whom 500 persons died, 48,000 were \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n11\nhospitalized, and another 1,000 had permanent brain damage \nfrom measles encephalitis (134).\nThrough a successful 2-dose measles vaccination program \n(i.e., a first dose at age 12\u201315 months and a second dose \nbetween ages 4\u20136 years) (135) and better measles control \nthroughout the region of the Americas (136), endemic \ntransmission of measles was interrupted in the United States, \nand measles was declared eliminated from the country in 2000",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_79",
        "document_id": "rr6007",
        "text": "and measles was declared eliminated from the country in 2000 \n(137). However, measles remains widespread in the majority of \ncountries outside the Western Hemisphere, with an estimated \n20 million measles cases occurring worldwide (138) and \napproximately 164,000 related deaths (139). Thus, the United \nStates continues to experience international importations that \nmight lead to transmission among U.S. residents and limited \noutbreaks, especially in unvaccinated populations (140\u2013143).\nDuring 2001\u20132008, a total of 557 confirmed measles cases \nwere reported in the United States from 37 states and the District \nof Columbia (annual median: 56; range: 37 in 2004 to 140 in \n2008), representing an annual incidence of less than one case per",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_80",
        "document_id": "rr6007",
        "text": "2008), representing an annual incidence of less than one case per \nmillion population (144). Of the 557 reported case-patients, 126 \n(23%) were hospitalized (annual median: 16; range: 5\u201329); of \nthese, at least five case-patients were admitted to intensive care. \nTwo deaths were reported, both in 2003 (144).\nOf the 557 reported case-patients during 2001\u20132008, a \ntotal of 223 (40%) were adults, including 156 (28%) aged \n20\u201339 years and 67 (12%) aged \u226540 years. Of the 438 measles \ncases among U.S. residents, 285 (65%) cases were considered \npreventable (i.e., occurred among persons who were eligible \nfor vaccination but were unvaccinated) (144). The remaining \n153 (35%) cases were considered nonpreventable. Cases were \ndefined as nonpreventable if they occurred among U.S. resident",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_81",
        "document_id": "rr6007",
        "text": "defined as nonpreventable if they occurred among U.S. resident \ncase-patients who had received \u22651 dose of measles-containing \nvaccine, if patients were vaccinated as recommended if traveling \ninternationally, or if they were not vaccinated but had other \nevidence of immunity (i.e., were born before 1957 and \ntherefore presumed immune from natural disease in childhood, \nhad laboratory evidence of immunity, or had documentation \nof physician-diagnosed disease) or for whom vaccination is not \nrecommended. During 2001\u20132008, a total of 12.5% (one of \neight) of measles cases reported to CDC among HCP occurred \nin persons born before 1957; the other seven cases occurred \namong HCP born after 1957.\nMeasles-mumps-rubella (MMR) vaccination policies have",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_82",
        "document_id": "rr6007",
        "text": "among HCP born after 1957.\nMeasles-mumps-rubella (MMR) vaccination policies have \nbeen enforced with variable success in United States health-\ncare facilities over the past decade. Even though medical \nsettings were a primary site of measles transmission during \nthe 1989\u20131991 measles resurgence (145,146), as of September \n2011, only three states (New York, Oklahoma, and Rhode \nIsland) had laws mandating that all hospital personnel have \nproof of measles immunity and did not allow for religious or \nphilosophic exemptions (147).\nVaccine coverage in the United States is high; in 2010, a total \nof 91.5% of children aged 19\u201335 months had received 1 dose \nof MMR vaccine (21); during 2009\u20132010, a total of 94.8% \nof kindergartners had evidence of 2 doses (148); and in 2010,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_83",
        "document_id": "rr6007",
        "text": "of kindergartners had evidence of 2 doses (148); and in 2010, \na total of 90.5% of adolescents had evidence of 2 doses (22). \nNationally representative data on MMR vaccine coverage of \nU.S. HCP are not available.\nMeasles Transmission and the Costs of Mitigating \nMeasles Exposures in Health-Care Settings\nHealth-care\u2013associated cases of measles are of public health \nconcern. Because of the severity of measles, infected persons \nare likely to seek medical care in primary health-care facilities, \nemergency departments, or hospitals (141,149,150). Medical \nsettings played a prominent role in perpetuating outbreaks of \nmeasles transmission during the 1989\u20131991 measles resurgence \n(145,146) and were a primary site of measles transmission in a",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_84",
        "document_id": "rr6007",
        "text": "(145,146) and were a primary site of measles transmission in a \nhealth-care\u2013associated outbreak in 2008 (149). During 2001\u2013\n2008, a total of 27 reported measles cases were transmitted in \nU.S. health-care facilities, accounting for 5% of all reported \nU.S. measles cases.\nBecause of the greater opportunity for exposure, HCP are at \nhigher risk than the general population for becoming infected \nwith measles. A study conducted in 1996 in medical facilities \nin a county in Washington state indicated that HCP were 19 \ntimes more likely to develop measles than other adults (151). \nDuring 2001\u20132008, in the 23 health-care settings in which \nmeasles transmission was reported, eight cases occurred among \nHCP, six (75%) of whom were unvaccinated or had unknown",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_85",
        "document_id": "rr6007",
        "text": "HCP, six (75%) of whom were unvaccinated or had unknown \nvaccination status. One health-care provider was hospitalized \nin an intensive care unit for 6 days from severe measles \ncomplications (142). During a health-care\u2013associated measles \noutbreak in Arizona in 2008 with 14 cases, six cases were \nacquired in hospitals, and one was acquired in an outpatient \nsetting. One unvaccinated health-care worker developed \nmeasles and infected a hospital emergency room patient \nwho required intensive care following hospital admission for \nmeasles (149).\nHigh costs also are involved in evaluating and containing \nexposures and outbreaks in health-care facilities, as well as \na substantial disruption of regular hospital routines when \ncontrol measures are instituted, especially if hospitals do not",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_86",
        "document_id": "rr6007",
        "text": "control measures are instituted, especially if hospitals do not \nhave readily available data on the measles immunity status \nRecommendations and Reports\n12\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nof their staff and others included in the facility vaccination \nprogram. In 2005 in Indiana, one hospital spent more than \n$113,000 responding to a measles outbreak (142), and in 2008 \nin Arizona, two hospitals spent $799,136 responding to and \ncontaining cases in their facilities (149). The Arizona outbreak \nresponse required rapid review of measles documentation of \n14,844 HCP at seven hospitals and emergency vaccination \nof approximately 4,500 HCP who lacked documentation of \nmeasles immunity. Serologic testing at two hospitals among",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_87",
        "document_id": "rr6007",
        "text": "measles immunity. Serologic testing at two hospitals among \n1,583 HCP without documented history of vaccination or \nwithout documented laboratory evidence of measles immunity \nrevealed that 138 (9%) of these persons lacked measles IgG \nantibodies (149).\nVaccine Effectiveness, Duration of Immunity and \nSeroprevalence Studies, and Vaccine Safety\nVaccine Effectiveness\nMMR vaccine is highly effective in preventing measles with \na 1-dose vaccine effectiveness of 95% when administered on \nor after age 12 months and a 2-dose vaccine effectiveness of \n99% (135).\nDuration of Immunity and Seroprevalence Studies\nTwo doses of live measles vaccine are considered to provide \nlong-lasting immunity (135). Although antibody levels decline \nfollowing vaccination, a study examining neutralizing antibody",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_88",
        "document_id": "rr6007",
        "text": "following vaccination, a study examining neutralizing antibody \nlevels up to 10 years following the second dose of MMR vaccine \nin children indicates that antibodies remain above the level \nconsidered protective (152).\nStudies among HCP in the United States during the measles \nresurgence in the late 1980s through early 1990s demonstrated \nthat 4%\u201310% of all HCP lacked measles IgG antibodies \n(153\u2013156). During the 2008 Arizona outbreak, of the 1,077 \nhealth-care providers born during or after 1957 without \ndocumented measles immunity, 121 (11%) were seronegative \n(149). In a study of measles seroprevalence among 469 newly \nhired HCP at a hospital in North Carolina who were born \nbefore 1957, and thus considered immune by age, who could",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_89",
        "document_id": "rr6007",
        "text": "before 1957, and thus considered immune by age, who could \nnot provide written evidence of immunity to measles, serologic \ntesting indicated that six (1.3%) lacked measles IgG antibodies \n(157). Other serologic studies of hospital-based HCP indicate \nthat 2%\u20139% of those born before 1957 lacked antibodies to \nmeasles (156,158\u2013160).\nA survey conducted during 1999\u2013 2004 found a \nseroprevalence of measles antibodies of 95.9% among persons \nin the U.S. population aged 6\u201349 years (161). The survey \nindicated that the lowest prevalence, 92.4%, was among \nadults born during 1967\u20131976 (161). A 1999 study of U.S. \nresidents aged \u226520 years determined that 93% had antibodies \nto measles virus (162).\nVaccine Safety \nMeasles vaccine is administered in combination with the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_90",
        "document_id": "rr6007",
        "text": "to measles virus (162).\nVaccine Safety \nMeasles vaccine is administered in combination with the \nmumps and rubella components as the MMR vaccine in the \nUnited States. Monovalent measles vaccine rarely has been \nused in the United States in the past 2 decades and is no longer \navailable. After decades of use, evidence demonstrates that \nMMR vaccine has an excellent safety profile (134).\nThe majority of documented adverse events occur in \nchildren. In rare circumstances, MMR vaccination of adults \nhas been associated with the following adverse events: \nanaphylaxis (approximately 1.0\u20133.5 occurrences per million \ndoses administered) (134), thrombocytopenia from the measles \ncomponent or rubella component (a rate of three to four cases",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_91",
        "document_id": "rr6007",
        "text": "component or rubella component (a rate of three to four cases \nfor every 100,000 doses) (134), and acute arthritis from the \nrubella component (arthralgia develops among approximately \n25% of rubella-susceptible postpubertal females after MMR \nvaccination, and approximately 10% have acute arthritis-like \nsigns and symptoms) (135). When joint symptoms occur, they \ngenerally persist for 1 day\u20133 weeks and rarely recur (135). \nChronic joint symptoms attributable to the rubella component \nof the MMR vaccine are reported very rarely, if they occur at \nall. Evidence does not support an association between MMR \nvaccination and any of the following: hearing loss, retinopathy, \noptic neuritis, Guillain-Barr\u00e9 Syndrome, type 1 diabetes, \nCrohn\u2019s disease, or autism (135,163\u2013169).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_92",
        "document_id": "rr6007",
        "text": "Crohn\u2019s disease, or autism (135,163\u2013169).\nA woman can excrete the rubella vaccine virus in breast milk \nand transmit the virus to her infant, but the infection remains \nasymptomatic (135). Otherwise, persons who receive MMR \nor its component vaccines do not transmit measles, rubella, \nor mumps vaccine viruses (135). No transmission of MMR \nvaccine virus in a health-care setting has been documented.\nRecommendations\nVaccination\nAll persons who work in health-care facilities should \nhave presumptive evidence of immunity to measles. This \ninformation should be documented and readily available at \nthe work location. Recently vaccinated HCP do not require \nany restriction in their work activities.\nPresumptive evidence of immunity to measles for persons",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_93",
        "document_id": "rr6007",
        "text": "any restriction in their work activities.\nPresumptive evidence of immunity to measles for persons \nwho work in health-care facilities includes any of the following: \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n13\n\u2022 written documentation of vaccination with 2 doses of live \nmeasles or MMR vaccine administered at least 28 days \napart,\u2020\n\u2022 laboratory evidence of immunity,\u00a7\n\u2022 laboratory confirmation of disease, or\n\u2022 birth before 1957.\u00b6\nPrevaccination Testing\nPrevaccination antibody screening before MMR vaccination \nfor an employee who does not have adequate presumptive \nevidence of immunity is not necessary unless the medical \nfacility considers it cost effective (134,170\u2013172) although \nno recent studies have been conducted. For HCP who have",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_94",
        "document_id": "rr6007",
        "text": "no recent studies have been conducted. For HCP who have \n2 documented doses of MMR vaccine or other acceptable \nevidence of immunity to measles, serologic testing for immunity \nis not recommended. In the event that a HCP who has 2 \ndocumented doses of MMR vaccine is tested serologically and \ndetermined to have negative or equivocal measles titer results, it \nis not recommended that the person receive an additional dose \nof MMR vaccine. Such persons should be considered to have \npresumptive evidence of measles immunity. Documented age-\nappropriate vaccination supersedes the results of subsequent \nserologic testing. Because rapid vaccination is necessary to halt \ndisease transmission, during outbreaks of measles, serologic \nscreening before vaccination is not recommended.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_95",
        "document_id": "rr6007",
        "text": "screening before vaccination is not recommended.\nUse of Vaccine and Immune Globulin for Treating \nExposed Persons and Controlling Outbreaks\nFollowing airborne infection\u2013control precautions and \nimplementing other infection-control measures are important \nto control the spread of measles but might fail to prevent \nall nosocomial transmission, because transmission to other \nsusceptible persons might occur before illness is recognized. \nPersons infected with measles are infectious 4 days before rash \nonset through 4 days after rash onset.\nWhen a person who is suspected of having measles visits \na health-care facility, airborne infection\u2013control precautions \nshould be followed stringently. The patient should be asked \nimmediately to wear a medical mask and should be placed",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_96",
        "document_id": "rr6007",
        "text": "immediately to wear a medical mask and should be placed \nin an airborne-infection isolation room (i.e., a negative air-\npressure room) as soon as possible. If an airborne-infection \nisolation room is not available, the patient should be placed \nin a private room with the door closed and be asked to wear \na mask. If possible, only staff with presumptive evidence of \nimmunity should enter the room of a person with suspect or \nconfirmed measles. Regardless of presumptive immunity status, \nall staff entering the room should use respiratory protection \nconsistent with airborne infection\u2013control precautions (i.e., use \nof an N95 respirator or a respirator with similar effectiveness \nin preventing airborne transmission) (3,150).\nBecause of the possibility, albeit low (~1%), of measles",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_97",
        "document_id": "rr6007",
        "text": "Because of the possibility, albeit low (~1%), of measles \nvaccine failure in HCP exposed to infected patients (173), \nall HCP should observe airborne precautions in caring for \npatients with measles. HCP in whom measles occurs should \nbe excluded from work until \u22654 days following rash onset. \nContacts with measles-compatible symptoms should be \nisolated, and appropriate infection-control measures (e.g., rapid \nvaccination of susceptible contacts) should be implemented to \nprevent further spread (174).\nIf measles exposures occur in a health-care facility, all contacts \nshould be evaluated immediately for presumptive evidence of \nmeasles immunity. HCP without evidence of immunity should \nbe offered the first dose of MMR vaccine and excluded from",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_98",
        "document_id": "rr6007",
        "text": "be offered the first dose of MMR vaccine and excluded from \nwork from day 5\u201321 following exposure (135). HCP without \nevidence of immunity who are not vaccinated after exposure \nshould be removed from all patient contact and excluded from \nthe facility from day 5 after their first exposure through day 21 \nafter the last exposure, even if they have received postexposure \nintramuscular immune globulin of 0.25 mL/kg (40 mg IgG/\nkg) (135). Those with documentation of 1 vaccine dose may \nremain at work and should receive the second dose.\nCase-patient contacts who do not have presumptive \nevidence of measles immunity should be vaccinated, offered \nintramuscular immune globulin of 0.25 mL/kg (40 mg IgG/\nkg), which is the standard dosage for nonimmunocompromised",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_99",
        "document_id": "rr6007",
        "text": "kg), which is the standard dosage for nonimmunocompromised \npersons (135), or quarantined until 21 days after their \nexposure to the case-patient. Contacts with measles-compatible \nsymptoms should be isolated, and appropriate infection-\ncontrol measures should be implemented to prevent further \nspread. If immune globulin is administered to an exposed \nperson, observations should continue for signs and symptoms \nof measles for 28 days after exposure because immune globulin \nmight prolong the incubation period.\nAvailable data suggest that live virus measles vaccine, if \nadministered within 72 hours of measles exposure, will prevent, \nor modify disease (134). Even if it is too late to provide effective \npostexposure prophylaxis by administering MMR, the vaccine can",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_100",
        "document_id": "rr6007",
        "text": "postexposure prophylaxis by administering MMR, the vaccine can \nprovide protection against future exposure to all three infections. \nIdentifying persons who lack evidence of measles immunity during \n\u2020\tThe first dose of measles-containing vaccine should be administered on or after \nthe first birthday; the second dose should be administered no earlier than 28 \ndays after the first dose.\n\u00a7\tMeasles immunoglobulin (IgG) in the serum; equivocal results should be \nconsidered negative.\n\u00b6\tThe majority of persons born before 1957 are likely to have been infected \nnaturally and may be presumed immune, depending on current state or local \nrequirements. For unvaccinated personnel born before 1957 who lack laboratory \nevidence of measles immunity or laboratory confirmation of disease, health-care",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_101",
        "document_id": "rr6007",
        "text": "evidence of measles immunity or laboratory confirmation of disease, health-care \nfacilities should consider vaccinating personnel with 2 doses of MMR vaccine \nat the appropriate interval. For unvaccinated personnel born before 1957 who \nlack laboratory evidence of measles immunity or laboratory confirmation of \ndisease, health-care facilities should recommend 2 doses of MMR vaccine during \nan outbreak of measles.\nRecommendations and Reports\n14\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\ncontact investigations provides a good opportunity to offer MMR \nvaccine to protect against measles as well as mumps and rubella, \nnot only for HCP who are part of an organization\u2019s vaccination \nprogram, but also for patients and visitors. If an exposed person is",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_102",
        "document_id": "rr6007",
        "text": "program, but also for patients and visitors. If an exposed person is \nalready incubating measles, MMR vaccination will not exacerbate \nsymptoms. In these circumstances, persons should be advised that \na measles-like illness occurring shortly after vaccination could be \nattributable either to natural infection or to the vaccine strain. \nIn such circumstances, specimens should be submitted for viral \nstrain identification.\nMumps\nBackground\nEpidemiology and Risk Factors\nMumps is an acute viral infection characterized by fever and \ninflammation of the salivary glands (usually parotitis) (175). \nThe spectrum of illness ranges from subclinical infection (20%\u2013\n40%) to nonspecific respiratory illness, sialadenitis including \nclassic parotitis, deafness, orchitis, and meningoencephalitis;",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_103",
        "document_id": "rr6007",
        "text": "classic parotitis, deafness, orchitis, and meningoencephalitis; \nseverity increases with age (175). In the prevaccine era, mumps \nwas a common childhood illness, with approximately 186,000 \nmumps cases reported in the United States per year (176). After \nthe introduction of the Jeryl Lynn strain mumps vaccine in \n1967 and the implementation of the 1-dose mumps vaccine \npolicy for children in 1977 (177), reports of mumps cases in \nthe United States declined 99% (178). During 1986\u20131987, an \nincrease in reported mumps cases occurred, primarily affecting \nunvaccinated adolescents and young adults. In the late 1980s, \nsporadic outbreaks continued to occur that affected both \nunvaccinated and 1-dose vaccinated adolescents and young \nadults (178). In 1989, a second dose of MMR vaccine was",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_104",
        "document_id": "rr6007",
        "text": "adults (178). In 1989, a second dose of MMR vaccine was \nrecommended nationwide for better measles control among \nschool-aged children (179). Historically low rates of mumps \nfollowed with only several hundred reported cases per year in \nthe United States during 2000\u20132005.\nIn 1998, a national goal to eliminate mumps was set for 2010 \n(180). However, in 2006, a total of 6,584 mumps cases were \nreported in the United States, the largest U.S. mumps outbreak \nin nearly 20 years (181\u2013183). Whereas overall national mumps \nincidence was 2.2 per 100,000 population, eight states in \nthe Midwest were the most affected, with 2.5\u201366.1 cases per \n100,000 population (183). The highest incidence (31.1 cases \nper 100,000 population) was among persons aged 18\u201324",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_105",
        "document_id": "rr6007",
        "text": "per 100,000 population) was among persons aged 18\u201324 \nyears (e.g., college-aged students), the majority of whom had \nreceived 2 doses of mumps-containing vaccine. Of the 4,017 \ncase-patients for whom age and vaccination status were known, \n1,786 (44%) were aged \u226525 years (incidence: 7.2 cases per \n100,000 persons); of these 1,786 patients, 351 (20%) received \nat least 2 doses, 444 (25%) received 1 dose, 336 (19%) were \nunvaccinated, and 655 (37%) had unknown vaccination status.\nSince the 2006 resurgence, two additional large U.S. mumps \noutbreaks have occurred, both during 2009\u20132010, one among \nmembers of a religious community with cases occurring \nthroughout the northeastern United States (184) and the other \nin Guam (185); both outbreaks primarily affected children",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_106",
        "document_id": "rr6007",
        "text": "in Guam (185); both outbreaks primarily affected children \nand adolescents in crowded environments who had received \n2 doses of vaccine.\nVaccine coverage in the United States is high; in 2010, \napproximately 91.5% of children aged 19\u201335 months had \nreceived 1 dose of MMR vaccine (21); during 2009\u20132010, a \ntotal of 94.8% of kindergartners had evidence of 2 doses (148). \nIn 2010, a total of 90.5% of adolescents had evidence of 2 \ndoses (22). Nationally representative data on MMR vaccine \ncoverage of U.S. HCP are not available.\nMumps Transmission and the Costs of Mitigating \nMumps Exposures in Health-care Settings\nAlthough health-care\u2013associated transmission of mumps \nis infrequent, it might be underreported because of the high \npercentage (~20%\u201340%) of infected persons who might be",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_107",
        "document_id": "rr6007",
        "text": "percentage (~20%\u201340%) of infected persons who might be \nasymptomatic (186\u2013189). In a survey of 9,299 adults in \ndifferent professions conducted in 1968, before vaccine was \nused routinely, the rate of mumps acquisition was highest \namong dentists and HCP, with rates of 18% among dentists \nand 15% among physicians (37% for pediatricians), compared \nwith 9% among primary and secondary school teachers and \n2% among university staff members (190).\nIn the postvaccine era, mumps transmission also has \nbeen documented in medical settings (191\u2013193). During a \nTennessee mumps outbreak during 1986\u20131987, a total of 17 \n(12%) of 146 hospitals and three (50%) of six long-term\u2013care \nfacilities reported one or more practices that could contribute",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_108",
        "document_id": "rr6007",
        "text": "facilities reported one or more practices that could contribute \nto the spread of mumps, including not isolating patients with \nmumps, assigning susceptible staff to care for patients with \nmumps, and not immunizing susceptible employees. Health-\ncare\u2013associated transmission resulted in six cases of mumps \ninfections among health-care providers and nine cases of \nmumps infections among patients (191). In Utah in 1994, \ntwo health-care providers in a hospital developed mumps after \nthey had contact with an infected patient (192). During the \n2006 outbreak, one health-care facility in Chicago experienced \nongoing mumps transmission lasting 4 weeks (193).\nDuring the 2006 multistate U.S. outbreak, 144 (8.5%) \nof 1,705 adult case-patients in Iowa for whom occupation",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_109",
        "document_id": "rr6007",
        "text": "of 1,705 adult case-patients in Iowa for whom occupation \nwas known were health-care providers (Iowa Department \nof Public Health, unpublished data, 2006). Whether \ntransmission occurred from patients, coworkers, or persons in \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n15\nthe community is unknown. During the 2009\u20132010 outbreak \nin the northeastern region of the United States, seven (0.2%) \nof the 3,400 case-patients were health-care providers, six of \nwhom likely were infected by patients because they had no \nother known exposure.\nExposures to mumps in health-care settings also can result \nin added economic costs because of furlough or reassignment \nof staff members from patient-care duties or closure of wards",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_110",
        "document_id": "rr6007",
        "text": "of staff members from patient-care duties or closure of wards \n(194). In 2006, a Kansas hospital spent $98,682 containing a \nmumps outbreak (195). During a mumps outbreak in Chicago \nin 2006, one health-care facility spent $262,788 controlling \nthe outbreak (193).\nVaccine Effectiveness, Duration of Immunity and \nSeroprevalence Studies, and Vaccine Safety\nVaccine Effectiveness\nMMR vaccine has a 1-dose vaccine effectiveness in preventing \nmumps of 80%\u201385% (range: 75%\u201391%) (175,196\u2013199) and \na 2-dose vaccine effectiveness of 79%\u201395% (199\u2013202). In a \nstudy conducted on two Iowa college campuses during the \n2006 mumps outbreak among a population that was primarily \nvaccinated with 2 doses, 2-dose vaccine effectiveness ranged \nfrom 79% to 88% (202).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_111",
        "document_id": "rr6007",
        "text": "vaccinated with 2 doses, 2-dose vaccine effectiveness ranged \nfrom 79% to 88% (202).\nDuration of Immunity and Seroprevalence Studies\nMumps antibody levels wane over time following the first \nor second dose of vaccination (203,204), but the correlates \nof immunity to mumps are poorly understood and the \nsignificance of these waning antibody levels is unclear. A \nstudy on a university campus in Nebraska in 2006 indicated \nlower levels of mumps neutralizing antibodies among students \nwho had been vaccinated with a second MMR dose >15 \nyears previously than among those who had been vaccinated \n1\u20135 years previously, but the difference was not statistically \nsignificant (p>0.05) (205). In a 2006 study on a university \ncampus in Kansas, students with mumps were more likely",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_112",
        "document_id": "rr6007",
        "text": "campus in Kansas, students with mumps were more likely \nto have received a second dose of MMR vaccine \u226510 years \npreviously than were their roommates without mumps (206). \nHowever, another 2006 study from an Iowa college campus \nidentified no such association (202).\nDuring 1999\u20132004, national seroprevalence for mumps \nantibodies for persons aged 6\u201349 years was 90% (95% \nconfidence interval [CI]: 88.8\u201391.1) (207). In the Nebraska \nstudy, 414 (94%) of the 440 participants were seropositive for \nmumps antibodies (205). A study in Kansas in 2006 indicated \nthat 13% of hospital employees lacked antibodies to the mumps \nvirus (195). In a recent study on mumps seroprevalence among \n381 newly hired health-care personnel at a hospital in North",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_113",
        "document_id": "rr6007",
        "text": "381 newly hired health-care personnel at a hospital in North \nCarolina who were born before 1957 and thus considered \nimmune by age and who could not provide written evidence \nof immunity to mumps, serologic testing indicated that 14 \n(3.7%) lacked IgG antibodies to mumps (157).\nVaccine Safety\nMumps vaccine is administered in combination with the \nmeasles and rubella components as the MMR vaccine in the \nUnited States. Monovalent mumps vaccine has rarely been \nused in the United States in the past 2 decades and is no longer \navailable. After decades of use, evidence demonstrates that \nMMR vaccine has an excellent safety profile. The most common \nadverse reactions to the mumps component of the MMR vaccine \nare parotitis 10\u201314 days after vaccination and low-grade fever",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_114",
        "document_id": "rr6007",
        "text": "are parotitis 10\u201314 days after vaccination and low-grade fever \n(175). On the basis of biologic plausibility, orchitis, arthritis, \nor sensorineural deafness might rarely follow vaccination (175).\nThe majority of documented adverse events occur in \nchildren. In rare circumstances, MMR vaccination of \nadults has been associated with anaphylaxis (approximately \n1.0\u20133.5 occurrences per million doses administered) (134), \nthrombocytopenia from the measles component or rubella \ncomponent (rate: three to four cases for every 100,000 \ndoses) (134), and acute arthritis from the rubella component \n(arthralgia develops among approximately 25% of rubella-\nsusceptible postpubertal females after MMR vaccination, \nand approximately 10% have acute arthritis-like signs and",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_115",
        "document_id": "rr6007",
        "text": "and approximately 10% have acute arthritis-like signs and \nsymptoms) (135). When joint symptoms occur, they generally \npersist for 1 day\u20133 weeks and rarely recur (135). Chronic joint \nsymptoms attributable to the rubella component of the MMR \nvaccine are reported rarely, if they occur at all. Evidence does \nnot support a link between MMR vaccination and hearing loss, \nretinopathy, optic neuritis, Guillain-Barr\u00e9 Syndrome, type 1 \ndiabetes, Crohn\u2019s disease, or autism (135,163\u2013169).\nA woman can excrete the rubella vaccine virus in breast milk \nand transmit the virus to her infant, but the infection remains \nasymptomatic (135). Otherwise, persons who receive MMR \nor its component vaccines do not transmit measles, rubella, \nor mumps vaccine viruses (135). No transmission of MMR",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_116",
        "document_id": "rr6007",
        "text": "or mumps vaccine viruses (135). No transmission of MMR \nvaccine virus in a health-care setting has been documented.\nRecommendations\nVaccination\nAll persons who work in health-care facilities should \nhave presumptive evidence of immunity to mumps. This \ninformation should be documented and readily available at \nthe work location. Recently vaccinated HCP do not require \nany restriction in their work activities.\nPresumptive evidence of immunity to mumps for persons \nwho work in health-care facilities includes any of the following: \nRecommendations and Reports\n16\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\n\u2022 written documentation of vaccination with 2 doses of live \nmumps or MMR vaccine administered at least 28 days \napart,**\n\u2022 laboratory evidence of immunity,\u2020\u2020",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_117",
        "document_id": "rr6007",
        "text": "mumps or MMR vaccine administered at least 28 days \napart,**\n\u2022 laboratory evidence of immunity,\u2020\u2020\n\u2022 laboratory confirmation of disease, or\n\u2022 birth before 1957.\u00a7\u00a7\nPrevaccination Testing \nFor HCP who do not have adequate presumptive evidence \nof mumps immunity, prevaccination antibody screening \nbefore MMR vaccination is not necessary (135,175). For \nHCP who have 2 documented doses of MMR vaccine or \nother acceptable evidence of immunity to mumps, serologic \ntesting for immunity is not recommended. In the event \nthat a health-care provider who has 2 documented doses \nof MMR vaccine is tested serologically and determined to \nhave negative or equivocal mumps titer results, it is not \nrecommended that the person receive an additional dose of",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_118",
        "document_id": "rr6007",
        "text": "recommended that the person receive an additional dose of \nMMR vaccine. Such persons should be considered immune to \nmumps. Documented age-appropriate vaccination supersedes \nthe results of subsequent serologic testing. Likewise, during \noutbreaks of mumps, serologic screening before vaccination \nis not recommended because rapid vaccination is necessary to \nhalt disease transmission.\nControlling Mumps Outbreaks in Health-Care Settings\nPlacing patients in droplet precautions and implementing \nother infection-control measures is important to control the \nspread of mumps but might fail to prevent all nosocomial \ntransmission, because transmission to other susceptible persons \nmight occur before illness is recognized (208). When a person",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_119",
        "document_id": "rr6007",
        "text": "might occur before illness is recognized (208). When a person \nsuspected of having mumps visits a health-care facility, only \nHCP with adequate presumptive evidence of immunity \nshould be exposed to the person, and in addition to standard \nprecautions, droplet precautions should be followed. The index \ncase-patient should be isolated, and respiratory precautions \n(gown and gloves) should be used for patient contact. Negative \npressure rooms are not required. The patient should be isolated \nfor 5 days after the onset of parotitis, during which time \nshedding of virus is likely to occur (209).\nIf mumps exposures occur in a health-care facility, all contacts \nshould be evaluated for evidence of mumps immunity. HCP \nwith no evidence of mumps immunity who are exposed to",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_120",
        "document_id": "rr6007",
        "text": "with no evidence of mumps immunity who are exposed to \npatients with mumps should be offered the first dose of MMR \nvaccine as soon as possible, but vaccine can be administered \nat any interval following exposure; they should be excluded \nfrom duty from day 12 after the first unprotected exposure \nthrough day 25 after the most recent exposure. HCP with \ndocumentation of 1 vaccine dose may remain at work and \nshould receive the second dose. HCP with mumps should be \nexcluded from work for 5 days from the onset of parotitis (209).\nAntibody response to the mumps component of MMR \nvaccine generally is believed not to develop soon enough \nto provide effective prophylaxis after exposure to suspected \nmumps (191,210), but data are insufficient to rule out",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_121",
        "document_id": "rr6007",
        "text": "mumps (191,210), but data are insufficient to rule out \na prophylactic effect. Nonetheless, the vaccine is not \nrecommended for prophylactic purposes after exposure. \nHowever, identifying persons who lack presumptive evidence \nof mumps immunity during contact investigations provides \na good opportunity to offer MMR vaccine to protect against \nmumps as well as measles and rubella, not only for HCP who \nare part of an organization\u2019s vaccination program, but also for \npatients and visitors. If an exposed person already is incubating \nmumps, MMR vaccination will not exacerbate the symptoms. \nIn these circumstances persons should be advised that a \nmumps-like illness occurring shortly after vaccination is likely \nto be attributable to natural infection. In such circumstances,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_122",
        "document_id": "rr6007",
        "text": "to be attributable to natural infection. In such circumstances, \nspecimens should be submitted for viral strain identification \nto differentiate between vaccine and wild type virus. Immune \nglobulin is not routinely used for postexposure protection from \nmumps because no evidence exists that it is effective (135).\nRubella\nBackground\nEpidemiology and Risk Factors\nRubella (German measles) is a viral disease characterized \nby rash, low-grade fever, lymphadenopathy, and malaise \n(211). Although rubella is considered a benign disease, \ntransient arthralgia and arthritis are observed commonly in \ninfected adults, particularly among postpubertal females. \nChronic arthritis has been reported after rubella infection, \nbut such reports are rare, and evidence of an association is",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_123",
        "document_id": "rr6007",
        "text": "but such reports are rare, and evidence of an association is \nweak (212). Other complications that occur infrequently \n\t**\tThe first dose of mumps-containing vaccine should be administered on or \nafter the first birthday; the second dose should be administered no earlier than \n28 days after the first dose.\n\t\u2020\u2020\tMumps immunoglobulin (IgG) in the serum; equivocal results should be \nconsidered negative.\n\t\u00a7\u00a7\tThe majority of persons born before 1957 are likely to have been infected \nnaturally between birth and 1977, the year that mumps vaccination was \nrecommended for routine use, and may be presumed immune, even if they \nhave not had clinically recognizable mumps disease. (This might vary \ndepending on current state or local requirements.) For unvaccinated personnel",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_124",
        "document_id": "rr6007",
        "text": "depending on current state or local requirements.) For unvaccinated personnel \nborn before 1957 who lack laboratory evidence of mumps immunity or \nlaboratory confirmation of disease, health-care facilities should consider \nvaccinating personnel with 2 doses of MMR vaccine at the appropriate interval; \nfor unvaccinated personnel born before 1957 who lack laboratory evidence \nof mumps immunity or laboratory confirmation of disease, health-care facilities \nshould recommend 2 doses of MMR vaccine during an outbreak of mumps.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n17\nare thrombocytopenia and encephalitis (211). Infection is \nasymptomatic in 25%\u201350% of cases (213). Clinical diagnosis \nof rubella is unreliable and should not be considered in",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_125",
        "document_id": "rr6007",
        "text": "of rubella is unreliable and should not be considered in \nassessing immune status. Many rash illnesses might mimic \nrubella infection and many rubella infections are unrecognized. \nThe only reliable evidence of previous rubella infection is the \npresence of serum rubella IgG antibody (211).\nOf primary concern are the effects that rubella can have \nwhen a pregnant woman becomes infected, especially during \nthe first trimester, which can result in miscarriages, stillbirths, \ntherapeutic abortions, and congenital rubella syndrome \n(CRS), a constellation of birth defects that often includes \nblindness, deafness, mental retardation, and congenital heart \ndefects (211,213). Postnatal rubella is transmitted through \ndirect or droplet contact from nasopharyngeal secretions. The",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_126",
        "document_id": "rr6007",
        "text": "direct or droplet contact from nasopharyngeal secretions. The \nincubation period ranges from 12 to 23 days (214,215). An \nill person is most contagious when the rash first appears, but \nthe period of maximal communicability extends from a few \ndays before to 7 days after rash onset (213). Rubella is less \ncontagious than measles.\nIn the prevaccine era, rubella was an endemic disease globally \nwith larger epidemics that occurred; in the United States, \nrubella epidemics occurred approximately every 7 years (211). \nDuring the 1964\u20131965 global rubella epidemic, an estimated \n12.5 million cases of rubella occurred in the United States, \nresulting in approximately 2,000 cases of encephalitis, 11,250 \nfetal deaths attributable to spontaneous or surgical abortions,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_127",
        "document_id": "rr6007",
        "text": "fetal deaths attributable to spontaneous or surgical abortions, \n2,100 infants who were stillborn or died soon after birth, and \n20,000 infants born with CRS. The economic impact of this \nepidemic in the United States alone was estimated at $1.5 \nbillion in 1965 dollars ($10 billion in 2010 dollars) (216).\nAfter the rubella vaccine was licensed in the United States in \n1969, reported rubella cases decreased from 57,686 in 1969 \nto 12,491 in 1976 (216), and CRS cases reported nationwide \ndecreased from 68 in 1970 to 23 in 1976 (217). Declines \nin rubella age-specific incidence occurred in all age groups, \nincluding adolescents and adults, but the greatest declines were \namong children aged <15 years (216). During 1977\u20131978, \na resurgence of rubella occurred, primarily among older",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_128",
        "document_id": "rr6007",
        "text": "a resurgence of rubella occurred, primarily among older \nadolescents and young adults, because the initial vaccination \nstrategy targeted children (218). During this resurgence, 62% \nof reported rubella cases occurred among persons aged >15 \nyears compared with 23% of cases during 1966\u20131968 (135). \nAs a result of the change in the epidemiologic profile of rubella, \nin 1977, ACIP modified its recommendations to include the \nvaccination of susceptible postpubertal girls and women. In \n1989, a second MMR vaccination dose was recommended in \nresponse to large measles outbreaks nationwide (179). During \n2001\u20132004, the annual numbers of rubella and CRS cases \nwere extremely low, with 23 reported rubella cases in 2001, \na total of 18 in 2002, a total of 7 in 2003, and a total of 9 in",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_129",
        "document_id": "rr6007",
        "text": "a total of 18 in 2002, a total of 7 in 2003, and a total of 9 in \n2004 (219).\nRubella was declared eliminated from the United States in \n2004 (219,220). During 2005\u20132009, a total of 54 cases of \nrubella were reported; the majority of the cases occurred among \npersons aged >20 years. Of the reported cases, 23 (43%) were \nimport-associated; only two outbreaks of rubella were reported \nduring this time, and both involved only three cases (CDC, \nunpublished data, 2009). Since 2005, only four cases of CRS \nhave been reported, with two cases reported in 2009; three \n(75%) cases were acquired internationally, and the other had \nan unknown source (CDC, unpublished data, 2009). Rubella \nimportations are expected to continue in the immediate future.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_130",
        "document_id": "rr6007",
        "text": "importations are expected to continue in the immediate future.\nAs of September 2011, only three states (i.e., New York, \nOklahoma, and Rhode Island) had laws mandating that all \nhospital personnel have proof of rubella immunity and did \nnot allow for religious or philosophical exemptions (147). \nAdditional states had requirements for specific types of facilities \nor for certain employees within those facilities, but they did \nnot have universal laws mandating proof of rubella immunity \nfor all hospital personnel (147).\nMMR vaccine coverage in the United States is high; in \n2010, an estimated 91.5% of children aged 19\u201335 months \nhad received 1 dose of MMR vaccine (21); during 2009\u20132010, \na total of 94.8% of kindergarteners had evidence of 2 doses",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_131",
        "document_id": "rr6007",
        "text": "a total of 94.8% of kindergarteners had evidence of 2 doses \n(148); and in 2010, a total of 90.5% of adolescents had \nevidence of 2 doses (22). Nationally representative data on \nMMR vaccine coverage of U.S. HCP are not available.\nRubella Transmission and the Costs of Mitigating \nRubella Exposures in Health-Care Settings\nNo documented transmission of rubella to HCP or other \nhospital staff or patients in U.S. health-care facilities has occurred \nsince elimination was declared. However, in the decades before \nelimination, rubella transmission was documented in at least \n10 U.S. medical settings (221\u2013231) and led to outbreaks \nwith serious consequences, including pregnancy terminations, \ndisruption of hospital routine, absenteeism from work, expensive",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_132",
        "document_id": "rr6007",
        "text": "disruption of hospital routine, absenteeism from work, expensive \ncontainment measures, negative publicity, and the threat of \nlitigation (232). In these outbreaks, transmission occurred \nfrom HCP to susceptible coworkers and patients, as well as \nfrom patients to HCP and other patients. No data are available \non whether HCP are at increased risk for acquiring rubella \ncompared with other professions.\nRecommendations and Reports\n18\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nVaccine Effectiveness, Duration of Immunity and \nSeroprevalence Studies, and Vaccine Safety\nVaccine Effectiveness\nVaccine effectiveness of the RA 27/3 rubella vaccine against \nclinical rubella is 95% (85%\u201399% CI) and >99% for clinical \nlaboratory confirmed rubella (211,233). Antibody responses",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_133",
        "document_id": "rr6007",
        "text": "laboratory confirmed rubella (211,233). Antibody responses \nto rubella as part of MMR vaccine are equal (i.e., >99%) to \nthose seen after the single-antigen RA 27/3 rubella vaccine \n(211,234).\nDuration of Immunity and Seroprevalence Studies\nIn clinical trials, 97%\u201399% of susceptible persons who \nreceived a single dose of the RA 27/3 rubella vaccine when \nthey were aged \u226512 months developed antibody (211,235,236). \nTwo studies have demonstrated that vaccine-induced rubella \nantibodies might wane after 12\u201315 years (237,238); however, \nrubella surveillance data do not indicate that rubella and CRS \nare increasing among vaccinated persons.\nNational seroprevalence for rubella antibodies among \npersons aged 6\u201349 years during 1999\u20132004 was 91% (239).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_134",
        "document_id": "rr6007",
        "text": "persons aged 6\u201349 years during 1999\u20132004 was 91% (239). \nDuring 1986\u20131990, serologic surveys in one hospital indicated \nthat 5% of HCP (including persons born in 1957 or earlier) \ndid not have detectable rubella antibody (240). Earlier studies \nindicated that up to 14%\u201319% of U.S. hospital personnel, \nincluding young women of childbearing age, lacked detectable \nrubella antibody (225,241,242). In a recent study on rubella \nseroprevalence among 477 newly hired HCP at a hospital \nin North Carolina who were born before 1957, and thus \nconsidered immune by age, who could not provide written \nevidence of immunity to rubella, serologic testing revealed that \n14 (3.1%) lacked detectable levels of antibody to rubella (157).\nBecause of the potential for contact with pregnant women in",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_135",
        "document_id": "rr6007",
        "text": "Because of the potential for contact with pregnant women in \nany type of health-care facility, all HCP should have documented \npresumptive evidence of immunity to rubella. History of disease \nis not considered adequate evidence of immunity.\nVaccine Safety \nRubella vaccine is administered in combination with the \nmeasles and mumps components as the MMR vaccine in \nthe United States. Monovalent rubella vaccine has been used \nrarely in the United States in the past 2 decades and is no \nlonger available. After decades of use, evidence demonstrates \nthat MMR vaccine has an excellent safety profile. The most \ncommon adverse reactions to the rubella component of the \nMMR vaccine are transient rashes, which usually appear 7\u201310 \ndays after vaccination in approximately 5% of vaccinated",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_136",
        "document_id": "rr6007",
        "text": "days after vaccination in approximately 5% of vaccinated \npersons, or transient lymphadenopathy, fever, sore throat, and \nheadache (135,211).\nThe majority of documented adverse events occur in \nchildren. In rare circumstances, MMR vaccination of adults \nhas been associated with the following adverse events: \nanaphylaxis (approximately 1.0\u20133.5 occurrences per million \ndoses administered) (134), thrombocytopenia from the measles \ncomponent or rubella component (rate: three to four cases \nfor every 100,000 doses) (134), and acute arthritis from the \nrubella component (arthralgia develops among approximately \n25% of rubella-susceptible postpubertal females after MMR \nvaccination, and approximately 10% have acute arthritis-\nlike signs and symptoms from the rubella component of the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_137",
        "document_id": "rr6007",
        "text": "like signs and symptoms from the rubella component of the \nvaccine) (135). When joint symptoms occur, they generally \npersist for 1 day\u20133 weeks and rarely recur (135). Chronic joint \nsymptoms attributable to the rubella component of the MMR \nvaccine are very rarely reported, if they occur at all.\nAs a result of the theoretic risk to the fetus, women should \nbe counseled to avoid becoming pregnant for 28 days after \nreceipt of a rubella-containing vaccine (243). However, receipt \nof rubella-containing vaccine during pregnancy should not \nbe a reason to consider termination of pregnancy; data from \n18 years of following to term 321 known rubella-susceptible \nwomen who were vaccinated within 3 months before or 3 \nmonths after conception indicated that none of the 324",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_138",
        "document_id": "rr6007",
        "text": "months after conception indicated that none of the 324 \ninfants born to these mothers had malformations compatible \nwith congenital rubella syndrome, but five had evidence of \nsubclinical rubella infection (244). The estimated risk for \nserious malformations to fetuses attributable to the mother \nreceiving RA 27/3 vaccine is considered to range from zero \nto 1.6% (135,244).\nEvidence does not support a link between MMR vaccination \nand any of the following: hearing loss, retinopathy, optic \nneuritis, Guillain-Barr\u00e9 Syndrome, type 1 diabetes, Crohn\u2019s \ndisease, or autism (135,163\u2013169).\nA woman can excrete the rubella vaccine virus in breast milk \nand transmit the virus to her infant, but the infection remains \nasymptomatic (135). Otherwise, persons who receive MMR",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_139",
        "document_id": "rr6007",
        "text": "asymptomatic (135). Otherwise, persons who receive MMR \nor its component vaccines do not transmit measles, rubella, \nor mumps vaccine viruses (135). No transmission of MMR \nvaccine virus in a health-care setting has been documented.\nRecommendations\nVaccination\nAll persons who work in health-care facilities should have \npresumptive evidence of immunity to rubella. Adequate rubella \nvaccination for HCP consists of 1 dose of MMR vaccine. \nHowever, because of the 2-dose vaccination requirements for \nmeasles and mumps, the use of the combined MMR vaccine \nwill result in the majority of HCP receiving 2 doses of rubella-\ncontaining vaccine, which should provide an additional safeguard \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n19",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_140",
        "document_id": "rr6007",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n19\nagainst primary rubella vaccine failure. Recently vaccinated HCP \ndo not require any restriction in their work activities.\nPresumptive evidence of immunity to rubella for persons \nwho work in health-care facilities includes any of the following: \n\u2022 written documentation of vaccination with 1 dose of live \nrubella or MMR vaccine,\n\u2022 laboratory evidence of immunity,\u00b6\u00b6\n\u2022 laboratory confirmation of rubella infection or disease, or\n\u2022 birth before 1957*** (except women of childbearing \npotential who could become pregnant, although pregnancy \nin this age group would be exceedingly rare\u2020\u2020\u2020).\nPrevaccination Testing \nFor HCP who do not have adequate presumptive evidence",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_141",
        "document_id": "rr6007",
        "text": "Prevaccination Testing \nFor HCP who do not have adequate presumptive evidence \nof rubella immunity, prevaccination antibody screening \nbefore MMR vaccination is not necessary unless the medical \nfacility considers it cost effective (135). For HCP who have \n1 documented dose of MMR vaccine or other acceptable \nevidence of immunity to rubella, serologic testing for immunity \nis not recommended. In the event that a health-care provider \nwho has at least 1 documented dose of rubella-containing \nvaccine is tested serologically and determined to have negative \nor equivocal rubella titer results, receipt of an additional dose of \nMMR vaccine for prevention of rubella is not recommended. \nSuch persons should be considered immune to rubella.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_142",
        "document_id": "rr6007",
        "text": "Such persons should be considered immune to rubella. \nHowever, if the provider requires a second dose of measles \nor mumps vaccine, then a second dose of MMR should be \nadministered. Documented age-appropriate vaccination \nsupersedes the results of subsequent serologic testing. Likewise, \nduring outbreaks of rubella, serologic screening before \nvaccination is not recommended because rapid vaccination is \nnecessary to halt disease transmission.\nControlling Rubella Outbreaks\nTo prevent transmission of rubella in health-care settings, \npatients suspected to have rubella should be placed in private \nrooms. In addition to standard precautions, droplet precautions \nshould be followed until 7 days after onset of symptoms. Room \ndoors can remain open, and special ventilation is not required.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_143",
        "document_id": "rr6007",
        "text": "doors can remain open, and special ventilation is not required.\nAny exposed HCP who do not have adequate presumptive \nevidence of rubella immunity should be excluded from duty \nbeginning 7 days after exposure to rubella and continuing \nthrough either 1) 23 days after the most recent exposure or \n2) 7 days after rash appears if the provider develops rubella \n(213\u2013215). Exposed HCP who do not have adequate \npresumptive evidence of immunity who are vaccinated \npostexposure should be excluded from duty for 23 days after \nthe most recent exposure to rubella because no evidence exists \nthat postexposure vaccination is effective in preventing rubella \ninfection (244).\nNeither rubella-containing vaccine (244) nor immune \nglobulin (IG) (211,244) is effective for postexposure",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_144",
        "document_id": "rr6007",
        "text": "globulin (IG) (211,244) is effective for postexposure \nprophylaxis of rubella. Although intramuscular administration \nof 20 mL of immune globulin within 72 hours of rubella \nexposure might reduce the risk for rubella, it will not eliminate \nthe risk (135,245); infants with congenital rubella have been \nborn to women who received IG shortly after exposure (213). \nIn addition, administration of IG after exposure to rubella \nmight modify or suppress symptoms and create an unwarranted \nsense of security with respect to transmission.\nIf exposure to rubella does not cause infection, postexposure \nvaccination with MMR vaccine should induce protection \nagainst subsequent infection of rubella, as well as measles \nand mumps. If the exposure results in infection, no evidence",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_145",
        "document_id": "rr6007",
        "text": "and mumps. If the exposure results in infection, no evidence \nindicates that administration of MMR vaccine during the \npresymptomatic or prodromal stage of illness increases the risk \nfor vaccine-associated adverse events (213).\nPertussis\nBackground\nEpidemiology and Risk Factors \nPertussis is a highly contagious bacterial infection. Secondary \nattack rates among susceptible household contacts exceed \n80% (246,247). Transmission occurs by direct contact with \nrespiratory secretions or large aerosolized droplets from the \nrespiratory tract of infected persons. The incubation period is \ngenerally 7\u201310 days but can be as long as 21 days. The period \nof communicability starts with the onset of the catarrhal stage \nand extends into the paroxysmal stage. Symptoms of early",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_146",
        "document_id": "rr6007",
        "text": "and extends into the paroxysmal stage. Symptoms of early \npertussis (catarrhal phase) are indistinguishable from other \nupper respiratory infections.\nVaccinated adolescents and adults, whose immunity from \nchildhood vaccinations wanes 5\u201310 years after the most recent \ndose of vaccine (usually administered at age 4\u20136 years), are an \n\t \u00b6\u00b6\tRubella immunoglobulin (IgG) in the serum; equivocal results should be \nconsidered negative.\n\t***\tDepending on current state or local requirements, for unvaccinated personnel \nborn before 1957 who lack laboratory evidence of rubella immunity or \nlaboratory confirmation of infection or disease, health-care facilities should \nconsider vaccinating personnel with one dose of MMR vaccine; for",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_147",
        "document_id": "rr6007",
        "text": "consider vaccinating personnel with one dose of MMR vaccine; for \nunvaccinated personnel born before 1957 who lack laboratory evidence of \nrubella immunity or laboratory confirmation of infection or disease, health-\ncare facilities should recommend 1 dose of MMR vaccine during an outbreak \nof rubella.\n\t\u2020\u2020\u2020\tBecause rubella can occur in some persons born before 1957 and because \ncongenital rubella and congenital rubella syndrome can occur in the offspring \nof women infected with rubella virus during pregnancy, birth before 1957 \nis not acceptable evidence of rubella immunity for women who could become \npregnant.\nRecommendations and Reports\n20\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nimportant source of pertussis infection for susceptible infants.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_148",
        "document_id": "rr6007",
        "text": "important source of pertussis infection for susceptible infants. \nInfants too young to be vaccinated are at greatest risk for severe \npertussis, including hospitalization and death. The disease \ncan be transmitted from adults to close contacts, especially \nunvaccinated children.\nVaccination coverage among infants and children for \ndiphtheria and tetanus toxoids and acellular pertussis (DTaP) \nvaccine remains high. In 2010, coverage for children aged \n19\u201335 months who have received \u22654 doses of DTaP/diphtheria \nand tetanus toxoids and pertussis vaccine (DTP)/diphtheria \nand tetanus toxoids vaccine (DT) was 84% (21). Among \nchildren entering kindergarten for the 2009\u20132010 school \nyear, DTaP coverage was 93% (148). Vaccination coverage",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_149",
        "document_id": "rr6007",
        "text": "year, DTaP coverage was 93% (148). Vaccination coverage \nfor tetanus toxoid, reduced diphtheria toxoid and acellular \npertussis (Tdap) vaccine was 68.7% among adolescents in 2010 \nand <7% among adults in 2009 (22,248). Tdap vaccination \ncoverage among HCP was 17.0% in 2009 (248).\nDisease in Health-Care Settings and Impact on Health-\nCare Personnel and Patients\nIn hospital settings, transmission of pertussis has occurred \nfrom hospital visitors to patients, from HCP to patients, and \nfrom patients to HCP (249\u2013252). Although of limited size \n(range: 2\u201317 patients and 5\u201313 staff), documented outbreaks \nwere costly and disruptive. In each outbreak, HCP were \nevaluated for cough illness and required diagnostic testing, \nprophylactic antibiotics, and exclusion from work.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_150",
        "document_id": "rr6007",
        "text": "prophylactic antibiotics, and exclusion from work.\nDuring outbreaks that occur in hospitals, the risk for \ncontracting pertussis among patients or staff is often difficult \nto quantify because exposure is not well defined. Serologic \nstudies conducted among hospital staff indicate that exposure \nto pertussis is much more frequent than suggested by attack \nrates of clinical disease (246,249\u2013254). In one outbreak, \nseroprevalence of pertussis agglutinating antibodies among \nHCP correlated with the degree of patient contact and \nwas highest among pediatric house staff (82%) and ward \nnurses (71%) and lowest among nurses with administrative \nresponsibilities (35%) (251).\nA model to estimate the cost of vaccinating HCP and the net \nreturn from preventing nosocomial pertussis was constructed",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_151",
        "document_id": "rr6007",
        "text": "return from preventing nosocomial pertussis was constructed \nusing probabilistic methods and a hypothetical cohort of \n1,000 HCP with direct patient contact followed for 10 years \n(255). Baseline assumptions, determined from data in the \nliterature, included incidence of pertussis in HCP, ratio of \nidentified exposures per HCP case, symptomatic percentage of \nseroconfirmed pertussis infections in HCP, cost of infection-\ncontrol measures per exposed person, vaccine efficacy, vaccine \ncoverage, employment turnover rate, adverse events, and cost \nof vaccine (255). In a 10-year period, the cost of infection \ncontrol would be $388,000 without Tdap vaccination of \nHCP compared with $69,000 with such a program (255). \nIntroduction of a vaccination program would result in a net",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_152",
        "document_id": "rr6007",
        "text": "Introduction of a vaccination program would result in a net \nsavings as high as $535,000 and a benefit-cost ratio of 2.38 \n(i.e., for every dollar spent on the vaccination program, the \nhospital would save $2.38 on control measures) (255).\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nA prelicensure immunogenicity and safety study in \nadolescents and adults of a vaccine containing acellular \npertussis estimated vaccine efficacy to be 92% (256). Recent \npostlicensure studies of Tdap demonstrate vaccine effectiveness \nat 78% and 66% (257,258). Duration of immunity from \nvaccination has yet to be evaluated. Data from pre- and \npostlicensure studies support the safety of Tdap in adolescents \nand adults (259\u2013263).\nSince the 2005 Tdap recommendations for HCP, one study",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_153",
        "document_id": "rr6007",
        "text": "and adults (259\u2013263).\nSince the 2005 Tdap recommendations for HCP, one study \ntried to determine if postexposure prophylaxis following pertussis \nexposure was necessary for Tdap-vaccinated HCP (264). \nDuring the study period, 116 exposures occurred among 94 \nHCP. Pertussis infection occurred in 2% of those who received \npostexposure prophylaxis compared with 10% of those who did \nnot, suggesting a possible benefit of postexposure prophylaxis \namong Tdap-vaccinated HCP (264). Because Tdap coverage is \nsuboptimal among HCP, and the duration of protection afforded \nby Tdap is unknown, vaccination status does not change the \napproach to evaluate the need for postexposure prophylaxis in \nexposed HCP. Postexposure prophylaxis is necessary for HCP in",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_154",
        "document_id": "rr6007",
        "text": "exposed HCP. Postexposure prophylaxis is necessary for HCP in \ncontact with persons at risk for severe disease. Other HCP either \nshould receive postexposure prophylaxis or be monitored for 21 \ndays after pertussis exposure and treated at the onset of signs and \nsymptoms of pertussis. Recommended postexposure prophylaxis \nantibiotics for HCP exposed to pertussis include azithromycin, \nclarithroymycin, or erythromycin. HCP are not at greater risk \nfor diphtheria or tetanus than the general population.\nRecommendations\nVaccination\nRegardless of age, HCP should receive a single dose of Tdap \nas soon as feasible if they have not previously received Tdap and \nregardless of the time since their most recent Td vaccination. \nVaccinating HCP with Tdap will protect them against pertussis",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_155",
        "document_id": "rr6007",
        "text": "Vaccinating HCP with Tdap will protect them against pertussis \nand is expected to reduce transmission to patients, other HCP, \nhousehold members, and persons in the community. Tdap \nis not licensed for multiple administrations; therefore, after \nreceipt of Tdap, HCP should receive Td for future booster \nvaccination against tetanus and diphtheria. Hospitals and \nambulatory-care facilities should provide Tdap for HCP and \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n21\nuse approaches that maximize vaccination rates (e.g., education \nabout the benefits of vaccination, convenient access, and the \nprovision of Tdap at no charge).\nPrevaccination Testing\nPrevaccination serologic testing is not recommended.\nDemonstrating Immunity",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_156",
        "document_id": "rr6007",
        "text": "Prevaccination Testing\nPrevaccination serologic testing is not recommended.\nDemonstrating Immunity\nImmunity cannot be demonstrated through serologic \ntesting because serologic correlates of protection are not well \nestablished.\nControlling Pertussis Outbreaks in Health-Care \nSettings\nPrevention of pertussis transmission in health-care settings \ninvolves diagnosis and early treatment of clinical cases, droplet \nisolation of infectious patients who are hospitalized, exclusion \nfrom work of HCP who are infectious, and postexposure \nprophylaxis. Early diagnosis of pertussis, before secondary \ntransmission occurs, is difficult because the disease is highly \ncommunicable during the catarrhal stage, when symptoms are \nstill nonspecific. Pertussis should be considered in the differential",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_157",
        "document_id": "rr6007",
        "text": "still nonspecific. Pertussis should be considered in the differential \ndiagnoses for any patient with an acute cough illness with severe \nor prolonged paroxysmal cough, particularly if characterized \nby posttussive vomiting, whoop, or apnea. Nasopharyngeal \nspecimens should be taken, if possible, from the posterior \nnasopharynx with a calcium alginate or Dacron swab for cultures \nand/or polymerase chain reaction (PCR) assay.\nHealth-care facilities should maximize efforts to prevent \ntransmission of Bordetella pertussis. Precautions to prevent \nrespiratory droplet transmission or spread by close or direct \ncontact should be employed in the care of patients admitted \nto hospital with suspected or confirmed pertussis (265). \nThese precautions should remain in effect until patients are",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_158",
        "document_id": "rr6007",
        "text": "These precautions should remain in effect until patients are \nimproved clinically and have completed at least 5 days of \nappropriate antimicrobial therapy. HCP in whom symptoms \n(i.e., unexplained rhinitis or acute cough) develop after known \npertussis exposure might be at risk for transmitting pertussis \nand should be excluded from work until 5 days after the start \nof appropriate therapy (3).\nData on the need for postexposure prophylaxis in Tdap-\nvaccinated HCP are inconclusive (264). Certain vaccinated \nHCP are still at risk for B. pertussis. Tdap might not preclude \nthe need for postexposure prophylaxis. Postexposure \nantimicrobial prophylaxis is recommended for all HCP who \nhave unprotected exposure to pertussis and are likely to expose",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_159",
        "document_id": "rr6007",
        "text": "have unprotected exposure to pertussis and are likely to expose \na patient at risk for severe pertussis (e.g., hospitalized neonates \nand pregnant women). Other HCP should either receive \npostexposure antimicrobial prophylaxis or be monitored daily \nfor 21 days after pertussis exposure and treated at the onset of \nsigns and symptoms of pertussis.\nVaricella\nBackground\nEpidemiology and Risk Factors\nVaricella is a highly infectious disease caused by primary \ninfection with varicella-zoster virus (VZV). VZV is transmitted \nfrom person to person by direct contact, inhalation of aerosols \nfrom vesicular fluid of skin lesions of varicella or herpes zoster \n(HZ), a localized, generally painful vesicular rash commonly \ncalled shingles, or infected respiratory tract secretions that also",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_160",
        "document_id": "rr6007",
        "text": "called shingles, or infected respiratory tract secretions that also \nmight be aerosolized (266). The average incubation period is \n14\u201316 days after exposure to rash (range: 10\u201321 days). Infected \npersons are contagious an estimated 1\u20132 days before rash \nonset until all lesions are crusted, typically 4\u20137 days after rash \nonset (266). Varicella secondary attack rates can reach 90% \namong susceptible contacts. Typically, primary infection with \nVZV results in lifetime immunity. VZV remains dormant in \nsensory-nerve ganglia and can reactivate at a later time, causing \nHZ. Before the U.S. childhood varicella vaccination program \nbegan in 1995, approximately 90% of varicella disease occurred \namong children aged <15 years (266). During 1997\u20132009,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_161",
        "document_id": "rr6007",
        "text": "among children aged <15 years (266). During 1997\u20132009, \nnational varicella vaccine coverage among children aged 19\u201335 \nmonths increased from 27% to 90%, leading to dramatic \ndeclines of >85% in varicella incidence, hospitalizations, and \ndeaths (267\u2013269). The decline in disease incidence was greatest \namong children for whom vaccination was recommended; \nhowever, declines occurred in every age group including infants \ntoo young to be vaccinated and adults, indicating reduced \ncommunitywide transmission of VZV.\nCurrent incidence of varicella among adults is low \n(<0.1/1,000 population), and adult cases represent <10% of \nall reported varicella cases (270). National seroprevalence data \nfrom 1999\u20132004 demonstrated that, in the early vaccine era,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_162",
        "document_id": "rr6007",
        "text": "from 1999\u20132004 demonstrated that, in the early vaccine era, \nadults continued to have high immunity to varicella (271). In \nthis study, 98% of persons aged 20\u201349 years had VZV-specific \nIgG antibodies. However, with declining likelihood of exposure \nto VZV, children and adolescents who did not receive 2 doses \nof varicella vaccine could remain susceptible to VZV infection \nas they age into adulthood, when varicella can be more severe.\nThe clinical presentation of varicella has changed since the \nimplementation of the varicella vaccination program, with \nmore than half of varicella cases reported in 2008 occurring \namong persons who were vaccinated previously, the majority \nof them children. Varicella disease in vaccinated children",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_163",
        "document_id": "rr6007",
        "text": "of them children. Varicella disease in vaccinated children \n(breakthrough varicella) usually has a modified or atypical \npresentation; the rash is typically mild, with <50 lesions that are \nRecommendations and Reports\n22\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nmore likely to be predominantly maculopapular than vesicular \n(266). Fever is less common, and the duration of illness is \nshorter. Nevertheless, breakthrough varicella is infectious. One \nstudy indicated that vaccinated children with varicella with \n<50 lesions were only one third as infectious as unvaccinated \nchildren whereas those with \u226550 lesions were as infectious as \nunvaccinated children (272). Because the majority of adults \nare immune and few need vaccination, fewer breakthrough",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_164",
        "document_id": "rr6007",
        "text": "are immune and few need vaccination, fewer breakthrough \ncases have been reported among adults than among children, \nand breakthrough varicella in adults has tended to be milder \nthan varicella in unvaccinated adults (273,274).\nThe epidemiology of varicella in tropical and subtropical \nregions differs from that in the United States. In these regions, \na higher proportion of VZV infections are acquired later in life. \nPersons emigrating from these regions might be more likely \nto be susceptible to varicella compared to U.S.-born persons \nand, therefore, are at a higher risk for developing varicella if \nunvaccinated and exposed (275,276).\nDisease in Health-Care Settings and Impact on Health-\nCare Personnel and Patients\nAlthough relatively rare in the United States since",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_165",
        "document_id": "rr6007",
        "text": "Care Personnel and Patients\nAlthough relatively rare in the United States since \nintroduction of varicella vaccine, nosocomial transmission \nof VZV is well recognized and can be life-threatening to \ncertain patients (277\u2013289). In addition to hospital settings, \nnosocomial VZV transmission has been reported in long-\nterm\u2013care facilities and a hospital-associated residential facility \n(290,291). Sources of nosocomial exposure that have resulted \nin transmission include patients, HCP, and visitors with either \nvaricella or HZ. Both localized and disseminated HZ in \nimmunocompetent as well as immunocompromised patients \nhave been identified as sources of nosocomial transmission of \nVZV. Localized HZ has been demonstrated to be much less",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_166",
        "document_id": "rr6007",
        "text": "VZV. Localized HZ has been demonstrated to be much less \ninfectious than varicella; disseminated HZ is considered to be as \ninfectious as varicella (266). Nosocomial transmission has been \nattributed to delays in the diagnosis or reporting of varicella or \nHZ and in failures to implement control measures promptly. In \nhospitals and other health-care settings, airborne transmission \nof VZV from patients with either varicella or HZ has resulted in \nvaricella in HCP and patients who had no direct contact with \nthe index case-patient (284\u2013288,291). Although all susceptible \npatients in health-care settings are at risk for severe varicella \ndisease with complications, certain patients without evidence \nof immunity are at increased risk: pregnant women, premature",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_167",
        "document_id": "rr6007",
        "text": "of immunity are at increased risk: pregnant women, premature \ninfants born to susceptible mothers, infants born at <28 weeks\u2019 \ngestation or who weigh \u22641,000 grams regardless of maternal \nimmune status, and immunocompromised persons of all ages \n(including persons who are undergoing immunosuppressive \ntherapy, have malignant disease, or are immunodeficient).\nVZV exposures among patients and HCP can be disruptive \nto patient care, time-consuming, and costly even when they do \nnot result in VZV transmission (281,282,292). Studies of VZV \nexposure in health-care settings have documented that a single \nprovider with unrecognized varicella can result in the exposure \nof >30 patients and >30 employees (292). Identification \nof susceptible patients and staff, medical management of",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_168",
        "document_id": "rr6007",
        "text": "of susceptible patients and staff, medical management of \nsusceptible exposed patients at risk for complications of \nvaricella, and furloughing of susceptible exposed HCP are \ntime-consuming and costly (281,282).\nWith the overall reduction in varicella disease attributable to \nthe success of the vaccination program, the risk for exposure \nto VZV from varicella cases in health-care settings is likely \ndeclining. In addition, an increasing proportion of varicella \ncases occur in vaccinated persons who are less contagious. \nDiagnosis of varicella has become increasingly challenging \nas a growing proportion of cases occur in vaccinated persons \nin whom disease is mild, and HCP encounter patients with \nvaricella less frequently. Although not currently routinely",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_169",
        "document_id": "rr6007",
        "text": "varicella less frequently. Although not currently routinely \nrecommended for the diagnosis and management of varicella, \nlaboratory testing of suspected varicella cases is likely to become \nincreasingly useful in health-care settings, especially as the \npositive predictive value of clinical diagnosis declines.\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nVaccine Effectiveness\nFormal studies to evaluate vaccine efficacy or effectiveness \nhave not been performed among adults. Studies of varicella \nvaccine effectiveness performed among children indicated good \nperformance of 1 dose for prevention of all varicella (80%\u2013\n85%) and >95% effectiveness for prevention of moderate \nand severe disease (266,293). Studies have indicated that a",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_170",
        "document_id": "rr6007",
        "text": "and severe disease (266,293). Studies have indicated that a \nsecond dose among children produces an improved humoral \nand cellular immune response that correlates with improved \nprotection against disease (266,294).\nVaricella vaccine effectiveness is expected to be lower in \nadults than in children. Adolescents and adults require 2 \ndoses to achieve seroconversion rates similar to those seen in \nchildren after 1 dose (266). A study of adults who received 2 \ndoses of varicella vaccine 4 or 8 weeks apart and were exposed \nsubsequently to varicella in the household estimated an 80% \nreduction in the expected number of cases (295).\nDuration of Immunity\nSerologic correlates of protection against varicella using \ncommercially available assays have not been established for",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_171",
        "document_id": "rr6007",
        "text": "commercially available assays have not been established for \nadults (266). In clinical studies, detectable antibody levels \nhave persisted for at least 5 years in 97% of adolescents and \nadults who were administered 2 doses of varicella vaccine \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n23\n4\u20138 weeks apart, but boosts in antibody levels were observed \nfollowing exposures to varicella, which could account for \nthe long-term persistence of antibodies after vaccination in \nthese studies (295). Studies have demonstrated that whereas \n25%\u201331% of adult vaccine recipients who seroconverted lost \ndetectable antibodies 1\u201311 years after vaccination (273,296), \nvaccine-induced VZV-specific T-cell proliferation (marker for",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_172",
        "document_id": "rr6007",
        "text": "vaccine-induced VZV-specific T-cell proliferation (marker for \ncell-mediated immunity [CMI]) was maintained in 94% of \nadults 1 and 5 years postvaccination (297). Disease was mild \nin vaccinated persons who developed varicella after exposure \nto VZV, even among vaccinees who did not seroconvert or \nwho lost detectable antibody (273,274). Severity of illness \nand attack rates among vaccinated adults did not increase \nover time. These studies suggest that VZV-specific CMI \naffords protection to vaccinated adults, even in the absence of \ndetectable antibody response.\nVaccine Safety\nThe varicella vaccine has an excellent safety profile. In clinical \ntrials, the most common adverse events among adolescents and \nadults were injection-site complaints (24.4% after the first dose",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_173",
        "document_id": "rr6007",
        "text": "adults were injection-site complaints (24.4% after the first dose \nand 32.5% after the second dose) (266,295). Varicella-like rash \nat the injection site occurred in 3% of vaccine recipients after \nthe first dose and in 1% after the second. A nonlocalized rash \noccurred in 5.5% of vaccine recipients after the first dose and \nin 0.9% after the second, with a median number of lesions \nof five, at a peak of 7\u201321 and 0\u201323 days postvaccination, \nrespectively (295). Data on serious adverse events among adults \nafter varicella vaccination are limited, but the proportion of \nserious adverse events among all adverse events reported to the \nVaccine Adverse Events Reporting System during 1995\u20132005 \nwas low (5%) among both children and adults (298). Serious",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_174",
        "document_id": "rr6007",
        "text": "was low (5%) among both children and adults (298). Serious \nadverse events reported among children included pneumonia, \nhepatitis, HZ (some hospitalized), meningitis with HZ, \nataxia, encephalitis, thrombocytopenic purpura. Not all \nadverse events reported after varicella vaccination have been \nlaboratory confirmed to be attributable to the vaccine strain \nVZV (266,298).\nRisk for transmission of vaccine virus was assessed in placebo \nrecipients who were siblings of vaccinated children and among \nhealthy siblings of vaccinated leukemic children (266). The \nfindings suggest that transmission of varicella vaccine virus \nfrom healthy persons to susceptible contacts is very rare. The \nrisk might be increased in vaccinees in whom a varicella-like",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_175",
        "document_id": "rr6007",
        "text": "risk might be increased in vaccinees in whom a varicella-like \nrash develops after vaccination. However, this risk is also \nlow. The benefits of vaccinating HCP without evidence of \nimmunity outweigh this extremely low potential risk. Since \nimplementation of the varicella vaccine program, transmission \nof vaccine virus has been documented from eight persons \n(all of whom had a rash after vaccination) resulting in nine \nsecondary infections among household and long-term\u2013care \nfacility contacts (299). No transmission has been documented \nfrom vaccinated HCP.\nRecommendations\nVaccination\nHealth-care institutions should ensure that all HCP have \nevidence of immunity to varicella. This information should \nbe documented and readily available at the work location.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_176",
        "document_id": "rr6007",
        "text": "be documented and readily available at the work location. \nHCP without evidence of immunity to varicella should receive \n2 doses of varicella vaccine administered 4\u20138 weeks apart. \nIf >8 weeks elapse after the first dose, the second dose may \nbe administered without restarting the schedule. Recently \nvaccinated HCP do not require any restriction in their work \nactivities; however, HCP who develop a vaccine-related rash \nafter vaccination should avoid contact with persons without \nevidence of immunity to varicella who are at risk for severe \ndisease and complications until all lesions resolve (i.e., are \ncrusted over) or, if they develop lesions that do not crust \n(macules and papules only), until no new lesions appear within \na 24-hour period.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_177",
        "document_id": "rr6007",
        "text": "(macules and papules only), until no new lesions appear within \na 24-hour period.\nEvidence of immunity for HCP includes any of the following \n(266):\n\u2022 written documentation of vaccination with 2 doses of \nvaricella vaccine,\n\u2022 laboratory evidence of immunity\u00a7\u00a7\u00a7 or laboratory \nconfirmation of disease,\n\u2022 diagnosis or verification of a history of varicella disease by \na health-care provider,\u00b6\u00b6\u00b6 or \n\u2022 diagnosis or verification of a history of HZ by a health-care \nprovider.\nIn health-care settings, serologic screening before vaccination \nof personnel without evidence of immunity is likely to be cost \neffective. Key factors determining cost-effectiveness include \nsensitivity and specificity of serologic tests, the nosocomial \ntransmission rate, seroprevalence of VZV antibody in the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_178",
        "document_id": "rr6007",
        "text": "transmission rate, seroprevalence of VZV antibody in the \npersonnel population, and policies for managing vaccine \nrecipients developing postvaccination rash or who are \n\t\u00a7\u00a7\u00a7\tCommercial assays can be used to assess disease-induced immunity, but they \noften lack sensitivity to detect vaccine-induced immunity (i.e., they might \nyield false-negative results).\n\t\u00b6\u00b6\u00b6\tVerification of history or diagnosis of typical disease can be provided by any \nhealth-care provider (e.g., a school or occupational clinic nurse, nurse \npractitioner, physician assistant, or physician). For persons reporting a history \nof, or reporting with, atypical or mild cases, assessment by a physician or \ntheir designee is recommended, and one of the following should be sought:",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_179",
        "document_id": "rr6007",
        "text": "their designee is recommended, and one of the following should be sought: \n1) an epidemiologic link to a typical varicella case or to a laboratory-\nconfirmed case or 2) evidence of laboratory confirmation if it was performed \nat the time of acute disease. When such documentation is lacking, persons \nshould not be considered as having a valid history of disease because other \ndiseases might mimic mild atypical varicella.\nRecommendations and Reports\n24\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nexposed subsequently to VZV. Institutions may elect to test \nall unvaccinated HCP, regardless of disease history, because a \nsmall proportion of persons with a positive history of disease \nmight be susceptible. For the purpose of screening HCP, a",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_180",
        "document_id": "rr6007",
        "text": "might be susceptible. For the purpose of screening HCP, a \nless sensitive and more specific commercial ELISA should be \nconsidered. The latex agglutination test can produce false-\npositive results, and HCP who remained unvaccinated because \nof false test results subsequently contracted varicella (289).\nRoutine testing for varicella immunity after 2 doses of \nvaccine is not recommended. Available commercial assays are \nnot sensitive enough to detect antibody after vaccination in \nall instances. Sensitive tests that are not generally available \nhave indicated that 92%\u201399% of adults develop antibodies \nafter the second dose (266). Seroconversion does not always \nresult in full protection against disease and, given the role of \nCMI for providing long-term protection, absence of antibodies",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_181",
        "document_id": "rr6007",
        "text": "CMI for providing long-term protection, absence of antibodies \ndoes not necessarily mean susceptibility. Documented receipt \nof 2 doses of varicella vaccine supersedes results of subsequent \nserologic testing.\nHealth-care institutions should establish protocols and \nrecommendations for screening and vaccinating HCP and \nfor management of HCP after exposures in the work place. \nInstitutions also should consider precautions for HCP in \nwhom rash occurs after vaccination, although they should \nalso consider the possibility of wild-type disease in HCP with \nrecent exposure to varicella or HZ. \nA vaccine to prevent HZ is available and recommended \nfor all persons aged \u226560 years without contraindications to \nvaccination. HZ vaccine is not indicated for HCP for the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_182",
        "document_id": "rr6007",
        "text": "vaccination. HZ vaccine is not indicated for HCP for the \nprevention of nosocomial transmission, but HCP aged \u226560 \nyears may receive the vaccine on the basis of the general \nrecommendation for HZ vaccination, to reduce their \nindividual risk for HZ.\nVaricella Control Strategies \nAppropriate measures should be implemented to manage \ncases and control outbreaks (300).\nPatient Care\nOnly HCP with evidence of immunity to varicella should \ncare for patients who have confirmed or suspected varicella or \nHZ. Airborne precautions (i.e., negative air-flow rooms) and \ncontact precautions should be employed for all patients with \nvaricella or disseminated HZ and for immunocompromised \npatients with localized HZ until disseminated infection is ruled",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_183",
        "document_id": "rr6007",
        "text": "patients with localized HZ until disseminated infection is ruled \nout. These precautions should be kept in place until lesions are \ndry and crusted. If negative air-flow rooms are not available, \npatients should be isolated in closed rooms and should not \nhave contact with persons without evidence of immunity to \nvaricella. For immunocompetent persons with localized HZ, \nstandard precautions and complete covering of the lesions are \nrecommended.\nPostexposure Management of HCP and Patients\nExposure to VZV is defined as close contact with an \ninfectious person, such as close indoor contact (e.g., in the \nsame room) or face-to-face contact. Experts differ regarding the \nduration of contact; some suggest 5 minutes, and others up to 1",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_184",
        "document_id": "rr6007",
        "text": "duration of contact; some suggest 5 minutes, and others up to 1 \nhour; all agree that it does not include transitory contact (301).\nAll exposed, susceptible patients and HCP should be \nidentified using the criteria for evidence of immunity. An \nadditional criterion of evidence of immunity only for patients \nwho are not immunocompromised or pregnant is birth in the \nUnited States before 1980. Postexposure prophylaxis with \nvaccination or varicella-zoster immunoglobulin, depending on \nimmune status, of exposed HCP and patients without evidence \nof immunity is recommended (266).\nHCP who have received 2 doses of vaccine and who are \nexposed to VZV (varicella, disseminated HZ, and uncovered \nlesions of a localized HZ) should be monitored daily during",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_185",
        "document_id": "rr6007",
        "text": "lesions of a localized HZ) should be monitored daily during \ndays 8\u201321 after exposure for fever, skin lesions, and systemic \nsymptoms suggestive of varicella. HCP can be monitored \ndirectly by occupational health program or infection-control \npractitioners or instructed to report fever, headache, or \nother constitutional symptoms and any atypical skin lesions \nimmediately. HCP should be excluded from a work facility \nimmediately if symptoms occur. HCP who have received \n1 dose of vaccine and who are exposed to VZV (varicella, \ndisseminated HZ, and uncovered lesions of a localized HZ) \n(in the community or health-care setting/workplace) should \nreceive the second dose within 3\u20135 days after exposure to \nrash (provided 4 weeks have elapsed after the first dose). After",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_186",
        "document_id": "rr6007",
        "text": "rash (provided 4 weeks have elapsed after the first dose). After \nvaccination, management is similar to that of 2-dose vaccine \nrecipients. Those who did not receive a second dose or who \nreceived the second dose >5 days after exposure should be \nexcluded from work for 8\u201321 days after exposure.\nUnvaccinated HCP who have no other evidence of immunity \nwho are exposed to VZV (varicella, disseminated HZ, and \nuncovered lesions of a localized HZ) are potentially infective \nfrom days 8\u201321 after exposure and should be furloughed during \nthis period. They should receive postexposure vaccination as \nsoon as possible. Vaccination within 3\u20135 days of exposure to \nrash might modify the disease if infection occurred. Vaccination \n>5 days postexposure is still indicated because it induces",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_187",
        "document_id": "rr6007",
        "text": ">5 days postexposure is still indicated because it induces \nprotection against subsequent exposures (if the current exposure \ndid not cause infection). For HCP at risk for severe disease for \nwhom varicella vaccination is contraindicated (e.g., pregnant or \nimmunocomprosed HCP), varicella-zoster immune globulin \nafter exposure is recommended. The varicella-zoster immune \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n25\nglobulin product currently used in the United States, VariZIG \n(Cangene Corporation, Winnipeg, Canada), is available under \nan Investigational New Drug Application Expanded Access \nprotocol; a sample release form is available at http://www.fda.\ngov/downloads/BiologicsBloodVaccines/SafetyAvailability/",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_188",
        "document_id": "rr6007",
        "text": "gov/downloads/BiologicsBloodVaccines/SafetyAvailability/\nUCM176031.pdf. Varicella-zoster immune globulin might \nprolong the incubation period by a week, thus extending the \ntime during which personnel should not work from 21 to \n28 days. In case of an outbreak, HCP without evidence of \nimmunity who have contraindications to vaccination should \nbe excluded from the outbreak setting through 21 days after \nrash onset of the last identified case-patient because of the risk \nfor severe disease in these groups. If the VZV exposure was \nto localized HZ with covered lesions, no work restrictions are \nneeded if the exposed HCP had previously received at least \n1 dose of vaccine or received the first dose within 3\u20135 days \npostexposure. A second dose should be administered at the",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_189",
        "document_id": "rr6007",
        "text": "postexposure. A second dose should be administered at the \nappropriate interval. HCP should be monitored daily during \ndays 8\u201321 after exposure for fever, skin lesions, and systemic \nsymptoms suggestive of varicella and excluded from a work \nfacility if symptoms occur. If at least 1 dose was not received, \nrestriction from patient contact is recommended.\nDiseases for Which Vaccination Might \nBe Indicated in Certain \nCircumstances\nHealth-care facilities and other organizations should consider \nincluding in their vaccination programs vaccines to prevent \nmeningococcal disease, typhoid fever, and polio for HCP who \nhave certain health conditions or who work in laboratories \nor regions outside the United States where the risk for work-\nrelated exposure exists.\nMeningococcal Disease\nBackground",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_190",
        "document_id": "rr6007",
        "text": "related exposure exists.\nMeningococcal Disease\nBackground\nEpidemiology and Risk Factors\nMeningococcal disease is rare among adults in the United \nStates and incidence has decreased to historic lows; during \n1998\u20132007 the average annual incidence of meningococcal \ndisease was 0.28 (range: 0.26\u20130.31) cases per 100,000 \npopulation among persons aged 25\u201364 years (302).\nRoutine vaccination with meningococcal conjugate vaccine is \nrecommended by ACIP for adolescents aged 11\u201318 years, with \nthe primary dose at age 11\u201312 years and the booster dose at \nage 16 years. In 2010, coverage with meningococcal conjugate \nvaccine among persons aged 13\u201317 years was 62.7% (22).\nNosocomial transmission of Neisseria meningitidis is rare, \nbut HCP have become infected after direct contact with",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_191",
        "document_id": "rr6007",
        "text": "but HCP have become infected after direct contact with \nrespiratory secretions of infected persons (e.g., managing of an \nairway during resuscitation) and in a laboratory setting. HCP \ncan decrease the risk for infection by adhering to precautions \nto prevent exposure to respiratory droplets (303,304) and by \ntaking antimicrobial chemoprophylaxis if exposed directly to \nrespiratory secretions.\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nTwo quadrivalent (A, C, W-135, Y) conjugate meningococcal \nvaccines (MCV4) are licensed for persons aged through \n55 years (305,306). Both protect against two of the three \nserogroups that cause the majority of meningococcal disease \nin the United States and against 75% of disease among adults.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_192",
        "document_id": "rr6007",
        "text": "in the United States and against 75% of disease among adults. \nAvailable data indicate that the majority of persons do not have \nenough circulating functional antibody to be protected \u22655 \nyears after a single dose of MCV4. Both vaccines had similar \nsafety profiles in clinical trials. Quadrivalent (A, C, W-135, Y) \nmeningococcal polysaccharide vaccine (MPSV4) is available \nfor use in persons aged >55 years. No vaccine for serogroup B \nmeningococcal disease is licensed in the United States. \nRecommendations\nVaccination\nMCV4 is not recommended routinely for all HCP.\nHCP Recommended to Receive Vaccine to Prevent \nMeningococcal Disease\nA 2-dose vaccine series is recommended for HCP with \nknown asplenia or persistent complement component",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_193",
        "document_id": "rr6007",
        "text": "known asplenia or persistent complement component \ndeficiencies, because these conditions increase the risk for \nmeningococcal disease. HCP traveling to countries in which \nmeningococcal disease is hyperendemic or epidemic also are at \nincreased risk for infection and should receive vaccine. Those \nwith known asplenia or persistent complement component \ndeficiencies should receive a 2-dose vaccine series. All other \nHCP traveling to work to high-risk areas should receive a single \ndose of MCV4 before travel if they have never received it or if \nthey received it >5 years previously. Clinical microbiologists \nand research microbiologists who might be exposed routinely \nto isolates of N. meningitides should receive a single dose of",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_194",
        "document_id": "rr6007",
        "text": "to isolates of N. meningitides should receive a single dose of \nMCV4 and receive a booster dose every 5 years if they remain \nat increased risk. Health-care personnel aged >55 years who \nhave any of the above risk factors for meningococcal disease \nshould be vaccinated with MPSV4 (305).\nRecommendations and Reports\n26\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nHCP Who May Elect to Receive Vaccine to Prevent \nMeningococcal Disease\nHCP with known HIV infection are likely at increased risk \nfor meningococcal disease and may elect vaccination. If these \nHCP are vaccinated, they should receive a 2-dose vaccine \nseries (307).\nBooster Doses\nHCP who receive the 2-dose MCV4 vaccine series and/or \nremain in a group at increased risk should receive a booster \ndose every 5 years (306).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_195",
        "document_id": "rr6007",
        "text": "remain in a group at increased risk should receive a booster \ndose every 5 years (306).\nPostexposure Management of Exposed HCP\nPostexposure prophylaxis is advised for all persons who \nhave had intensive, unprotected contact (i.e., without wearing \na mask) with infected patients (e.g., via mouth-to-mouth \nresuscitation, endotracheal intubation, or endotracheal tube \nmanagement), including HCP who have been vaccinated with \neither the conjugate or polysaccharide vaccine (3).\nAntimicrobial prophylaxis can eradicate carriage of N. \nmeningitidis and prevent infections in persons who have \nunprotected exposure to patients with meningococcal \ninfections (305). Rifampin, ciprofloxacin, and ceftriaxone \nare effective in eradicating nasopharyngeal carriage of N.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_196",
        "document_id": "rr6007",
        "text": "are effective in eradicating nasopharyngeal carriage of N. \nmeningitidis. In areas of the United States where ciprofloxacin-\nresistant strains of N. meningitidis have been detected (as of \nAugust 30, 2011, only parts of Minnesota and North Dakota), \nciprofloxacin should not be used for chemoprophylaxis (308). \nAzithromycin can be used as an alternative. Ceftriaxone can \nbe used during pregnancy. Postexposure prophylaxis should \nbe administered within 24 hours of exposure when feasible; \npostexposure prophylaxis administered >14 days after exposure \nis of limited or no value (305). HCP not otherwise indicated \nfor vaccination may be recommended to be vaccinated with \nmeningococcal vaccine in the setting of a community or \ninstitutional outbreak of meningococcal disease caused by a",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_197",
        "document_id": "rr6007",
        "text": "institutional outbreak of meningococcal disease caused by a \nserogroup contained in the vaccine.\nTyphoid Fever\nBackground\nEpidemiology and Risk Factors\nThe incidence of typhoid fever declined steadily in the \nUnited States during 1900\u20131960 and has since remained \nlow. During 1999\u20132006, on average, 237 cases were reported \nannually to the National Typhoid and Paratyphoid Fever \nSurveillance System (309). The median age of patients was 22 \nyears and 54% were male; 79% reported foreign travel during \nthe 30 days before onset of symptoms. Among international \ntravelers, the risk for Salmonella Typhi infection appears to be \nhighest for those who visit friends and relatives in countries in \nwhich typhoid fever is endemic and for those who visit (even",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_198",
        "document_id": "rr6007",
        "text": "which typhoid fever is endemic and for those who visit (even \nfor a short time) the most highly endemic areas (e.g., the Indian \nsubcontinent) (310).\nIncreasing resistance to fluoroquinolones such as \nciprofloxacin, which are used to treat multidrug-resistant. \nS. Typhi, has been seen particularly among travelers to south \nand southeast Asia (311). Isolates with decreased susceptibility \nto ciprofloxacin (DCS) do not qualify as resistant according \nto current Clinical and Laboratory Standards Institute criteria \nbut are associated with poorer clinical outcomes (311,312). \nResistance to nalidixic acid, a quinolone, is a marker for DCS \nand increased from 19% in 1999 to 59% in 2008 (313). Nine \nisolates resistant to ciprofloxacin also were seen during this \ntime period (313).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_199",
        "document_id": "rr6007",
        "text": "isolates resistant to ciprofloxacin also were seen during this \ntime period (313).\nAlthough overall S. Typhi infections have declined in the \nUnited States, increased incidence and antimicrobial resistance \nincluding resistance to fluoroquinolones have been seen for \nparatyphoid fever caused by Paratyphi A (314). No vaccines \nthat protect against Paratyphi A infection are available.\nTransmission and Exposure in Health-Care Settings\nDuring 1985\u20131994, seven cases of laboratory-acquired typhoid \nfever were reported among persons working in microbiology \nlaboratories, only one of whom had been vaccinated (315). \nAdditionally, S. Typhi might be transmitted nosocomially via the \nhands of infected persons (315).\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_200",
        "document_id": "rr6007",
        "text": "hands of infected persons (315).\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nTwo typhoid vaccines are distributed in the United States: oral \nlive-attenuated Ty21a vaccine (one enteric-coated capsule taken \non alternate days for a total of four capsules) and the capsular \npolysaccharide parenteral vaccine (1 0.5 mL intramuscular dose). \nBoth vaccines protect 50%\u201380% of recipients. To maintain \nimmunity, booster doses of the oral vaccine are required every 5 \nyears, and booster doses of the injected vaccine are required every \n2 years. Complication rates are low for both types of S. Typhi \nvaccines. During 1994\u20131999, serious adverse events requiring \nhospitalization occurred in an estimated 0.47 to 1.3 per 100,000",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_201",
        "document_id": "rr6007",
        "text": "hospitalization occurred in an estimated 0.47 to 1.3 per 100,000 \ndoses, and no deaths occurred (310). However, live-attenuated \nTy21a vaccine should not be used among immunocompromised \npersons, including those infected with HIV (316). Theoretic \nconcerns have been raised about the immunogenicity of live, \nattenuated Ty21a vaccine in persons concurrently receiving \nantimicrobials (including antimalarial chemoprophylaxis), viral \nvaccines, or immune globulin (317). A third type of vaccine, \na parenteral heat-inactivated vaccine associated with higher \nreactogenicity, was discontinued in 2000 (310,318). \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n27\nRecommendations\nVaccination\nMicrobiologists and others who work frequently with",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_202",
        "document_id": "rr6007",
        "text": "27\nRecommendations\nVaccination\nMicrobiologists and others who work frequently with \nS. Typhi should be vaccinated with either of the two licensed \nand available vaccines. Booster vaccinations should be \nadministered on schedule according to the manufacturers\u2019 \nrecommendations.\nControlling the Spread of Typhoid Fever\nPersonal hygiene, particularly hand hygiene before and after \nall patient contacts, will minimize risk for transmitting enteric \npathogens to patients. However, HCP who contract an acute \ndiarrheal illness accompanied by fever, cramps, or bloody \nstools are likely to excrete substantial numbers of infective \norganisms in their feces. Excluding these HCP from care of \npatients until the illness has been evaluated and treated can \nprevent transmission (3).\nPoliomyelitis",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_203",
        "document_id": "rr6007",
        "text": "prevent transmission (3).\nPoliomyelitis\nBackground\nEpidemiology and Risk Factors\nIn the United States, the last indigenously acquired cases \nof poliomyelitis caused by wild poliovirus occurred in 1979, \nand the Americas were certified to be free of indigenous wild \npoliovirus in 1994 (319,320). With the complete transition \nfrom use of oral poliovirus vaccine (OPV) to inactivated \npoliovirus vaccine (IPV) in 2000, vaccine-associated \nparalytic poliomyelitis (VAPP) attributable to OPV also \nhas been eliminated (321,322), so the risk for exposure to \nany live poliovirus in the United States is limited. However, \nglobal eradication of poliomyelitis has not yet occurred, \nso reintroductions of poliovirus into the United States are \npossible. Two cases of paralytic polio from vaccine-derived",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_204",
        "document_id": "rr6007",
        "text": "possible. Two cases of paralytic polio from vaccine-derived \npoliovirus have occurred since 2000 (one imported case in \n2005 and one case in an immunodeficient person in 2008), \nand evidence of limited circulating vaccine-derived poliovirus \nin an undervaccinated community was documented in 2005 \n(323\u2013325).\nTransmission and Exposure in Health-Care Settings\nPoliovirus can be recovered from infected persons, including \nfrom pharyngeal specimens, feces, urine, and (rarely) \ncerebrospinal fluid. HCP and laboratory workers might be \nexposed if they come into close contact with infected persons \n(e.g., travelers returning from areas where polio is endemic) \nor with specimens that contain poliovirus.\nVaccine Effectiveness, Duration of Immunity, and \nVaccine Safety",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_205",
        "document_id": "rr6007",
        "text": "Vaccine Effectiveness, Duration of Immunity, and \nVaccine Safety\nBoth IPV and OPV are highly immunogenic and effective \nwhen administered according to their schedules. In studies \nconducted in the United States, 3 doses of IPV resulted \nin 100% serocoversion for types 2 and 3 poliovirus and \n96%\u2013100% for type 1 (326). Immunity is prolonged and \nmight be lifelong. IPV is well tolerated, and no serious adverse \nevents have been associated with its use. IPV is an inactivated \nvaccine and does not cause VAPP. IPV is contraindicated in \npersons with a history of hypersensitivity to any component \nof the vaccine, including 2-phenoxyethanol, formaldehyde, \nneomycin, streptomycin, and polymyxin B. OPV is no longer \navailable in the United States.\nRecommendations\nVaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_206",
        "document_id": "rr6007",
        "text": "available in the United States.\nRecommendations\nVaccination\nBecause the majority of adults born in the United States \nare likely immune to polio as a result of vaccination during \nchildhood, poliovirus vaccine is not routinely recommended \nfor persons aged \u226518 years. The childhood recommendation \nfor poliovirus vaccine consists of 4 doses at ages 2, 4, and 6\u201318 \nmonths and 4\u20136 years.\nHowever, vaccination is recommended for HCP who are \nat greater risk for exposure to polioviruses than the general \npopulation, including laboratory workers who handle \nspecimens that might contain polioviruses and HCP who \nhave close contact with patients who might be excreting wild \npolioviruses, including HCP who travel to work in areas where \npolioviruses are circulating.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_207",
        "document_id": "rr6007",
        "text": "polioviruses, including HCP who travel to work in areas where \npolioviruses are circulating.\nUnvaccinated HCP should receive a 3-dose series of IPV, \nwith dose 2 administered 4\u20138 weeks after dose 1, and dose \n3 administered 6\u201312 months after dose 2. HCP who have \npreviously completed a routine series of poliovirus vaccine and \nwho are at increased risk can receive a lifetime booster dose \nof IPV if they remain at increased risk for exposure. Available \ndata do not indicate the need for more than a single lifetime \nbooster dose with IPV for adults.\nControlling the Spread of Poliovirus\nStandard precautions always should be practiced when \nhandling biologic specimens. Suspect cases require an \nimmediate investigation including collection of appropriate",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_208",
        "document_id": "rr6007",
        "text": "immediate investigation including collection of appropriate \nlaboratory specimens and control measures. All suspect or \nconfirmed cases should be reported immediately to the local \nor state health department.\nRecommendations and Reports\n28\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nOther Vaccines Recommended \nfor Adults\nCertain vaccines are recommended for adults based on age \nor other individual risk factors but not because of occupational \nexposure (327). Vaccine-specific ACIP recommendations \nshould be consulted for details on schedules, indications, \ncontraindications, and precautions for these vaccines.\n\u2022 Pneumococcal polysaccharide vaccine (PPSV). PPSV \nis recommended for healthy persons aged \u226565 years. PPSV \nis also recommended for persons aged <65 years with",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_209",
        "document_id": "rr6007",
        "text": "is also recommended for persons aged <65 years with \ncertain underlying medical conditions, including anatomic \nor functional asplenia, immunocompromise (including \nHIV infection), chronic lung, heart or kidney disease, and \ndiabetes.\n\u2022 Tetanus and diphtheria toxoids (Td). All adults should \nhave documentation of having received an age-appropriate \nseries of Td-containing vaccine and a routine booster dose \nevery 10 years. Persons without documentation of having \nreceived a Td series should receive a 3-dose series. The first \ndose of the series should be administered as Tdap (see \nPertussis).\n\u2022 Human papillomavirus (HPV) vaccine. Either \nquadrivalent HPV vaccine (Gardasil) or bivalent HPV \nvaccine (Cervarix) is recommended for females at age 11",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_210",
        "document_id": "rr6007",
        "text": "vaccine (Cervarix) is recommended for females at age 11 \nor 12 years with catch-up vaccination recommended \nthrough age 26 years. Quadrivalent HPV vaccine \n(Gardasil) may be administered to males aged 9\u201326 years.\n\u2022 Zoster vaccine. Zoster vaccine contains the same live \nattenuated varicella zoster virus as varicella vaccine but at \na higher concentration (approximately 14 times more \nvaccine virus per dose). Zoster vaccine is recommended \nfor the prevention of HZ (shingles) in persons aged \u226560 \nyears. Transmission of vaccine virus from the recipient to \na contact has not been reported. Consequently, limiting \nor restricting work activities for persons who recently \nreceived zoster vaccine is not necessary.\n\u2022 Hepatitis A vaccine. HCP have not been demonstrated",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_211",
        "document_id": "rr6007",
        "text": "received zoster vaccine is not necessary.\n\u2022 Hepatitis A vaccine. HCP have not been demonstrated \nto be at increased risk for hepatitis A virus infection \nbecause of occupational exposure, including persons \nexposed to sewage. Hepatitis A vaccine is recommended \nfor person with chronic liver disease, international \ntravelers, and certain other groups at increased risk for \nexposure to hepatitis A.\nCatch-Up and Travel Vaccination\nCatch-Up Programs\nManagers of health-care facilities should implement catch-up \nvaccination programs for HCP who already are employed, in \naddition to developing policies for achieving high vaccination \ncoverage among newly hired HCP. HCP vaccination records \ncould be reviewed annually during the influenza vaccination",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_212",
        "document_id": "rr6007",
        "text": "could be reviewed annually during the influenza vaccination \nseason or concurrent with annual TB testing. This strategy could \nhelp prevent outbreaks of vaccine-preventable diseases. Because \neducation, especially when combined with other interventions \nsuch as reminder/recall systems and low or no out-of-pocket \ncosts, enhances the success of many vaccination programs, \ninformational materials should be available to assist in answering \nquestions from HCP regarding the diseases, vaccines, and toxoids \nas well as the program or policy being implemented (120,328). \nConducting educational workshops or seminars several weeks \nbefore the initiation of a catch-up vaccination program might \npromote acceptance of program goals.\nTravel\nHospital personnel and other HCP who perform research",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_213",
        "document_id": "rr6007",
        "text": "promote acceptance of program goals.\nTravel\nHospital personnel and other HCP who perform research \nor health-care work in foreign countries might be at increased \nrisk for acquiring certain diseases that can be prevented by \nvaccines recommended in the United States (e.g., hepatitis \nB, influenza, MMR, Tdap, poliovirus, varicella, and \nmeningococcal vaccines) and travel-related vaccines (e.g., \nhepatitis A, Japanese encephalitis, rabies, typhoid, or yellow \nfever vaccines) (329). Elevated risks for acquiring these diseases \nmight stem from exposure to patients in health-care settings \n(e.g., poliomyelitis and meningococcal disease) but also might \narise from circumstances unrelated to patient care (e.g., high \nendemicity of hepatitis A or exposure to arthropod-vector",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_214",
        "document_id": "rr6007",
        "text": "endemicity of hepatitis A or exposure to arthropod-vector \ndiseases [e.g., yellow fever]). All HCP should seek the advice \nof a health-care provider familiar with travel medicine at least \n4\u20136 weeks before travel to ensure that they are up to date \non routine vaccinations and that they receive vaccinations \nrecommended for their destination (329). Although bacille \nCalmette-Gu\u00e9rin vaccination is not recommended routinely \nin the United States, HCP should discuss potential beneficial \nand other consequences of this vaccination with their health-\ncare provider.\nWork Restrictions\nWork restrictions for susceptible HCP (i.e., no history \nof vaccination or documented lack of immunity) exposed \nto or infected with certain vaccine-preventable diseases can",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_215",
        "document_id": "rr6007",
        "text": "to or infected with certain vaccine-preventable diseases can \nrange from restricting individual HCP from patient contact \nto complete exclusion from duty (Table 5). A furloughed \nemployee should be considered in the same category as an \nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n29\nemployee excluded from the facility. Specific recommendations \nconcerning work restrictions in these circumstances have been \npublished previously (3,11).\nAcknowledgments\nThe following persons contributed to this report: Rachel J. Wilson, \nGeoff A. Beckett, MPH, Division of Viral Hepatitis, National Center \nfor HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; \nLaDora O. Woods, BS, Carter Consulting, Inc., Atlanta, Georgia.\nReferences",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_216",
        "document_id": "rr6007",
        "text": "LaDora O. Woods, BS, Carter Consulting, Inc., Atlanta, Georgia.\nReferences\n\t 1.\tCDC. Immunization of health-care workers: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP) and the \nHospital Infection Control Practices Advisory Committee (HICPAC). \nMMWR 1997;46(No. RR-18).\n\t 2.\tUS Department of Health and Human Services. Definition of health-\ncare personnel (HCP). Available at http://www.hhs.gov/ash/programs/\ninitiatives/vacctoolkit/definition.html. Accessed October 5, 2011.\n\t 3.\tBolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, \nDeitchman SD, Hospital Infection Control Practices Advisory \nCommittee (HICPAC). Guideline for infection control in healthcare \npersonnel, 1998. Infect Control Hosp Epidemiol 1998;19:407\u201363.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_217",
        "document_id": "rr6007",
        "text": "personnel, 1998. Infect Control Hosp Epidemiol 1998;19:407\u201363.\n\t 4.\tCDC. General recommendations on immunization: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). MMWR \n2011;60(No. RR-2).\n\t 5.\tDayan GH, Ortega-S\u00e1nchez IR, LeBaron CW, Quinlisk MP. Iowa \nMeasles Response Team. The cost of containing one case of measles: the \neconomic impact on the public health infrastructure\u2014Iowa, 2004. \nPediatrics 2005;116:e1\u20134.\n\t 6.\t CDC. Preventing tetanus, diphtheria, and pertussis among adults: use \nof tetanus toxoid, reduced diphtheria toxoid and acellular pertussis \nvaccine. MMWR 2006;55(No. RR-17).\n\t 7.\t CDC. Local health department costs associated with response to a \nschool-based pertussis outbreak\u2014Omaha, Nebraska, September\u2013\nNovember 2008. MMWR 2011;60:5\u20139.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_218",
        "document_id": "rr6007",
        "text": "school-based pertussis outbreak\u2014Omaha, Nebraska, September\u2013\nNovember 2008. MMWR 2011;60:5\u20139.\n\t 8.\tAmerican Hospital Association. Immunization: management advisory on \nhealth care delivery. Chicago, IL American Hospital Association; 1992.\n\t 9.\tCDC. State immunization laws for healthcare personnel and patients. \nAvailable at http://www2a.cdc.gov/nip/StateVaccApp/statevaccsApp/\ndefault.asp. Accessed October 5, 2011.\n\t10.\tMiller BL, Ahmed F, Lindley MC, Wortley PM. Institutional \nrequirements for influenza vaccination of healthcare personnel: results \nfrom a nationally representative survey of acute care hospitals\u2014United \nStates, 2011. Clin Infect Dis 2011;53(11):1051-9.\n\t11.\tBeltrami EM, Bolyard EA. Personnel health services. In: Jarvis W, ed.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_219",
        "document_id": "rr6007",
        "text": "11.\tBeltrami EM, Bolyard EA. Personnel health services. In: Jarvis W, ed. \nBennett and Brachman\u2019s hospital infections. Philadelphia, PA: Lippincott \nWilliams & Wilkins; 2007:45\u201363.\n\t12.\tCDC. Manual for the surveillance of vaccine-preventable diseases. \nAvailable at http://www.cdc.gov/vaccines/pubs/surv-manual/index.html. \nAccessed October 5, 2011.\n\t13.\tCDC. Summary of notifiable diseases\u2014United States, 2009. MMWR \n2009:58(No.53).\n\t14.\tBeltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and \nmanagement of blood-borne infections in health care workers. Clin \nMicrobiol Rev 2000;13:385\u2013407. \n\t15.\tWerner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive \ninoculations. Ann Intern Med 1982;97:367\u20139.\n\t16.\tBond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_220",
        "document_id": "rr6007",
        "text": "16.\tBond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard \nJE. Survival of hepatitis B virus after drying and storage for one week. \nLancet 1981;1:550\u20131.\n\t17.\tCDC. Viral hepatitis surveillance\u20142009 surveillance. Available at http://\nwww.cdc.gov/hepatitis/Statistics/2009Surveillance/index.htm. Accessed \nOctober 5, 2011.\n\t18.\tCDC. Surveillance for acute viral hepatitis\u2014United States, 2007. \nMMWR 2009;58(No. SS-3).\n\t19.\tInstitute of Medicine. Hepatitis and liver cancer: a national strategy for \nprevention and control of hepatitis B and C. Washington, DC: The \nNational Academies Press; 2010.\n\t20.\tCDC. Achievements in public health: hepatitis B vaccination\u2014United \nStates, 1982\u20132002. MMWR 2002;51:549\u201352.\n\t21.\tCDC. National and state vaccination coverage among children aged",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_221",
        "document_id": "rr6007",
        "text": "21.\tCDC. National and state vaccination coverage among children aged \n19\u201335 months\u2014United States, 2010. MMWR 2011;60:1157\u201363.\n\t22.\tCDC. National and state vaccination coverage among adolescents aged \n13\u201317 years\u2014United States, 2010. MMWR 2011;60:1117\u201323.\n\t23.\tLu P-J, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination \ncoverage among high-risk adults 18\u201349 years, U.S. 2009. Vaccine \n2011;29:7049\u201357.\n\t24.\tCDC. Hepatitis surveillance report No. 60. Atlanta, GA: US Department \nof Health and Human Services, CDC; 2005.\n\t25.\tAlter MJ, Hadler SC, Margolis MD, et al. The changing epidemiology \nof hepatitis B in the United States: need for alternative vaccination \nstrategies. JAMA 1990;263:1218\u201322.\n\t26.\tOsterholm MT, Garayale SM. Clinical viral hepatitis B among Minnesota",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_222",
        "document_id": "rr6007",
        "text": "26.\tOsterholm MT, Garayale SM. Clinical viral hepatitis B among Minnesota \nhospital personnel: results of a ten-year statewide survey. JAMA \n1985;254:3207\u201312.\n\t27.\tThomas DL, Factor SH, Gabon D, et al. Viral hepatitis in health care \npersonnel at the Johns Hopkins Hospital. Arch Intern Med 1993;\u200b\n153:1705\u201312.\n\t28.\tDienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in \nhospital personnel: infection or immunization? Am J Epidemiol \n1982;115:26\u201339.\n\t29.\tShapiro CN, Tokars JI, Chamberland ME, et al. Use of the hepatitis B \nvaccine and infection with hepatitis B and C among orthopaedic \nsurgeons. J Bone Joint Surg 1996;78-A:1791\u2013800.\n\t30.\tGibas A, Blewett DR, Schoenfled DA, Dienstag JL. Prevalence and \nincidence of viral hepatitis in health workers in the prehepatitis B",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_223",
        "document_id": "rr6007",
        "text": "incidence of viral hepatitis in health workers in the prehepatitis B \nvaccination era. Am J Epidemiol 1992;136:603\u201310.\n\t31.\tHadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B \ninfection in hospital workers. Infection Control 1985;6:24\u201331.\n\t32.\tThompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of \nhepatitis B virus infection and the need for innovative glucose monitoring \ntechnologies. J Diabetes Sci Technol 2009;3:283\u20138. \n\t33.\tKlonoff DC, Perz JF. Assisted monitoring of blood glucose: special safety \nneeds for a new paradigm in testing glucose. J Diabetes Sci Technol \n2010;4:1027\u201331.\n\t34.\tCDC. Transmission of hepatitis B virus among persons undergoing \nblood glucose monitoring in long-term\u2013care facilities\u2014Mississippi,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_224",
        "document_id": "rr6007",
        "text": "blood glucose monitoring in long-term\u2013care facilities\u2014Mississippi, \nNorth Carolina, and Los Angeles County, California, 2003\u20132004. \nMMWR 2005;54:220\u20133.\n\t35.\tUS Department of Labor. Bloodborne pathogens: the standard. Federal \nRegister 1991;60:64175\u201382. \n\t36.\tAgerton TB, Mahoney, SJ, Polish UB, Shapiro CN. Impact of the \nBloodborne Pathogens Standard on vaccination of healthcare workers \nwith hepatitis B vaccine. Infect Control Hospital Epidemiol 1995;\u200b\n16:287\u201391.\n\t37.\tSimard EP, Miller JT, George PA, et al. Hepatitis B vaccination coverage \nlevels among healthcare workers in the United States, 2002\u20132003. Infect \nControl Hosp Epidemiol 2007;28:783\u201390.\n\t38.\tLu PJ, Euler GL. Influenza, hepatitis B, and tetanus vaccination coverage",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_225",
        "document_id": "rr6007",
        "text": "38.\tLu PJ, Euler GL. Influenza, hepatitis B, and tetanus vaccination coverage \namong healthcare personnel in the United States. Am J Infect Control \n2011;39:488\u201394.\n\t39.\tUS Department of Health and Human Services. Proposed Healthy \nPeople 2020 objectives. Available at http://www.healthypeople.gov/\nhp2020/Objectives/TopicAreas.aspx. Accessed October 5, 2011.\nRecommendations and Reports\n30\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\n\t40.\tDienstag JL, Werner BG, Polk BF, et al. Hepatitis B vaccine in health-\ncare personnel: safety, immunogenicity, and indicators of efficacy. Ann \nIntern Med 1984;101:34\u201340.\n\t41.\tZajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical \nstudies with hepatitis B vaccine made by recombinant DNA. J Infect \n1986;13(Suppl A):39\u201345.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_226",
        "document_id": "rr6007",
        "text": "studies with hepatitis B vaccine made by recombinant DNA. J Infect \n1986;13(Suppl A):39\u201345.\n\t42.\tFrancis DP, Hadler SC, Thompson SE, et al. The prevention of \nhepatitis B with vaccine: report of the Centers for Disease Control \nmulti-center efficacy trial among homosexual men. Ann Intern Med \n1982;\u200b97:362\u20136.\n\t43.\tAverhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. \nImmunogenicity of hepatitis B vaccines: implications for persons at \noccupational risk for hepatitis B virus infection. Am J Prev Med \n1998;15:1\u20138.\n\t44.\tShaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection \nsite, age and smoking on the immune response to hepatitis B vaccination. \nVaccine 1989;7:425\u201330.\n\t45.\tWeber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_227",
        "document_id": "rr6007",
        "text": "Vaccine 1989;7:425\u201330.\n\t45.\tWeber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity \nas a predictor of poor antibody response to hepatitis B plasma vaccine. \nJAMA 1985;254:3187\u20139.\n\t46.\tWood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, \nOsterholm MT. Risk factors for lack of detectable antibody following \nhepatitis B vaccination of Minnesota health care workers. JAMA \n1993;270:2935\u20139.\n\t47.\tMcMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and \nprotection after hepatitis B vaccine: results of a 22-year follow-up study \nand response to a booster dose. J Infect Dis 2009;200:1390\u20136.\n\t48.\tLeuridan E, Van Damme P. Hepatitis B and the need for a booster dose. \nClin Infect Dis 2011;53:68\u201375.\n\t49.\tHadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_228",
        "document_id": "rr6007",
        "text": "49.\tHadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity \nand efficacy of hepatitis B vaccine in homosexual men. N Engl J Med \n1986;315:209\u201314.\n\t50.\tJack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of \nhepatitis B antibody is protective? J Infect Dis 1999;179:489\u201392.\n\t51.\tStevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of \nhepatitis B virus infection: implications of childhood vaccination and \nlong-term protection. Pediatrics 1992;90(1 Pt 2):170\u20133.\n\t52.\tCDC. A comprehensive immunization strategy to eliminate transmission \nof hepatitis B virus infection in the United States: recommendations of \nthe Advisory Committee on Immunization Practices. Part II: \nimmunization of adults. MMWR 2006;55(No. RR-16).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_229",
        "document_id": "rr6007",
        "text": "immunization of adults. MMWR 2006;55(No. RR-16).\n\t53.\tClemens R, Sanger R, Kruppenbacher J, et al. Booster immunization \nof low- and non-responders after a standard three dose hepatitis B vaccine \nschedule\u2013results of a post-marketing surveillance. Vaccine \n1997;15:349\u201352.\n\t54.\tCraven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to \nhepatitis B vaccine in health care workers. Results of revaccination and \ngenetic typings. Ann Intern Med 1986;105:356\u201360.\n\t55.\tGoldwater PN. Randomized, comparative trial of 20 micrograms vs 40 \nmicrograms Engerix B vaccine in hepatitis B vaccine non-responders. \nVaccine 1997;15:353\u20136.\n\t56.\tKim MJ, Nafziger AN, Harro CD, et al. Revaccination of healthy \nnonresponders with hepatitis B vaccine and prediction of seroprotection",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_230",
        "document_id": "rr6007",
        "text": "nonresponders with hepatitis B vaccine and prediction of seroprotection \nresponse. Vaccine 2003;21:1174\u20139.\n\t57.\tBertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of \nstandard or high-dose S subunit recombinant hepatitis B vaccine versus \na vaccine containing S subunit, pre-S1, and pre-S2 particles for \nrevaccination of healthy adult nonresponders. J Infect Dis 1997;\u200b\n175:678\u201381.\n\t58.\tWeissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. \nLack of response to recombinant hepatitis B vaccine in nonresponders \nto the plasma vaccine. JAMA 1988;260:1734\u20138.\n\t59.\tAlper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of \nnonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708\u201312.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_231",
        "document_id": "rr6007",
        "text": "nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708\u201312.\n\t60.\tInstitute of Medicine. Immunization safety review: hepatitis B vaccine \nand demyelinating disorders. Washington, DC: The National Academies \nPress; 2002.\n\t61.\tInstitute of Medicine. Adverse effects of vaccines: evidence and causality. \nAvailable at http://www.iom.edu/Reports/2011/Adverse-Effects-of-\nVaccines-Evidence-and-Causality.aspx Accessed October 5, 2011.\n\t62.\tGlobal Advisory Committee on Vaccine Safety. 12\u201313 December 2007. \nWkly Epidemiol Record 2008;83:37\u201344.\n\t63.\tSundberg JP, Silva KA, Sundberg BA, et al. Recombinant human \nhepatitis B vaccine initiating alopecia areata: testing the hypothesis using \nC3H/HeJ mouse model. Vet Dermatol 2009;20:99\u2013104.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_232",
        "document_id": "rr6007",
        "text": "C3H/HeJ mouse model. Vet Dermatol 2009;20:99\u2013104.\n\t64.\tGlaxoSmithKline Biologicals. Engerix-B [Package insert]. Rixensart, \nBelgium: GlaxoSmithKline Biologicals; 2010.\n\t65.\tMerck & Co., Inc. Recombivax HB: hepatitis B vaccine (recombinant) \n[Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011.\n\t66.\tGlaxoSmithKline Biologicals. Twinrix [Package insert]. Rixensart, \nBelgium: GlaxoSmithKline Biologicals; 2011.\n\t67.\tCDC. Hepatitis B vaccine information statement. Available at http://\nwww.cdc.gov/vaccines/pubs/vis/default.htm. Accessed October 5, 2011.\n\t68.\tLevy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal \nsafety. Am J Perinatol 1991;8:227\u201332.\n\t69.\tCDC. Recommendations for preventing transmission of HIV and HBV",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_233",
        "document_id": "rr6007",
        "text": "69.\tCDC. Recommendations for preventing transmission of HIV and HBV \nvirus to patients during exposure-prone invasive procedures. MMWR \n1991;40(No. RR-8).\n\t70.\tCDC. Hepatitis B virus: a comprehensive strategy for eliminating \ntransmission in the United States through universal childhood \nvaccination: recommendations of the Immunization Practices Advisory \nCommittee (ACIP). MMWR 1991;40(No. RR-13).\n\t71.\tCDC. Recommendations for identification and public health \nmanagement of persons with chronic hepatitis B virus infection. MMWR \n2008;57(No. RR-8).\n\t72.\tCDC. Updated U.S. Public Health Service guidelines for the \nmanagement of occupational exposures to HBV, HCV, and HIV and \nrecommendations for postexposure prophylaxis. MMWR 2001;50\u200b\n(No. RR-11).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_234",
        "document_id": "rr6007",
        "text": "recommendations for postexposure prophylaxis. MMWR 2001;50\u200b\n(No. RR-11).\n\t73.\tEckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of \nscreening for chronic Hepatitis B infection in the United States. Clin \nInfect Dis2011;52:1294\u2013306.\n\t74.\tThompson WW, Weintraub E, Dhankhar P, et al. Estimates of US \ninfluenza-associated deaths made using four different methods. Influenza \nOther Respi Viruses 2009;3:37\u201349.\n\t75.\t CDC. Estimates of deaths associated with seasonal influenza\u2014United \nStates, 1976\u20132007. MMWR 2010;59:1057\u201362.\n\t76.\tThompson WW, Shay DK, Weintraub E, et al. Influenza-associated \nhospitalizations in the United States. JAMA 2004;292:1333\u201340.\n\t77.\tCDC. Prevention and control of influenza with vaccines: recommendations",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_235",
        "document_id": "rr6007",
        "text": "77.\tCDC. Prevention and control of influenza with vaccines: recommendations \nof the Advisory Committee on Immunization Practices (ACIP), 2010. \nMMWR 2010(No. RR-8).\n\t78.\tJain R, Goldman RD. Novel influenza A(H1N1): clinical presentation, \ndiagnosis, and management. Pediatr Emerg Care 2009;25:791\u20136.\n\t79.\tLester RT, McGeer A, Tomlinson G, et al. Use of, effectiveness of, and \nattitudes regarding influenza vaccine among house staff. Infect Control \nHosp Epidemiol 2003;24:839\u201344.\n\t80.\tSaxen HVirtanen M. Randomized, placebo-controlled double blind \nstudy on the efficacy of influenza immunization on absenteeism of health \ncare workers. Pediatr Infect Dis J 1999;18:779.\n\t81.\tWilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_236",
        "document_id": "rr6007",
        "text": "81.\tWilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine \nin health care professionals: a randomized trial. JAMA 1999;\u200b\n281:908\u201313.\n\t82.\tMalavaud S, Malavaud B, Sandres K, et al. Nosocomial outbreak of \ninfluenza virus A (H3N2) infection in a solid organ transplant \ndepartment. Transplantation 2001;72:535\u20137.\n\t83.\tMaltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp \nInfect 2003;55:83\u201391.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n31\n\t 84.\tHall CB, Douglas RG Jr. Nosocomial influenza infection as a cause of \nintercurrent fevers in infants. Pediatrics 1975;55:673\u20137.\n\t 85.\tWeinstock DM, Eagan J, Malak SA, et al. Control of influenza A on \na bone marrow transplant unit. Infect Control Hosp Epidemiol \n2000;21:730\u20132.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_237",
        "document_id": "rr6007",
        "text": "a bone marrow transplant unit. Infect Control Hosp Epidemiol \n2000;21:730\u20132.\n\t 86.\tSalgado CD, Giannetta ET, Hayden FG, et al. Preventing nosocomial \ninfluenza by improving the vaccine acceptance rate of clinicians. Infect \nControl Hosp Epidemiol 2004;25:923\u20138.\n\t 87.\tAdal KA, Flowers RH, Anglim AM, et al. Prevention of nosocomial \ninfluenza. Infect Control Hosp Epidemiol 1996;17:641\u20138.\n\t 88.\tCunney RJ, Bialachowski A, Thornley D, et al. An outbreak of influenza \nA in a neonatal intensive care unit. Infect Control Hosp Epidemiol \n2000;21:449\u201354.\n\t 89.\tBridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: \nimplications for control in health care settings. Clin Infect Dis \n2003;37:1094\u2013101.\n\t 90.\tSartor C, Zandotti C, Romain F, et al. Disruption of services in an",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_238",
        "document_id": "rr6007",
        "text": "2003;37:1094\u2013101.\n\t 90.\tSartor C, Zandotti C, Romain F, et al. Disruption of services in an \ninternal medicine unit due to a nosocomial influenza outbreak. Infect \nControl Hosp Epidemiol 2002;23:615\u20139.\n\t 91.\tSaito R, Suzuki H, Oshitani H, et al. The effectiveness of influenza \nvaccine against influenza a (H3N2) virus infections in nursing homes \nin Niigata, Japan, during the 1998\u20131999 and 1999\u20132000 seasons. \nInfect Control Hosp Epidemiol 2002;23:82\u20136.\n\t 92.\tLemaitre M, Meret T, Rothan-Tondeur M, et al. Effect of influenza \nvaccination of nursing home staff on mortality of residents: a cluster-\nrandomized trial. J Am Geriatr Soc 2009;57:1580\u20136.\n\t 93.\tCarman WF, Elder AG, Wallace LA, et al. Effects of influenza \nvaccination of health-care workers on mortality of elderly people in",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_239",
        "document_id": "rr6007",
        "text": "vaccination of health-care workers on mortality of elderly people in \nlong-term care: a randomised controlled trial. Lancet 2000;355:93\u20137.\n\t 94.\tHayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza \nvaccine programme for care home staff to prevent death, morbidity, \nand health service use among residents: cluster randomised controlled \ntrial. BMJ 2006;333:1241.\n\t 95.\tPotter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health \ncare workers in long-term-care hospitals reduces the mortality of elderly \npatients. J Infect Dis 1997;175:1\u20136.\n\t 96.\tThomas RE, Jefferson TO, Demicheli V, et al. Influenza vaccination \nfor health-care workers who work with elderly people in institutions: \na systematic review. Lancet Infect Dis 2006;6:273\u20139.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_240",
        "document_id": "rr6007",
        "text": "a systematic review. Lancet Infect Dis 2006;6:273\u20139.\n\t 97.\tThomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for \nhealthcare workers who work with the elderly. Cochrane Database Syst \nRev 2010;2:CD005187.\n\t 98.\tNational Foundation for Infectious Diseases. Call to action: influenza \nimmunization among health-care workers, 2003. Available at http://\nwww.nfid.org/pdf/publications/fluhealthcarecta08.pdf. Accessed \nOctober 5, 2011.\n\t 99.\tPavia AT. Mandate to protect patients from health care-associated \ninfluenza. Clin Infect Dis 2010;50:465\u20137.\n\t100.\tPoland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for \nhealth care workers: seven truths we must accept. Vaccine 2005;\u200b\n23:2251\u20135.\n\t101.\tCDC. 2009 Adult vaccination coverage. The National Health Interview",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_241",
        "document_id": "rr6007",
        "text": "23:2251\u20135.\n\t101.\tCDC. 2009 Adult vaccination coverage. The National Health Interview \nSurvey. Available at http://www.cdc.gov/vaccines/stats-surv/nhis/2009-\nnhis.htm. Accessed October 5, 2011.\n\t102.\tLaVela SL, Smith B, Weaver FM, et al. Attitudes and practices regarding \ninfluenza vaccination among healthcare workers providing services to \nindividuals with spinal cord injuries and disorders. Infect Control Hosp \nEpidemiol 2004;25:933\u201340.\n\t103.\tBegue RE, Gee SQ. Improving influenza immunization among \nhealthcare workers. Infect Control Hosp Epidemiol 1998;19:518\u201320.\n\t104.\tOfstead CL, Tucker SJ, Beebe TJ, et al. Influenza vaccination among \nregistered nurses: information receipt, knowledge, and decision-making \nat an institution with a multifaceted educational program. Infect",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_242",
        "document_id": "rr6007",
        "text": "at an institution with a multifaceted educational program. Infect \nControl Hosp Epidemiol 2008;29:99\u2013106.\n\t105.\tGoldstein AO, Kincade JE, Gamble G, et al. Policies and practices for \nimproving influenza immunization rates among healthcare workers. \nInfect Control Hosp Epidemiol 2004;25:908\u201311.\n\t106.\tOng AK, Srimanunthiphol J, Frankel RI. Influenza vaccination status \nof healthcare workers and the extent of their domestic contact with \nindividuals at high risk for influenza-related complications. Infect \nControl Hosp Epidemiol 2000;21:735\u20137.\n\t107.\tWeingarten S, Riedinger M, Bolton LB, et al. Barriers to influenza \nvaccine acceptance: a survey of physicians and nurses. Am J Infect \nControl 1989;17:202\u20137.\n\t108.\tHofmann F, Ferracin C, Marsh G, et al. Influenza vaccination of",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_243",
        "document_id": "rr6007",
        "text": "Control 1989;17:202\u20137.\n\t108.\tHofmann F, Ferracin C, Marsh G, et al. Influenza vaccination of \nhealthcare workers: a literature review of attitudes and beliefs. Infection \n2006;34:142\u20137.\n\t109.\tHollmeyer HG, Hayden F, Poland G, et al. Influenza vaccination of \nhealth care workers in hospitals\u2013a review of studies on attitudes and \npredictors. Vaccine 2009;27:3935\u201344.\n\t110.\tHarbarth S, Siegrist CA, Schira JC, et al. Influenza immunization: \nimproving compliance of healthcare workers. Infect Control Hosp \nEpidemiol 1998;19:337\u201342.\n\t111.\tNichol KLHauge M. Influenza vaccination of healthcare workers. Infect \nControl Hosp Epidemiol 1997;18:189\u201394.\n\t112.\tWatanakunakorn C, Ellis G, Gemmel D. Attitude of healthcare \npersonnel regarding influenza immunization. Infect Control Hosp",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_244",
        "document_id": "rr6007",
        "text": "personnel regarding influenza immunization. Infect Control Hosp \nEpidemiol 1993;14:17\u201320.\n\t113.\tBryant KA, Stover B, Cain L, et al. Improving influenza immunization \nrates among healthcare workers caring for high-risk pediatric patients. \nInfect Control Hosp Epidemiol 2004;25:912\u20137.\n\t114.\tBertin M, Scarpelli M, Proctor AW, et al. Novel use of the intranet to \ndocument health care personnel participation in a mandatory influenza \nvaccination reporting program. Am J Infect Control 2007;35:33\u20137.\n\t115.\tAjenjo MC, Woeltje KF, Babcock HM, et al. Influenza vaccination \namong healthcare workers: ten-year experience of a large healthcare \norganization. Infect Control Hosp Epidemiol 2010;31:233\u201340.\n\t116.\tManuel DG, Henry B, Hockin J, et al. Health behavior associated with",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_245",
        "document_id": "rr6007",
        "text": "116.\tManuel DG, Henry B, Hockin J, et al. Health behavior associated with \ninfluenza vaccination among healthcare workers in long-term-care \nfacilities. Infect Control Hosp Epidemiol 2002;23:609\u201314.\n\t117.\tNafziger DA, Herwaldt LA. Attitudes of internal medicine residents \nregarding influenza vaccination. Infect Control Hosp Epidemiol \n1994;15:32\u20135.\n\t118.\tOhrt CK, McKinney WP. Achieving compliance with influenza \nimmunization of medical house staff and students. A randomized \ncontrolled trial. JAMA 1992;267:1377\u201380.\n\t119.\tMcArthur MA, Simor AE, Campbell B, et al. Influenza vaccination in \nlong-term-care facilities: structuring programs for success. Infect \nControl Hosp Epidemiol 1999;20:499\u2013503.\n\t120.\tCDC. Interventions to increase influenza vaccination of health-care",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_246",
        "document_id": "rr6007",
        "text": "120.\tCDC. Interventions to increase influenza vaccination of health-care \nworkers\u2014California and Minnesota. MMWR 2005;54:196\u20139.\n\t121.\tPolgreen PM, Septimus EJ, Parry MF, et al. Relationship of influenza \nvaccination declination statements and influenza vaccination rates for \nhealthcare workers in 22 US hospitals. Infect Control Hosp Epidemiol \n2008;29:675\u20137.\n\t122.\tTalbot TR. Do declination statements increase health care worker \ninfluenza vaccination rates? Clin Infect Dis 2009;49:773\u20139.\nRecommendations and Reports\n32\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\n\t123.\tPolgreen PM, Chen Y, Beekmann S, et al. Elements of influenza \nvaccination programs that predict higher vaccination rates: results of \nan emerging infections network survey. Clin Infect Dis 2008;\u200b\n46:14\u20139.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_247",
        "document_id": "rr6007",
        "text": "an emerging infections network survey. Clin Infect Dis 2008;\u200b\n46:14\u20139.\n\t124.\tCDC. Influenza vaccination of health-care personnel: recommendations \nof the Healthcare Infection Control Practices Advisory Committee \n(HICPAC) and the Advisory Committee on Immunization Practices \n(ACIP). MMWR 2006;55(No. RR-2).\n\t125.\tPoland GA, Ofstead CL, Tucker SJ, et al. Receptivity to mandatory \ninfluenza vaccination policies for healthcare workers among registered \nnurses working on inpatient units. Infect Control Hosp Epidemiol \n2008;29:170\u20133.\n\t126.\tBabcock HM, Gemeinhart N, Jones M, et al. Mandatory influenza \nvaccination of health care workers: translating policy to practice. Clin \nInfect Dis 2010;50:459\u201364.\n\t127.\tJoint Commission on Accreditation of Healthcare Organizations. New",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_248",
        "document_id": "rr6007",
        "text": "127.\tJoint Commission on Accreditation of Healthcare Organizations. New \ninfection control requirement for offering influenza vaccination to staff \nand licensed independent practitioners. Jt Comm Perspect \n2006;26:10\u20131.\n\t128.\tNational Quality Forum. National voluntary consensus standards for \ninfluenza and pneumococcal immunizations. Available at http://www.\nqualityforum.org/Publications/2008/12/National_Voluntary_\nConsensus_Standards_for_Influenza_and_Pneumococcal_\nImmunizations.aspx. Accessed October 5, 2011.\n\t129.\tGovaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza \nvaccine in elderly people: randomised double blind placebo controlled \ntrial. BMJ 1993;307:988\u201390.\n\t130.\tMargolis KL, Nichol KL, Poland GA, et al. Frequency of adverse",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_249",
        "document_id": "rr6007",
        "text": "trial. BMJ 1993;307:988\u201390.\n\t130.\tMargolis KL, Nichol KL, Poland GA, et al. Frequency of adverse \nreactions to influenza vaccine in the elderly: a randomized, placebo-\ncontrolled trial. JAMA 1990;264:1139\u201341.\n\t131.\tCDC. Prevention and control of influenza with vaccines: \nrecommendations of the Advisory Committee on Immunization \nPractices (ACIP), 2011. MMWR 2011;60:1128\u201332.\n\t132.\tHarper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults \nand children\u2014diagnosis, treatment, chemoprophylaxis, and \ninstitutional outbreak management: clinical practice guidelines of the \nInfectious Diseases Society of America. Clin Infect Dis 2009;\u200b\n48:1003\u201332.\n\t133.\tCDC. Antiviral agents for the treatment and chemoprophylaxis of \ninfluenza: recommendations of the Advisory Committee on",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_250",
        "document_id": "rr6007",
        "text": "influenza: recommendations of the Advisory Committee on \nImmunization Practices (ACIP). MMWR 2011;60(No. RR-1).\n\t134.\tStrebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccine. In: \nPlotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, \nPA: W.B. Saunders; 2008:353\u201398.\n\t135.\tCDC. Measles, mumps, and rubella\u2014vaccine use and strategies for \nelimination of measles, rubella, and congenital rubella syndrome and \ncontrol of mumps: recommendations of the Advisory Committee on \nImmunization Practices (ACIP). MMWR 1998;47(No. RR-8).\n\t136.\tCDC. Progress toward measles elimination\u2014region of the Americas, \n2002\u20132003. MMWR 2004;53:304\u20136.\n\t137.\tOrenstein WA, Papania MH, Wharton ME. Measles elimination in \nthe United States. J Infect Dis 2004;189(Suppl 1):S1\u20133.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_251",
        "document_id": "rr6007",
        "text": "the United States. J Infect Dis 2004;189(Suppl 1):S1\u20133.\n\t138.\tWorld Health Organization. Measles fact sheet No.286. Available at \nhttp://www.who.int/mediacentre/factsheets/fs286/en/index.html. \nAccessed October 5, 2011.\n\t139.\tCDC. Global measles mortality, 2000\u20132008. MMWR 2009;\u200b\n58:1321\u20136.\n\t140.\tCDC. Outbreak of measles\u2014San Diego, California, January\u2013February \n2008. MMWR 2008;57:203\u20136.\n\t141.\tSugerman DE, Barskey, Delea MG, et al. Measles outbreak in a highly \nvaccinated population, San Diego, 2008: role of the intentionally \nundervaccinated. Pediatrics 2010;125:747\u201355.\n\t142.\tParker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles \noutbreak in Indiana for sustained elimination of measles in the United \nStates. N Engl J Med 2006;355:447\u201355.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_252",
        "document_id": "rr6007",
        "text": "States. N Engl J Med 2006;355:447\u201355.\n\t143.\tCDC. Measles\u2014United States, January\u2013July 2008. MMWR 2008;\u200b\n57:893\u20136.\n\t144.\tParker Fiebelkorn A, Redd SB, Gallagher, et al. Measles in the United \nStates during the postelimination era. J Infect Dis 2010;202:1520\u20138.\n\t145.\tFarizo KM, Stehr-Green PA, Simpson, DM, Markowitz LE. Pediatric \nemergency room visits\u2014a risk factor for acquiring measles. Pediatrics \n1991;87:74\u20139.\n\t146.\tRivera ME, Mason WH, Ross LA, Wright HT Jr. Nosocomial measles \ninfection in a pediatric hospital during a community-wide epidemic. \nJ Pediatr 1991;119:183\u20136.\n\t147.\tCDC. Immunization administration requirements for hospital \nemployees for MMR. Available at http://www2a.cdc.gov/nip/\nStateVaccApp/statevaccsApp/AdministrationbyVaccine.asp?\u200b",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_253",
        "document_id": "rr6007",
        "text": "StateVaccApp/statevaccsApp/AdministrationbyVaccine.asp?\u200b\nVaccinetmp=MMR. Accessed October 5, 2011.\n\t148.\tCDC. Coverage estimates for school entry vaccinations for school year \n2009\u20132010. School and childcare vaccination survey. Available at \nhttp://www2.cdc.gov/nip/schoolsurv/nationalavg.asp. Accessed \nOctober 5, 2011.\n\t149.\tChen SY, Anderson S, Kutty PK, et al. Health care-associated measles \noutbreak in the United States after an importation: challenges and \neconomic impact. J Infect Dis 2011;203:1517\u201325.\n\t150.\tSiegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare \nInfection Control Practices Advisory Committee. Guideline for \nisolation precautions: preventing transmission of infectious agents in \nhealthcare settings. 2007. Am J Infect Control 2007;35(10 Suppl 2):\u200b\nS65\u2013164.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_254",
        "document_id": "rr6007",
        "text": "healthcare settings. 2007. Am J Infect Control 2007;35(10 Suppl 2):\u200b\nS65\u2013164.\n\t151.\tSteingart KR, Thomas AR, Dykewicz CA, Redd SC. Transmission of \nmeasles virus in healthcare settings during a communitywide outbreak. \nInfect Control Hosp Epidemiol 1999;20:115\u20139.\n\t152.\tLeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles \nantibodies after 2 doses of measles vaccine in a postelimination \nenvironment. Arch Pediatr Adolesc Med 2007;161:294\u2013301.\n\t153.\tWilly ME, Kozoil DE, Fleisher T, et al. Measles immunity in a \npopulation of health-care workers. Infect Control Hosp Epidemiol \n1994;15:12\u20137.\n\t154.\tSchwarcz S, Mccaw B, Fukushima P. Prevalence of measles susceptibility \nin hospital staff: evidence to support expanding the recommendations",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_255",
        "document_id": "rr6007",
        "text": "in hospital staff: evidence to support expanding the recommendations \nof the Immunization Practices Advisory Committee. Arch Intern Med \n1992;152:1481\u20133.\n\t155.\tHouck P, Scottjohnson G, Krebs L. Measles immunity among \ncommunity hospital employees. Infect Control Hosp Epidemiol \n1991;12:663\u20138.\n\t156.\tWright LJ, Carlquist JF. Measles immunity in employees of a \nmultihospital health-care provider. Infect Control Hosp Epidemiol \n1994;15:8\u201311.\n\t157.\tWeber DJ, Consoil S, Sickbert-Bennett E, Miller MB, Rutala WA. \nSusceptibility to measles, mumps, and rubella in newly hired (2006\u2013\n2008) healthcare workers born before 1957. Infect Control Hosp \nEpidemiol 2010;31:655\u20137.\n\t158.\tBraunstein H, Thomas S, Ito R. Immunity to measles in a large",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_256",
        "document_id": "rr6007",
        "text": "Epidemiol 2010;31:655\u20137.\n\t158.\tBraunstein H, Thomas S, Ito R. Immunity to measles in a large \npopulation of varying age\u2014significance with respect to vaccination. \nAm J Dis Child 1990;144:296\u20138.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n33\n\t159.\tSmith E, Welch W, Berhow M, Wong VK. Measles susceptibility of \nhospital employees as determined by ELISA. Clin Res 1990;38:A183.\n\t160.\tKim M, LaPointe J, Liu FJ. Epidemiology of measles immunity in a \npopulation of healthcare workers. Infect Control Hosp Epidemiol \n1992;13:399\u2013402.\n\t161.\tMcQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, \nDayan GH. Seroprevalence of measles antibody in the US population, \n1999\u20132004. J Infect Dis 2007;196:1459\u201364.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_257",
        "document_id": "rr6007",
        "text": "1999\u20132004. J Infect Dis 2007;196:1459\u201364.\n\t162.\tHutchins SS, Bellini WJ, Coronado V, Jiles R, Wooten K, Deladisma \nA. Population immunity to measles in the United States, 1999. J Infect \nDis 2004;189:S91\u20137.\n\t163.\tBrodsky L, Stanievich J. Sensorineural hearing loss following live \nmeasles virus vaccination. Int J Pediatr Otorhinolaryngol 1985;\u200b\n10:159\u201363.\n\t164.\tMarshall GS, Wright PF, Fenichel GM, Karzon DT. Diffuse retinopathy \nfollowing measles, mumps, and rubella vaccination. Pediatrics \n1985;76:989\u2013991.\n\t165.\tKazarian EL, Gager W E. Optic neuritis complicating measles, mumps, \nand rubella vaccination. Am J Ophthalmol 1978;86:544\u20137.\n\t166.\tdaSilveira CM, Salisbury DM, deQuadros CA. Measles vaccination \nand Guillain-Barr\u00e9 syndrome. Lancet 1997;349(9044):14\u20136.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_258",
        "document_id": "rr6007",
        "text": "and Guillain-Barr\u00e9 syndrome. Lancet 1997;349(9044):14\u20136.\n\t167.\tHviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination \nand type 1 diabetes. N Engl J Med 2004;350:1398\u2013404.\n\t168.\tBernstein CN, Rawsthorne P, Blanchard JF. Population-based case-\ncontrol study of measles, mumps, and rubella and inflammatory bowel \ndisease. Inflamm Bowel Dis 2007;13:759\u201362.\n\t169.\tTaylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. \nMeasles, mumps, and rubella vaccination and bowel problems or \ndevelopmental regression in children with autism: population study. \nBMJ 2002;324(7334):393\u20136.\n\t170.\tGrabowsky M, Markowitz L. Serologic screening, mass immunization, \nand implications for immunization programs. J Infect Dis 1991;\u200b\n164:1237\u20138.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_259",
        "document_id": "rr6007",
        "text": "and implications for immunization programs. J Infect Dis 1991;\u200b\n164:1237\u20138.\n\t171.\tSubbarao EK, Amin S, Kumar ML. Prevaccination serologic screening \nfor measles in health-care workers. J Infect Dis 1991;163:876\u20138.\n\t172.\tSellick JA, Longbine D, Schifeling R, Mylotte JM. Screening hospital \nemployees for measles immunity is more cost-effective than blind \nimmunization. Ann InternMed 1992;116:982\u20134.\n\t173.\tAmmari LK, Bell LM, Hodinka R L. Secondary measles-vaccine failure \nin health-care workers exposed to infected patients. Infect Control \nHosp Epidemiol 1993;14:81\u20136.\n\t174.\tDayan GH, Rota K, Bellini W, Redd S. Measles. In: CDC. Manual \nfor the surveillance of vaccine-preventable diseases. Available at http://\nwww.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.pdf.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_260",
        "document_id": "rr6007",
        "text": "www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.pdf. \nAccessed October 5, 2011.\n\t175.\tPlotkin SA, Rubin SA. Mumps vaccine. In: Plotkin S, Orenstein W, \nOffit P, eds. Vaccines. 5th ed. Philadelphia, PA: W.B. Saunders; \n2008:435\u201365.\n\t176.\tCDC. Current trends mumps\u2014United States, 1980\u20131983. MMWR \n1983;32:545\u20137.\n\t177.\tCDC. Mumps vaccine. MMWR 1977;26:393\u20134.\n\t178.\tvan Loon FPL, Holmes SJ, Sirotkin BI, et al. Mumps surveillance\u2014\nUnited States, 1988\u20131993. MMWR 1995;44(No. SS-3).\n\t179.\tCDC. Measles prevention. MMWR 1989;38(Suppl 9).\n\t180.\tUS Department of Health and Human Services. Healthy people 2010: \nunderstanding and improving health. Washington, DC: US \nDepartment of Health and Human Services; 2000.\n\t181.\tCDC. Mumps epidemic\u2014Iowa, 2006. MMWR 2006;55:366\u20138.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_261",
        "document_id": "rr6007",
        "text": "181.\tCDC. Mumps epidemic\u2014Iowa, 2006. MMWR 2006;55:366\u20138.\n\t182.\tCDC. Multistate outbreak of mumps\u2014United States, January 1\u2013May \n2, 2006. MMWR 2006;55:559\u201363.\n\t183.\tDayan GH, Quinlisk MP, Parker AA. Recent resurgence of mumps in \nthe United States. N Engl J Med 2008;358:1580\u20139.\n\t184.\tCDC. Mumps outbreak\u2014New York and New Jersey, June 2009\u2013\nJanuary 2010. MMWR 2010;59:125\u20139.\n\t185.\tNelson G, Lizama-Aguon A, Quiambao E, et al. Third dose MMR \nintervention during a mumps outbreak in a highly\u2013vaccinated \npopulation\u2014Guam 2009\u20132010 [Presentation]. Presented at the 45th \nNational Immunization Conference, Washington, DC; March 29, 2011.\n\t186.\tGordon JE, Kilham L. Ten years in the epidemiology of mumps. Am \nJ Med Sci 1949;218:338\u201359.\n\t187.\tPhilip RN, Reinhard KR, Lackman DB, Observations on a mumps",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_262",
        "document_id": "rr6007",
        "text": "J Med Sci 1949;218:338\u201359.\n\t187.\tPhilip RN, Reinhard KR, Lackman DB, Observations on a mumps \nepidemic in a virgin population. Am J Hyg 1959;69:91\u2013111.\n\t188.\tCDC. Mumps. In: Atkinson, Wolfe C, Hamborsky J, eds. Epidemiology \nand prevention of vaccine-preventable diseases. Washington, DC: \nPublic Health Foundation; 2009:189\u201398.\n\t189.\tMeyer MB. An epidemiologic study of mumps: its spread in schools \nand families. Am J Hyg 1962;75:259\u201381.\n\t190.\tHarris RW, Kehrer AF, Isacson P. Relationship of occupations to risk \nof clinical mumps in adults. Am J Epidemiol 1969;89:264\u201370.\n\t191.\tWharton M, Cochi SL, Hutcheson RH, Schaffner W. Mumps \ntransmission in hospitals. Arch Intern Med 1990;150:47\u20139.\n\t192.\tFischer PR, Brunetti C, Welch V, Christenson JC. Nosocomial mumps:",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_263",
        "document_id": "rr6007",
        "text": "192.\tFischer PR, Brunetti C, Welch V, Christenson JC. Nosocomial mumps: \nreport of an outbreak and its control. Am J Infect Control \n1996;24:13\u20138.\n\t193.\tBonebrake AL, Silkaitis C, Monga G, et al. Effects of mumps outbreak \nin hospital, Chicago, Illinois, USA, 2006. Emerg Infect Dis \n2010;16:426\u201332.\n\t194.\tCDC. Updated recommendations of the Advisory Committee on \nImmunization Practices (ACIP) for the control and elimination of \nmumps. MMWR 2006;55:629\u201330.\n\t195.\tWeber SH, Merkel D, Miller P, Tilzer L, Kliethermes J, Horvat R. \nHospital and clinical laboratory response to mumps exposures. \nLabmedicine 2007;38:285\u20138.\n\t196.\tGalazka AM, Robertson SE, Kraigher A, Mumps and mumps vaccine: \na global review. Bull World Health Organ 1999;77:3\u201314.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_264",
        "document_id": "rr6007",
        "text": "a global review. Bull World Health Organ 1999;77:3\u201314.\n\t197.\tHersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly \nvaccinated population. J Pediatr 1991;119:187\u201393.\n\t198.\tCheek JE, Baron R, Atlas H, Wilson DL, Crider RD. Mumps outbreak \nin a highly vaccinated school population: evidence for large-scale \nvaccination failure. Arch Pediatr Adolesc Med 1995;149:774\u20138.\n\t199.\tSchaffzin JK, Pollock L, Schulte C, et al. Effectiveness of previous \nmumps vaccination during a summer camp outbreak. Pediatrics \n2007;120:e862\u20138.\n\t200.\tCohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, \n2004\u20132005 mumps outbreak, England. Emerg Infect Dis 2007;\u200b\n13:12\u20137.\n\t201.\tHarling R, White JM, Ramsay ME, Macsween KF, van den Bosch C.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_265",
        "document_id": "rr6007",
        "text": "13:12\u20137.\n\t201.\tHarling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. \nThe effectiveness of the mumps component of the MMR vaccine: a \ncase control study. Vaccine 2005;23:4070\u20134.\n\t202.\tMarin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron \nCW. Mumps vaccination coverage and vaccine effectiveness in a large \noutbreak among college students\u2014Iowa, 2006. Vaccine 2008;\u200b\n26:3601\u20137.\n\t203.\tDavidkin I, Valle M, Julkunen I, Persistence of anti-mumps virus \nantibodies after a two-dose MMR vaccination. A nine-year follow-up. \nVaccine 1995;13:1617\u201322.\nRecommendations and Reports\n34\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\n\t204.\tRubin SA, Qi L, Audet SA. et al. Antibody induced by immunization \nwith the Jeryl Lynn mumps vaccine strain effectively neutralizes a",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_266",
        "document_id": "rr6007",
        "text": "with the Jeryl Lynn mumps vaccine strain effectively neutralizes a \nheterologous wild-type mumps virus associated with a large outbreak. \nJ Infect Dis 2008;198:508\u201315.\n\t205.\tDate AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps \nantibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations \nand antibody response after a third MMR vaccination among a \nuniversity population. J Infect Dis 2008;197:1662\u20138.\n\t206.\tCortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance \namong university students during a mumps outbreak. Clin Infect Dis \n2008;46:1172\u201380.\n\t207.\tKutty PK, Kruszon-Moran DM, Dayan GH, et al. Seroprevalence of \nantibody to mumps virus in the US population, 1999\u20132004. J Infect \nDis 2010;202:667\u201374.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_267",
        "document_id": "rr6007",
        "text": "antibody to mumps virus in the US population, 1999\u20132004. J Infect \nDis 2010;202:667\u201374.\n\t208.\tBrunell PA, Brickman A, O\u2019Hare D, Steinberg S. Ineffectiveness of \nisolation of patients as a method of preventing the spread of mumps. \nFailure of the mumps skin-test antigen to predict immune status. N \nEngl J Med 1968;279:1357\u201361.\n\t209.\tKutty PK, Kyaw MH, Dayan GH, et al. Guidance for isolation \nprecautions for mumps in the United States: a review of the scientific \nbasis for policy change. Clin Infect Dis 2010;50:1619\u201328.\n\t210.\tWharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. \nA large outbreak of mumps in the postvaccine era. J Infect Dis \n1988;158:1253\u201360.\n\t211.\tPlotkin SA, Reef SE. Rubella vaccine. In: Plotkin S, Orenstein W,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_268",
        "document_id": "rr6007",
        "text": "1988;158:1253\u201360.\n\t211.\tPlotkin SA, Reef SE. Rubella vaccine. In: Plotkin S, Orenstein W, \nOffit P, eds. Vacciness 5th ed. Philadelphia, PA: W.B. Saunders; \n2008:735\u201371.\n\t212.\tBosma TJ, Etherington J, O\u2019Shea S, et al. Rubella virus and chronic joint \ndisease: is there an association? J Clin Microbiol 1998;36:3524\u20136.\n\t213.\tAmerican Academy of Pediatrics. Rubella. In: Pickering LK, Baker CJ, \nKimberlin DW, Long SS, eds. 2009 red book: report of the Committee \non Infectious Diseases. 28th ed. Elk Grove Village, IL: American \nAcademy of Pediatrics; 2009:579\u201384.\n\t214.\tGreen RH, Balsamo MR, Giles JP, Krugman S, Mirick GS. Studies of \nthe natural history and prevention of rubella. Am J Dis Child \n1965;110:348\u201365.\n\t215.\tIngalls TH, Plotkin SA, Meyer HM Jr, Parkman PD. Rubella:",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_269",
        "document_id": "rr6007",
        "text": "1965;110:348\u201365.\n\t215.\tIngalls TH, Plotkin SA, Meyer HM Jr, Parkman PD. Rubella: \nepidemiology, virology, and immunology. Am J Med Sci 1967;\u200b\n253:349\u201373.\n\t216.\tOrenstein WA, Bart KJ, Hinman AR, et al. The opportunity and \nobligation to eliminate rubella from the United States. JAMA \n1984;251:1988\u201394.\n\t217.\tWilliams NM, Preblud SR. Rubella and congenital rubella surveillance, \n1983. MMWR 1984;33(No. SS-4):1\u201310.\n\t218.\tCochi SL, Edmonds LE, Dyer K, et al. Congenital rubella syndrome \nin the United States, 1970\u20131985: on the verge of elimination. Am J \nEpidemiol 1989;129:349\u201361.\n\t219.\tCDC. Achievements in public health: elimination of rubella and \ncongenital rubella syndrome\u2014United States, 1969\u2013 2004. MMWR \n2005;54:279\u201382.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_270",
        "document_id": "rr6007",
        "text": "congenital rubella syndrome\u2014United States, 1969\u2013 2004. MMWR \n2005;54:279\u201382.\n\t220.\tReef SE, Cochi SL. The evidence for the elimination of rubella and \ncongenital rubella syndrome in the United States: a public health \nachievement. Clin Infect Dis 2006;43(Suppl 3):S123\u20135.\n\t221.\tGreaves WL, Orenstein WA, Stetler HC, Preblud SR, Hinman AR, \nBart KJ. Prevention of rubella transmission in medical facilities. JAMA \n1982;248:861\u20134.\n\t222.\tGladstone JL. Rubella exposure in an obstetric clinic. Obstet Gynecol \n1981;57:182\u20136.\n\t223.\tCDC. Nosocomial rubella infection\u2014North Dakota, Alabama, Ohio. \nMMWR 1981;29:629\u201331.\n\t224.\tCDC. Exposure of patients to rubella by medical personnel\u2014\nCalifornia. MMWR 1978;27:123.\n\t225.\tStrassburg MA, Imagawa DT, Fannin SL, et al. Rubella outbreak among",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_271",
        "document_id": "rr6007",
        "text": "225.\tStrassburg MA, Imagawa DT, Fannin SL, et al. Rubella outbreak among \nhospital employees. Obstet Gynecol 1981;57:283\u20138.\n\t226.\tFliegel PE, Weinstein WM. Rubella outbreak in a prenatal clinic: \nmanagement and prevention. Am J Infect Control 1982;10:29\u201333.\n\t227.\tPolk BF, White JA, DeGirolami PC, Modlin JF. An outbreak of rubella \namong hospital personnel. N Engl J Med 1980;303:541\u20135.\n\t228.\tMcLaughlin MC, Gold LH. The New York rubella incident: a case for \nchanging hospital policy regarding rubella testing and immunization. \nAm J Public Health 1979;69:287\u20139.\n\t229.\tCDC. Rubella in hospital personnel and patients\u2014Colorado. MMWR \n1979;28:325\u20137.\n\t230.\tHeseltine PNR, Ripper M, Wohlford P. Nosocomial rubella: \nconsequences of an outbreak and efficacy of a mandatory immunization",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_272",
        "document_id": "rr6007",
        "text": "consequences of an outbreak and efficacy of a mandatory immunization \nprogram. Infect Control 1985;6:371\u20134.\n\t231.\tCDC. Epidemiologic notes and reports rubella in hospitals\u2014California. \nMMWR 1983;32:37\u20139.\n\t232.\tPapania M, Reef S, Jumaan A, Linigappa JR, Williams WW. \nNosocomial measles, mumps, rubella, and other viral infections. In: \nMayhall CG, ed. Hospital epidemiology and infection control. 3rd ed. \nPhiladelphia, PA: Lippincott Williams & Wilkins; 2004:829\u201349.\n\t233.\tde Valk H, Rebi\u00e8re I. [Epidemic of rubella: evaluation of the vaccine \nefficacy on the ground]. Saint Maurice, France: R\u00e9seau National de \nSant\u00e9 Publique; 1998:1\u201352.\n\t234.\tWeibel RE, Carlson AJ Jr, Villarejos VM, et al. Clinical and laboratory \nstudies of combined live measles, mumps, and rubella vaccines using",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_273",
        "document_id": "rr6007",
        "text": "studies of combined live measles, mumps, and rubella vaccines using \nthe RA 27/3 rubella virus. Proc Soc Exp Biol Med 1980;165:323\u20136.\n\t235.\tBalfour HH, Groth KE, Edelman CK, RA 27/3 rubella vaccine\u2014a \nfour-year follow-up. Am J Dis Child, 1980;134:350\u20133.\n\t236.\tWeibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, \nHilleman MR. Clinical and laboratory studies of live attenuated RA \n27/3 and HPV 77-DE rubella virus vaccines. Proc Soc Exp Biol Med \n1980;165:44\u20139.\n\t237.\tDavidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence \nof measles, mumps, and rubella antibodies in an MMR-vaccinated \ncohort: a 20-year follow-up. J Infect Dis 2008;197:950\u20136.\n\t238.\tLeBaron CW, Forghani B, Matter L, et al. Persistence of rubella",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_274",
        "document_id": "rr6007",
        "text": "238.\tLeBaron CW, Forghani B, Matter L, et al. Persistence of rubella \nantibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis \n2009;200:888\u201399.\n\t239.\tHyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani \nB, Reef SE. Rubella immunity levels in the United States population: \nhas the threshold of viral elimination been reached? Clin Infect Dis \n2006;43(Suppl 3):S146\u201350.\n\t240.\tFraser V, Spitznagel E, Medoff G, Dunagan WC. Results of a rubella \nscreening program for hospital employees: a five-year review (1986\u2013\n1990). Am J Epidemiol 1993;138:756\u201364.\n\t241.\tHartstein AI, Quan MA, Williams ML, Osterud HT, Foster LR. Rubella \nscreening and immunization of health care personnel: critical appraisal \nof a voluntary program. Am J Infect Control 1983;11:1\u20139.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_275",
        "document_id": "rr6007",
        "text": "of a voluntary program. Am J Infect Control 1983;11:1\u20139.\n\t242.\tWeiss KE, Flavo CD, Buimovici-Klein E, Magill JW, Cooper LZ. \nEvaluation of an employee health service as a setting for a rubella screening \nand immunization program. Am J Public Health 1979;69:281\u20133.\n\t243.\tCDC. Revised ACIP recommendation for avoiding pregnancy after \nreceiving a rubella-containing vaccine. MMWR 2001;50:1117.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n35\n\t244.\tCDC. Control and prevention of rubella: evaluation and management \nof suspected outbreaks, rubella in pregnant women, and surveillance \nfor congenital rubella syndrome. MMWR 2001;50(No. RR-12).\n\t245.\tSchiff GM. Titered lots of immune globulin (Ig). Efficacy in the \nprevention of rubella. Am J Dis Child 1969;118:322\u20137.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_276",
        "document_id": "rr6007",
        "text": "prevention of rubella. Am J Dis Child 1969;118:322\u20137.\n\t246.\tMortimer EA Jr. Pertussis vaccine. In: Plotkin SA, Mortimer EA, eds. \nVaccines. 2nd ed. Philadelphia, PA: W.B. Saunders; 1994:94. \n\t247.\tMortimer EA Jr. Pertussis and its prevention: a family affair. J Infect \nDis 1990;161:473\u20139. \n\t248.\tCDC. Updated Tdap vaccination coverage rates. 2009 Adult \nvaccination coverage, National Interview Survey. Available at http://\nwww.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm. Accessed \nOctober 5, 2011.\n\t249.\tChristie C, Glover AM, Willke MJ, Marx ML, Reising SF, Hutchinson \nNM. Containment of pertussis in the regional pediatric hospital during \nthe greater Cincinnati epidemic of 1993. Infect Control Hosp \nEpidemiol 1995;16:556\u201363.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_277",
        "document_id": "rr6007",
        "text": "the greater Cincinnati epidemic of 1993. Infect Control Hosp \nEpidemiol 1995;16:556\u201363. \n\t250.\tKurt TL, Yeager AS, Guennette S, Dunlop S. Spread of pertussis by \nhospital staff. JAMA 1972;221:264\u20137. \n\t251.\tLinnemann CC, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine \nin an epidemic involving hospital staff. Lancet 1975;2:540\u20133. \n\t252.\tValenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible \nspread by a hospital visitor. Am J Dis Child 1980;134:520\u20131.\n\t253.\tDeville JG, Cherry JD, Christenson PD, et al. Frequency of \nunrecognized Bordetella pertussis infections in adults. Clin Infect Dis \n1995;21:639\u201342.\n\t254.\tWright SW, Decker MD, Edwards KM. Incidence of pertussis infection \nin healthcare workers. Infect Control Hosp Epidemiol 1999;\u200b\n20:120\u20133.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_278",
        "document_id": "rr6007",
        "text": "in healthcare workers. Infect Control Hosp Epidemiol 1999;\u200b\n20:120\u20133.\n\t255.\tCalugar A, Ortega-S\u00e1nchez IR, Tiwari T, Oakes L, Jahre JA, Murphy \nTV. Nosocomial pertussis: costs of an outbreak and benefits of \nvaccinating health care workers. Clin Infect Dis 2006;42:981\u20138.\n\t256.\tWard JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis \nvaccine among adolescents and adults. N Engl J Med 2005;\u200b\n353:1555\u201363.\n\t257.\tRank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after \nmass immunization of high school students in Australia. Pediatr Infect \nDis J 2009;28:152\u20133. \n\t258.\tWei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult \ntetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap) \nagainst pertussis. Clin Infect Dis 2010;51:315\u201321.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_279",
        "document_id": "rr6007",
        "text": "against pertussis. Clin Infect Dis 2010;51:315\u201321.\n\t259.\tKlein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation \nof a tetanus toxoid, reduced diphtheria toxoid and 3-component \nacellular pertussis vaccine administered to a cohort of adolescents in a \nUnited States health maintenance organization. Pediatr Infect Dis J \n2010;29:613\u20137.\n\t260.\tBlatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity \nand safety of a tetanus toxoid, reduced diphtheria toxoid and three-\ncomponent acellular pertussis vaccine in adults 19\u201364 years of age. \nVaccine 2009;27:765\u201372.\n\t261.\tPichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, \ndiphtheria, and 5-component pertussis vaccine for use in adolescents \nand adults. JAMA 2005;293:3003\u201311.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_280",
        "document_id": "rr6007",
        "text": "and adults. JAMA 2005;293:3003\u201311.\n\t262.\tJackson LA, Yu O, Nelson J, et al. Risk of medically attended local \nreactions following diphtheria toxoid containing vaccines in adolescents \nand young adults: a Vaccine Safety Datalink study. Vaccine \n2009;27:4912\u20136.\n\t263.\tYih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety \nof adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) \nvaccine, using active surveillance for adverse events in the Vaccine Safety \nDatalink. Vaccine 2009;27:4257\u201362.\n\t264.\tGoins W, Edwards KM, Vnencak-Jones CL, et al. Comparison of two \nstrategies to prevent pertussis in vaccinated healthcare personnel \nfollowing pertussis exposure [Presentation]. Presented at the \nInternational Conference of Healthcare-Associated Infections, Atlanta,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_281",
        "document_id": "rr6007",
        "text": "International Conference of Healthcare-Associated Infections, Atlanta, \nGeorgia; March 18\u201322, 2010.\n\t265.\tGarner JS. Guideline for isolation precautions in hospitals. The Hospital \nInfection Control Practices Advisory Committee. Infect Control Hosp \nEpidemiol 1996;17:53\u201380.\n\t266.\tCDC. Prevention of varicella: recommendations of the Advisory \nCommittee on Immunization Practices (ACIP). MMWR 2007;56\u200b\n(No. RR-4).\n\t267.\tGuris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology \nin active surveillance sites\u2014United States, 1995\u20132005. J Infect Dis \n2008;197(Suppl 2):S71\u201375.\n\t268.\tLopez AS, Zhang J, Brown C, Bialek S. Varicella-related hospitalizations \nin the United States, 2000\u20132006: the 1-dose varicella vaccination era. \nPediatrics 2011;127:238\u201345.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_282",
        "document_id": "rr6007",
        "text": "in the United States, 2000\u20132006: the 1-dose varicella vaccination era. \nPediatrics 2011;127:238\u201345.\n\t269.\tMarin M, Zhang JX, Seward JF. Near elimination of varicella deaths \nin the US following implementation of the childhood vaccination \nprogram. Pediatrics 2011;128:214\u201320.\n\t270.\tKattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose \nvaccination on varicella epidemiology: Connecticut\u20132005\u20132008. J \nInfect Dis 2011;203:509\u201312.\n\t271.\tReynolds M, Kruszon-Moran D, Jumaan AO, Schmid DS, McQuillan \nGM. Varicella seroprevalence in the United States: data from the \nNational Health and Nutrition Examination Survey (NHANES), \n1999\u20132004. Public Health Rep 2010;125:860\u20139.\n\t272.\tSeward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_283",
        "document_id": "rr6007",
        "text": "272.\tSeward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. \nContagiousness of varicella in vaccinated cases: a household contact \nstudy. JAMA 2004;292:851\u20135.\n\t273.\tSaiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to \nvaricella-zoster virus vaccination among health care workers. Infect \nControl Hosp Epidemiol 2001;22:279\u201383.\n\t274.\tAmpofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon \nA. Persistence of immunity to live attenuated varicella vaccine in healthy \nadults. Clin Infect Dis 2002;34:774\u20139.\n\t275.\tLee BW. Review of varicella zoster seroepidemiology in India and \nSoutheast Asia. Trop Med Int Health 1998;3:886\u201390. \n\t276.\tLongfield JN, Winn Re, Gibson RL, Juchau SV, Hoffman PV. Varicella",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_284",
        "document_id": "rr6007",
        "text": "276.\tLongfield JN, Winn Re, Gibson RL, Juchau SV, Hoffman PV. Varicella \noutbreak in army recruits from Puerto Rico. Varicella susceptibility in \na population from the tropics. Arch Intern Med 1990;150:970\u20133.\n\t277.\tMeyers JD, MacQuarrie MB, Merigan TC, Jennison MH. Varicella. \nPart 1: outbreak in oncology patients at a children\u2019s hospital. West J \nMed 1979;130:196\u20139.\n\t278.\tGustafson TL, Shehab Z, Brunell PA. Outbreak of varicella in a \nnewborn intensive care nursery. Am J Dis Child 1984;138:548\u201350. \n\t279.\tHyams PJ, Stuewe MCS, Heitzer V. Herpes zoster causing varicella \n(chicken pox) in hospital employees: cost of a casual attitude. Am J \nInfect Control 1984;12:2\u20135. \n\t280.\tWeitekamp MR, Schan P, Aber RC. An algorithm for the control of",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_285",
        "document_id": "rr6007",
        "text": "Infect Control 1984;12:2\u20135. \n\t280.\tWeitekamp MR, Schan P, Aber RC. An algorithm for the control of \nvaricella-zoster virus. Am J Infect Control 1985;13:193\u20138. \n\t281.\tAlter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to \nvaricella-zoster virus among adults at high risk for exposure. Infect \nControl 1986;7:448\u201351. \nRecommendations and Reports\n36\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\n\t282.\tKrasinski K, Holzman RS, LaCouture R, Florman A. Hospital \nexperience with varicella-zoster virus. Infect Control 1986;7:312\u20136. \n\t283.\tWeber DJ, Rutala WA, Parham C. Impact and costs of varicella \nprevention in a university hospital. Am J Public Health 1988;\u200b\n78:19\u201323. \n\t284.\tAsano Y, Iwayama S, Miyata T, et al. Spread of varicella in hospitalized",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_286",
        "document_id": "rr6007",
        "text": "78:19\u201323. \n\t284.\tAsano Y, Iwayama S, Miyata T, et al. Spread of varicella in hospitalized \nchildren having no direct contact with an indicator zoster case and its \nprevention by a live vaccine. Biken J 1980;23:157\u201361. \n\t285.\tLeclair JM, Zaia JA, Levine MJ, Congdon RG, Goldmann DA. \nAirborne transmission of chickenpox in a hospital. N Engl J Med \n1980;302:450\u20133. \n\t286.\tGustafson TL, Lavely GB, Brawner ER, Hutcheson RH, Wright PF, \nSchaffner W. An outbreak of airborne varicella. Pediatrics 1982;\u200b\n70:550\u20136.\n\t287.\tJosephson A, Gombert ME. Airborne transmission of nosocomial \nvaricella from localized zoster. J Infect Dis 1988;158:238\u201341. \n\t288.\tSawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. \nDetection of varicella-zoster virus DNA in air samples from hospital",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_287",
        "document_id": "rr6007",
        "text": "Detection of varicella-zoster virus DNA in air samples from hospital \nroom. J Infect Dis 1994;169:91\u20134. \n\t289.\tBehrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary \nvaricella cases among healthcare workers with false-positive varicella \nzoster virus titers. Infect Control Hosp Epidemiol 2003;24:202\u20136.\n\t290.\tAdler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of \nvaricella with likely breakthrough disease in a population of pediatric \ncancer patients.Infect Control Hosp Epidemiol 2008;29:866\u201370.\n\t291.\tLopez SA, Burnett-Hartman A, Nambiar R, et al. Transmission of a \nnewly characterized strain of varicella-zoster virus from a patient with \nherpes zoster in a long-term-care facility, West Virginia, 2004. J Infect \nDis 2008;197:646\u201353.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_288",
        "document_id": "rr6007",
        "text": "herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect \nDis 2008;197:646\u201353.\n\t292.\tHaiduven-Griffiths D, Fecko H. Varicella in hospital personnel: a \nchallenge for the infection control practitioner. Am J Infect Control \n1987;15:207\u201311.\n\t293.\tSeward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the \nUS vaccination program: a review. J Infect Dis 2008;197(Suppl):S82\u20139.\n\t294.\tShapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of \nvaricella vaccine in children. J Infect Dis 2011;203:312\u20135\n\t295.\tMerck & Co., Inc. VARIVAX [Package insert]. Whitehouse Station, \nNJ: Merck & Co., Inc.; 1995.\n\t296.\tGershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, \nGelb L. Immunization of healthy adults with live attenuated varicella",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_289",
        "document_id": "rr6007",
        "text": "Gelb L. Immunization of healthy adults with live attenuated varicella \nvaccine. J Infect Dis 1988;158:132\u20137\n\t297.\tZerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of \nhumoral and cellular immunity in children and adults immunized with \nvaricella vaccine. J Infect Dis 1998;177:1701\u20134.\n\t298.\tChaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, \nSeward JF. Safety of varicella vaccine after licensure in the United States: \nexperience from reports to the Vaccine Adverse Event Reporting System, \n1995\u20132005. J Infect Dis. 2008;197(Suppl):S170\u20137.\n\t299.\tGershon AA, Takahashi M, Seward JF. Varicella vaccine. In: Plotkin \nSA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia, PA: \nW.B. Saunders. In press.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_290",
        "document_id": "rr6007",
        "text": "SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia, PA: \nW.B. Saunders. In press.\n\t300.\tLopez AS, Marin M. Strategies for the control and investigation of \nvaricella outbreaks, 2008. Available at http://www.cdc.gov/vaccines/\nvpd-vac/varicella/outbreaks/manual.htm. Accessed October 5, 2011.\n\t301.\tAmerican Academy of Pediatrics. Varicella-zoster. In: Pickering LK, \nBaker CJ, Kimberlin DW, Long SS, eds. 2009 red book: report of the \nCommittee on Infectious Diseases. 28th ed. Elk Grove Village, IL: \nAmerican Academy of Pediatrics; 2009:714\u201327.\n\t302.\tCohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria \nmeningitidis disease epidemiology in the United States, 1998\u20132007: \nimplications for prevention of meningococcal disease. Clin Infect Dis \n2010;50:184\u201391.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_291",
        "document_id": "rr6007",
        "text": "implications for prevention of meningococcal disease. Clin Infect Dis \n2010;50:184\u201391.\n\t303.\tCDC. Guideline for isolation precautions in hospitals. Recommendations \nof the Hospital Infection Control Practices Advisory Committee \n(HICPAC) and the National Center for Infectious Diseases. Infect \nControl Hosp Epidemiol 1996;17:53\u201380.\n\t304.\tCDC. Occupational transmission of Neisseria meningitidis\u2014California, \n2009. MMWR 2010:59;1480\u20133.\n\t305.\tCDC. Prevention and control of meningococcal disease: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). MMWR \n2005;54(No. RR-7).\n\t306.\tCDC. Licensure of a meningococcal conjugate vaccine (Menveo) and \nguidance for use\u2014Advisory Committee on Immunization Practices \n(ACIP), 2010. MMWR 2010;59:273.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_292",
        "document_id": "rr6007",
        "text": "guidance for use\u2014Advisory Committee on Immunization Practices \n(ACIP), 2010. MMWR 2010;59:273.\n\t307.\tCDC. Updated recommendations for use of meningococcal conjugate \nvaccines\u2014Advisory Committee on Immunization Practices (ACIP), \n2010. MMWR 2011;60:72\u20136. \n\t308.\tWu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-\nresistant Neisseria meningitidis in North America. New Eng J Med \n2009;360:886\u201392.\n\t309.\tLynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United \nStates, 1999\u20132006. JAMA. 2009;302:859\u201365. \n\t310.\tSteinberg EB, Bishop RB, Dempsey AF, et al. Typhoid fever in travelers: \nwho should be targeted for prevention? Clin Infect Dis 2004;\u200b\n39:186\u201391. \n\t311.\tCrump JA, Kretsinger K, Gay K, et al. Clinical response and outcome",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_293",
        "document_id": "rr6007",
        "text": "39:186\u201391. \n\t311.\tCrump JA, Kretsinger K, Gay K, et al. Clinical response and outcome \nof infection with Salmonella enterica serotype Typhi with decreased \nsusceptibility to fluoroquinolones: a United States FoodNet Multicenter \nretrospective Cohort Study. Antimicrob Agents Chemother 2008;\u200b\n52:1278\u201384.\n\t312.\tCrump JA, Barrett TJ, Nelson JT, et al. Reevaluating fluoroquinolone \nbreakpoints for Salmonella enterica serotype Typhi and non-Typhi \nSalmonellae. Antimicrobial Resistance 2003;37:75\u201381.\n\t313.\tCDC. National Antimicrobial Resistance Monitoring System for \nEnteric Bacteria (NARMS): human isolates final report, 2008. Atlanta, \nGA: US Department of Health and Human Services, CDC; 2010.\n\t314.\tGupta S, Medalla F, Omondi MW, et al. Laboratory-based surveillance",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_294",
        "document_id": "rr6007",
        "text": "314.\tGupta S, Medalla F, Omondi MW, et al. Laboratory-based surveillance \nfor paratyphoid fever in the United States: travel and antimicrobial \nresistance. Clin Infect Dis 2008;46:1656\u201363.\n\t315.\tMermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United \nStates, 1985\u20131994: changing risks of international travel and increasing \nantimicrobial resistance. Arch Intern Med 1998;158:633\u20138.\n\t316.\tCDC. Typhoid immunization: recommendations of the Advisory \nCommittee on Immunization Practices (ACIP). MMWR 1994;43 \n(No. RR-14).\n\t317.\tBhattarai A, Mintz E. Typhoid and paratyphoid. In: CDC health \ninformation for international travel 2012. New York, NY: Oxford \nUniversity Press; 2012.\n\t318.\tBegier EM, Burwen DR, Haber P, Ball R. Vaccine Adverse Event",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_295",
        "document_id": "rr6007",
        "text": "University Press; 2012.\n\t318.\tBegier EM, Burwen DR, Haber P, Ball R. Vaccine Adverse Event \nReporting System Working Group. Postmarketing safety surveillance \nfor typhoid fever vaccines from the Vaccine Adverse Event Reporting \nSystem, July 1990 through 2002. Clin Infect Dis 2004;38:771\u20139.\n\t319.\tStrebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis \nin the United States one decade after the last reported case of indigenous \nwild virus-associated disease. Clin Infect Dis 1992:14:568\u201379.\n\t320.\tCDC. Certification of poliomyelitis elimination\u2014the Americas, 1994. \nMMWR 1994;43:720\u20132.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n37\n\t321.\tCDC. Poliomyelitis prevention in the United States. MMWR \n2000;49(No. RR-5).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_296",
        "document_id": "rr6007",
        "text": "37\n\t321.\tCDC. Poliomyelitis prevention in the United States. MMWR \n2000;49(No. RR-5).\n\t322.\tAlexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes \nand epidemiology of poliomyelitis in the United States. JAMA \n2004;292:1696\u2013701.\n\t323.\tCDC. Imported vaccine-associated paralytic poliomyelitis\u2014United \nStates, 2005. MMWR 2006;55:97\u20139.\n\t324.\tDeVries AS, Harper J, Murray A, et al. Neuroinvasive immunodeficiency-\nassociated vaccine-derived poliomyelitis twelve years after infection\u2014\nMinnesota, 2008. N Engl J Med 2011;364:2316\u201323.\n\t325.\tAlexander JP, Jr., Ehresmann K, Seward J, et al. Transmission of \nimported vaccine-derived poliovirus in an undervaccinated community \nin Minnesota. J Infect Dis 2009;199:391\u20137.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_297",
        "document_id": "rr6007",
        "text": "in Minnesota. J Infect Dis 2009;199:391\u20137.\n\t326.\tVidor E, Meschievitz C, Plotkin S. Fifteen years of experience with \nVero-produced enhanced potency inactivated poliovirus vaccine. Pediatr \nInfect Dis J 1997;16:312\u201322.\n\t327.\tCDC. Recommended adult immunization schedule\u2014United States, \n2011. MMWR 2011;60:1\u20134.\n\t328.\tBriss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence \nregarding interventions to improve vaccination coverage in children, \nadolescents, and adults. The Task Force on Community Preventive \nServices. Am J Prev Med 2000;18(1 Suppl):97\u2013140.\n\t329.\tKroger A, Atkinson W. General recommendations for vaccination and \nimmunoprophylaxis. In: CDC. CDC health information for \ninternational travel 2012. New York, NY: Oxford University Press; 2012.\nRecommendations and Reports\n38",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_298",
        "document_id": "rr6007",
        "text": "Recommendations and Reports\n38\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nTABLE 1. Recommendations for immunization practices and use of \nimmunobiologics applicable to disease prevention among health-\ncare personnel* \u2014 Advisory Committee on Immunization Practices \n(ACIP), June 9, 1989\u2013August 26, 2011 \n Subject\nPublication in MMWR\nGeneral recommendations on immunization\n2011;60(No. RR-2)\nDiphtheria, tetanus, and pertussis\n1991;40(No. RR-10)\n1997;46(No. RR-7)\nHepatitis B\n1991;40;(No. RR-8)\u2020\n1991;40(No. RR-13)\n2001;50(No. RR-11)\u2020\n2006;55(No. RR-16)\n2008;57(No. RR-8)\u2020\nInfluenza\u00a7\n2010;59(No. RR-8)\n2011;60:1128\u201332\nMeasles, mumps, rubella (MMR)\n1998;47(No. RR-8)\nMeningococcal disease and outbreaks\n2005;54(No. RR-7)\n2011;60:72\u20136\nMumps (see also MMR and Measles)\n1989;38:388\u201392, 397\u2013400",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_299",
        "document_id": "rr6007",
        "text": "2005;54(No. RR-7)\n2011;60:72\u20136\nMumps (see also MMR and Measles)\n1989;38:388\u201392, 397\u2013400\n2006;55;629\u2013630\nPertussis, acellular (see also Diphtheria, \ntetanus, and pertussis)\n2006;55(No. RR-3)\n2006;55(No. RR-17)\n2008;57(No. RR-4)\n2011;60:13\u201315\nPoliomyelitis\n2000;49(No. RR-5)\n2009;58:829\u201330\nRubella (see also MMR, Measles, and Mumps)\n2001;50:1117\nTyphoid\n1994;43(No. RR-14)\nVaricella\n2007;56(No. RR-4)\n*\tPersons who provide health care to patients or work in institutions that provide \npatient care (e.g., physicians, nurses, emergency medical personnel, dental \nprofessionals and students, medical and nursing students, laboratory \ntechnicians, hospital volunteers, and administrative and support staff in health-\ncare institutions). Source: U.S. Department of Health and Human Services.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_300",
        "document_id": "rr6007",
        "text": "care institutions). Source: U.S. Department of Health and Human Services. \nDefinition of health-care personnel (HCP). Available at http://www.hhs.gov/\nask/initiatives/vacctoolkit/definition.html. \n\u2020\tThis report provides guidance from CDC and is not an ACIP statement.\n\u00a7\tEach year influenza vaccine recommendations are reviewed and amended to \nreflect updated information concerning influenza activity in the United States for \nthe preceding influenza season and to provide information on the vaccine available \nfor the upcoming influenza season. These recommendations are published \nperiodically in MMWR. The most current published recommendations should be \nconsulted (available at http://www.cdc.gov/vaccines/pubs/acip-list.htm). \nRecommendations and Reports",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_301",
        "document_id": "rr6007",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n39\nTABLE 2. Immunizing agents and immunization schedules for health-care personnel (HCP)* \nGeneric name\nPrimary schedule and \nbooster(s)\nIndications\nMajor precautions and \ncontraindications\nSpecial considerations\nImmunizing agents recommended for all HCP\nHepatitis B (HB) \nrecombinant vaccine\n2 doses 4 weeks apart; \nthird dose 5 months \nafter second; booster \ndoses not necessary; \nall doses should be \nadministered IM in the \ndeltoid\nPreexposure: HCP at risk for \nexposure to blood or body \nfluids; postexposure (see \nTable 4)\nOn the basis of limited data, \nno risk for adverse effects to \ndeveloping fetuses is apparent. \nPregnancy should not be \nconsidered a contraindication to \nvaccination of women. Previous",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_302",
        "document_id": "rr6007",
        "text": "Pregnancy should not be \nconsidered a contraindication to \nvaccination of women. Previous \nanaphylactic reaction to common \nbaker\u2019s yeast is a contraindication \nto vaccination.\nThe vaccine produces neither therapeutic \nnor adverse effects in HBV-infected persons. \nPrevaccination serologic screening is not \nindicated for persons being vaccinated because \nof occupational risk but might be indicated for \nHCP in certain high-risk populations. HCP at \nhigh risk for occupational\u2020 contact with blood or \nbody fluids should be tested 1\u20132 months after \nvaccination to determine serologic response.\nHepatitis B immune \nglobulin (HBIG)\n0.06 mL/kg IM as \nsoon as possible after \nexposure, if indicated \nPostexposure prophylaxis \n(see Table 4)\nSee package insert\u00a7\nInfluenza vaccine (TIV \nand LAIV)",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_303",
        "document_id": "rr6007",
        "text": "Postexposure prophylaxis \n(see Table 4)\nSee package insert\u00a7\nInfluenza vaccine (TIV \nand LAIV)\nAnnual vaccination \nwith current seasonal \nvaccine. TIV is \navailable in IM and \nID formulations. \nLAIV is administered \nintranasally.\nAll HCP \nHistory of severe  (e.g., \nanaphylactic) hypersensitivity to \neggs; prior severe allergic reaction \nto influenza vaccine\nNo evidence exists of risk to mother of fetus when \nthe vaccine is administered to a pregnant woman \nwith an underlying high-risk condition. Influenza \nvaccination is recommended for women who \nare or will be pregnant during influenza season \nbecause of increased risk for hospitalization \nand death. LAIV is recommended only for \nhealthy, non\u2013pregnant persons aged 2\u201349 years. \nIntradermal vaccine is indicated for persons",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_304",
        "document_id": "rr6007",
        "text": "healthy, non\u2013pregnant persons aged 2\u201349 years. \nIntradermal vaccine is indicated for persons \naged 18\u201364 years. HCP who care for severely \nimmunosuppressed persons who require a \nprotective environment should receive TIV rather \nthan LAIV.\nMeasles live\u2013virus \nvaccine\n2 doses SC; \u226528 days \napart\nVaccination should be \nrecommended for all HCP \nwho lack presumptive \nevidence of immunity;\u00b6 \nvaccination should be \nconsidered for those born \nbefore 1957.\nPregnancy; immunocompromised \npersons,** including HIV-infected \npersons who have evidence of \nsevere immunosuppression; \nanaphylaxis to gelatin or \ngelatin-containing products; \nanaphylaxis to neomycin; and \nrecent administration of immune \nglobulin.\nHCP vaccinated during 1963\u20131967 with a killed",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_305",
        "document_id": "rr6007",
        "text": "recent administration of immune \nglobulin.\nHCP vaccinated during 1963\u20131967 with a killed \nmeasles vaccine alone, killed vaccine followed by \nlive vaccine, or a vaccine of unknown type should \nbe revaccinated with 2 doses of live measles virus \nvaccine.\nMumps live\u2013virus \nvaccine\n2 doses SC; \u226528 days \napart\nVaccination should be \nrecommended for all HCP \nwho lack presumptive \nevidence of immunity.\u2020\u2020 \nVaccination should be \nconsidered for those born \nbefore 1957.\nPregnancy; immunocompromised \npersons,** including HIV-infected \npersons who have evidence of \nsevere immunosuppression; \nanaphylaxis to gelatin or gelatin-\ncontaining products; anaphylaxis \nto neomycin\nHCP vaccinated before 1979 with either killed \nmumps vaccine or mumps vaccine of unknown",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_306",
        "document_id": "rr6007",
        "text": "HCP vaccinated before 1979 with either killed \nmumps vaccine or mumps vaccine of unknown \ntype should consider revaccination with 2 doses \nof MMR vaccine. \nRubella live-virus \nvaccine\n1 dose SC; (However, \ndue to the 2-dose \nrequirements for \nmeasles and mumps \nvaccines, the use of \nMMR vaccine will result \nin most HCP receiving \n2 doses of rubella-\ncontaining vaccine.)\nVaccination should be \nrecommended for all HCP \nwho lack presumptive \nevidence of immunity.\u00a7\u00a7\nPregnancy; immunocompromised \npersons** including HIV\u2013infected \npersons who have evidence of \nsevere immunosuppression; \nanaphylaxis to gelatin or gelatin\u2013\ncontaining products; anaphylaxis \nto neomycin\nThe risk for rubella vaccine\u2013associated \nmalformations in the offspring of women \npregnant when vaccinated or who become",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_307",
        "document_id": "rr6007",
        "text": "malformations in the offspring of women \npregnant when vaccinated or who become \npregnant within 1 month after vaccination is \nnegligible.\u00b6\u00b6 Such women should be counseled \nregarding the theoretical basis of concern for the \nfetus. \nSee table footnotes on page 41\nRecommendations and Reports\n40\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nTABLE 2. (Continued) Immunizing agents and immunization schedules for health-care personnel (HCP)* \nGeneric name\nPrimary schedule and \nbooster(s)\nIndications\nMajor precautions and \ncontraindications\nSpecial considerations\nTetanus and \ndiphtheria (toxoids) \nand acellular \npertussis (Tdap)\n1 dose IM as soon as \nfeasible if Tdap not \nalready received and \nregardless of interval \nfrom last Td. After \nreceipt of Tdap, receive \nTd for routine booster",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_308",
        "document_id": "rr6007",
        "text": "regardless of interval \nfrom last Td. After \nreceipt of Tdap, receive \nTd for routine booster \nevery 10 years.\nAll HCP, regardless of age.\nHistory of serious allergic \nreaction (i.e., anaphylaxis) to any \ncomponent of Tdap. Because \nof the importance of tetanus \nvaccination, persons with history \nof anaphylaxis to components \nin Tdap or Td should be referred \nto an allergist to determine \nwhether they have a specific \nallergy to tetanus toxoid and \ncan safely receive tetanus \ntoxoid (TT) vaccine. Persons \nwith history of encephalopathy \n(e.g., coma or prolonged \nseizures) not attributable to an \nidentifiable cause within 7 days of \nadministration of a vaccine with \npertussis components should \nreceive Td instead of Tdap. \nTetanus prophylaxis in wound management if not",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_309",
        "document_id": "rr6007",
        "text": "receive Td instead of Tdap. \nTetanus prophylaxis in wound management if not \nyet received Tdap***\nVaricella vaccine \n(varicella zoster virus \nlive-virus vaccine)\n2 doses SC 4\u20138 weeks \napart if aged \u226513 years.\nAll HCP who do not have \nevidence of immunity \ndefined as: written \ndocumentation of \nvaccination with 2 doses \nof varicella vaccine: \nlaboratory evidence of \nimmunity\u2020\u2020\u2020 or laboratory \nconfirmation of disease; \ndiagnosis or verification \nof a history of varicella \ndisease by a health-care \nprovider,\u00a7\u00a7\u00a7 or diagnosis or \nverification of a history of \nherpes zoster by a health-\ncare provider.\nPregnancy; immunocompromised \npersons;** history of anaphylactic \nreaction after receipt of gelatin or \nneomycin. Varicella vaccination \nmay be considered for HIV-\ninfected adolescents and adults",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_310",
        "document_id": "rr6007",
        "text": "neomycin. Varicella vaccination \nmay be considered for HIV-\ninfected adolescents and adults \nwith CD4+ T-lymphocyte count \n>200 cells/uL. Avoid salicylate use \nfor 6 weeks after vaccination.\nBecause 71%\u201393% of adults without a history of \nvaricella are immune, serologic testing before \nvaccination is likely to be cost-effective.\nVaricella-zoster \nimmune globulin \n125U/10 kg IM \n(minimum dose: \n125U; maximum \ndose: 625U)\nPersons without evidence \nof immunity who have \ncontraindications for \nvaricella vaccination \nand who are at risk \nfor severe disease and \ncomplications\u00b6\u00b6\u00b6 known or \nlikely to be susceptible who \nhave direct, nontransient \nexposure to an infectious \nhospital staff worker or \npatient\nSerologic testing may help in assessing whether",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_311",
        "document_id": "rr6007",
        "text": "hospital staff worker or \npatient\nSerologic testing may help in assessing whether \nto administer varicella\u2013zoster immune globulin. \nIf use of varicella\u2013zoster immune globulin \nprevents varicella disease, patient should be \nvaccinated subsequently. The varicella\u2013zoster \nimmune globulin product currently used in the \nUnited States (VariZIG) (Cangene Corp. Winnipeg \nCanada) can be obtained 24 hours a day from the \nsole authorized U.S. distributor (FFF Enterprises, \nTemecula, California) at 1-800-843-7477 or http://\nwww.fffenterprises.com.\nOther immunobiologics that might be indicated in certain circumstances for HCP\nQuadrivalent \nmeningococcal \nconjugate vaccine \n(tetravalent (A,C,Y,W) \nfor HCP ages 19\u201354 \nyears, Quadrivalent \nmeningococcal \npolysaccharide \nvaccine for HCP age \n>55 years",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_312",
        "document_id": "rr6007",
        "text": "years, Quadrivalent \nmeningococcal \npolysaccharide \nvaccine for HCP age \n>55 years\n1 dose; booster dose \nin 5 years if person \nremains at increased \nrisk\nClinical and research \nmicrobiologists who might \nroutinely be exposed \nto isolates of Neisseria \nmeningitidis\nThe safety of the vaccine in \npregnant women has not been \nevaluated; it should not be \nadministered during pregnancy \nunless the risk for infection is high.\nSee table footnotes on page 41\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n41\nTABLE 2. (Continued) Immunizing agents and immunization schedules for health-care personnel (HCP)* \nGeneric name\nPrimary schedule and \nbooster(s)\nIndications\nMajor precautions and \ncontraindications\nSpecial considerations\nTyphoid vaccine IM, \nand oral",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_313",
        "document_id": "rr6007",
        "text": "Major precautions and \ncontraindications\nSpecial considerations\nTyphoid vaccine IM, \nand oral\nIM vaccine: 1 dose, \nbooster every 2 years.\nOral vaccine: 4 \ndoses on alternate \ndays. Manufacturer \nrecommends \nrevaccination with the \nentire 4-dose series \nevery 5 years.\nWorkers in microbiology \nlaboratories who \nfrequently work with \nSalmonella typhi.\nSevere local or systemic reaction \nto a previous dose.\nTy21a (oral) vaccine should \nnot be administered to \nimmunocompromised persons** \nor to persons receiving \nantimicrobial agents.\nVaccination should not be considered an \nalternative to the use of proper procedures \nwhen handling specimens and cultures in the \nlaboratory.\nInactivated poliovirus \nvaccine (IPV)\nFor unvaccinated \nadults, 2 doses should \nbe administered \nat intervals of 4\u20138",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_314",
        "document_id": "rr6007",
        "text": "vaccine (IPV)\nFor unvaccinated \nadults, 2 doses should \nbe administered \nat intervals of 4\u20138 \nweeks; a third \ndose should be \nadministered 6\u201312 \nmonths after the \nsecond dose.\nVaccination is \nrecommended for adults at \nincreased risk for exposure \nto polioviruses including \nhealth-care personnel \nwho have close contact \nwith patients who might \nbe excreting polioviruses. \nAdults who have previously \nreceived a complete course \nof poliovirus vaccine may \nreceive one lifetime booster \nif they remain at increased \nrisk for exposure.\nHypersensitivity or anaphylactic \nreactions to IPV or antibiotics \ncontained in IPV. IPV contains \ntrace amounts of streptomycin, \npolymyxin B, and neomycin.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_315",
        "document_id": "rr6007",
        "text": "contained in IPV. IPV contains \ntrace amounts of streptomycin, \npolymyxin B, and neomycin.\nAbbreviations: IM = intramuscular; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; SC = subcutaneous; HIV = human immunodeficiency virus; MMR = \nmeasles, mumps, rubella vaccine; TB = tuberculosis; HAV = hepatitis A virus; IgA = immune globulin A; ID = intradermal; TIV = trivalent inactivated split-virus vaccines; \nLAIV = live attenuated influenza vaccine; BCG = bacille Calmette-Gu\u00e9rin; OPV = oral poliovirus vaccine.\n\t *\tPersons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_316",
        "document_id": "rr6007",
        "text": "professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care \ninstitutions). Source: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/\nvacctoolkit/definition.html.\n\t\n\u2020\tHealth-care personnel and public safety workers at high risk for continued percutaneous or mucosal exposure to blood or body fluids include acupuncturists, \ndentists, dental hygienists, emergency medical technicians, first responders, laboratory technologists/technicians, nurses, nurse practitioners, phlebotomists,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_317",
        "document_id": "rr6007",
        "text": "physicians, physician assistants, and students entering these professions. Source: CDC. A comprehensive immunization strategy to eliminate transmission of \nhepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. Part II: immunization of adults. MMWR \n2006;55(No. RR-16).\n\t\n\u00a7\tThe package insert should be consulted to weigh the risks and benefits of giving HBIG to persons with IgA deficiency, or to persons who have had an anaphylactic \nreaction to an IgG containing biologic product.\n\t\n\u00b6\tWritten documentation of vaccination with 2 doses of live measles or MMR vaccine administered \u226528 days apart, or laboratory evidence of measles immunity, or \nlaboratory confirmation of measles disease, or birth before 1957.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_318",
        "document_id": "rr6007",
        "text": "laboratory confirmation of measles disease, or birth before 1957.\n\t **\tPersons immunocompromised because of immune deficiency diseases, HIV infection (who should primarily not receive BCG, OPV, and yellow fever vaccines), \nleukemia, lymphoma or generalized malignancy or immunosuppressed as a result of therapy with corticosteroids, alkylating drugs, antimetabolites, or radiation.\n\t \u2020\u2020\tWritten documentation of vaccination with 2 doses of live mumps or MMR vaccine administered \u226528 days apart, or laboratory evidence of mumps immunity, or \nlaboratory confirmation of mumps disease, or birth before 1957.\n\t \u00a7\u00a7\tWritten documentation of vaccination with 1 dose of live rubella or MMR vaccine, or laboratory evidence of immunity, or laboratory confirmation of rubella",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_319",
        "document_id": "rr6007",
        "text": "infection or disease, or birth before 1957, except women of childbearing potential who could become pregnant; though pregnancy in this age group would be \nexceedingly rare.\n\t \u00b6\u00b6\tSource: CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001;50:1117.\n\t***\tSource: CDC. Update on adult immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991:40(No. RR-12).\n\t\u2020\u2020\u2020\tCommercial assays can be used to assess disease\u2013induced immunity, but they often lack sensitivity to detect vaccine-induced immunity (i.e., they might yield \nfalse-negative results).",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_320",
        "document_id": "rr6007",
        "text": "false-negative results).\n\t\u00a7\u00a7\u00a7\tVerification of history or diagnosis of typical disease can be provided by any health-care provider (e.g., school or occupational clinic nurse, nurse practitioner, \nphysician assistant, or physician). For persons reporting a history of, or reporting with, atypical or mild cases, assessment by a physician or their designee is \nrecommended, and one of the following should be sought: 1) an epidemiologic link to a typical varicella case or to a laboratory\u2013confirmed case or 2) evidence \nof laboratory confirmation if it was performed at the time of acute disease. When such documentation is lacking, persons should not be considered as having a \nvalid history of disease because other diseases might mimic mild atypical varicella.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_321",
        "document_id": "rr6007",
        "text": "valid history of disease because other diseases might mimic mild atypical varicella.\n\t\u00b6\u00b6\u00b6\tFor example, immunocompromised patients or pregnant women.\nRecommendations and Reports\n42\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nTABLE 3. Summary of recommendations for immunization of health-care personnel* (HCP) with special certain conditions \u2014 Advisory \nCommittee on Immunization Practices, United States, 2011\nVaccine\nPregnancy\nHIV infection\nSevere \nimmunosuppression\u2020\nAsplenia\nRenal failure\nDiabetes\nAlcoholism and \nalcoholic cirrhosis\nHepatitis B \nR\nR\nR\nR\nR\nR\nR\nInfluenza\nR\u00a7\nR\nR\nR\nR\nR\nR\nMeasles, mumps, rubella\nC\nR\u00b6\nC\nR\nR\nR\nR\nMeningococcus\nUI\nUI\nUI\nR**\nUI\nUI\nUI\nIPV \u2020\u2020\nUI\nUI\nUI\nUI\nUI\nUI\nUI\nPertussis, tetanus, diphtheria\nR\nR\nR\nR\nR\nR\nR\nTyphoid, inactivated Vi\u00a7\u00a7\nUI\nUI\nUI\nUI\nUI\nUI\nUI",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_322",
        "document_id": "rr6007",
        "text": "UI\nUI\nPertussis, tetanus, diphtheria\nR\nR\nR\nR\nR\nR\nR\nTyphoid, inactivated Vi\u00a7\u00a7\nUI\nUI\nUI\nUI\nUI\nUI\nUI\nTyphoid, Ty21a\nUI\nC\nC\nUI\nUI\nUI\nUI\nVaricella\nC\nUI\u00b6\u00b6\nC\nR\nR\nR\nR\nAbbreviations: R = recommended; C = contraindicated; UI = use if indicated; IPV = inactivated poliovirus vaccine.\n\t *\tPersons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental \nprofessionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). \nSource: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/\ndefinition.html.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_323",
        "document_id": "rr6007",
        "text": "definition.html.\n\t \u2020\tSevere immunosuppression can be caused by congenital immunodeficiency, leukemia, lymphoma, generalized malignancy or therapy with alkylating agents, \nantimetabolites, ionizing radiation, or large amounts of corticosteroids.\n\t \u00a7\tWomen who are or will be pregnant  during the influenza season.\n\t \u00b6\tContraindicated in HIV-infected persons who have evidence of severe immunosuppression.\n\t**\tRecommendation is based on the person\u2019s underlying condition rather than occupation.\n\t\u2020\u2020\tVaccination is recommended for unvaccinated HCP who have close contact with patients who may be excreting wild polioviruses. HCP who have had a primary",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_324",
        "document_id": "rr6007",
        "text": "series of oral poliovirus vaccine (OPV) or IPV who are directly involved with the provision of care to patients who may be excreting poliovirus may receive another \ndose of either IPV or OPV. Any suspected case of poliomyelitis should be investigated immediately. If evidence suggests transmission of poliovirus, control measures \nto contain further transmission should be instituted immediately.\n\t\u00a7\u00a7\tCapsular polysaccharide parenteral vaccine.\n\t\u00b6\u00b6\tVaricella vaccine may be considered for HIV-infected adults without evidence of immunity and with CD4 T-lymphocyte count \u2265200 cells/Ul.\nTABLE 4. Recommended postexposure prophylaxis for percutaneous or permucosal \nexposure to hepatitis B virus \u2014 Advisory Committee on Immunization Practices, United States\nVaccination and antibody",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_325",
        "document_id": "rr6007",
        "text": "Vaccination and antibody \nresponse status of exposed \nperson\nTreatment\nSource HBsAg-positive\nSource HBsAg-negative\nSource not tested or status unknown\nUnvaccinated\nHBIG x 1; initiate HB vaccine series\nInitiate HB vaccine series\nInitiate HB vaccine series\nPreviously vaccinated\nKnown responder\nNo treatment\nNo treatment\nNo treatment\nKnown nonresponder\nAfter 3 doses\nHBIG x 1 and initiate revaccination\nNo treatment\nIf known high-risk source, treat as if source \nwere HBsAg-positive\nAfter 6 doses\nHBIG x 2 (separated by 1 month)\nNo treatment\nIf known high-risk source, treat as if source \nwere HBsAg-positive\nAntibody response unknown\nTest exposed person for anti-HBs\nIf adequate,* no treatment\nIf inadequate,* HBIG x 1 and vaccine booster\nNo treatment\nTest exposed person for anti-HBs",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_326",
        "document_id": "rr6007",
        "text": "If inadequate,* HBIG x 1 and vaccine booster\nNo treatment\nTest exposed person for anti-HBs\nIf adequate,* no treatment\nIf inadequate,* initiate revaccination\nAbbreviations: HBsAg = Hepatitis B surface antigen; HBIG = hepatitis B immune globulin; anti-HBs = antibody to hepatitis B surface antigen; HB = hepatitis B.\nSource: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR 2006;55(No. RR-16).\n*\tA seroprotective (adequate) level of anti-HBs after completion of a vaccination series is defined as anti-HBs \u226510 mlU/mL; a response < 10 mlU/mL is inadequate and",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_327",
        "document_id": "rr6007",
        "text": "is not a reliable indicator of protection.\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n43\nTABLE 5. Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected with certain \nvaccine-preventable diseases and conditions\nDisease/Condition \nWork restriction\nDuration\nHepatitis B\nHCP positive for HBsAg (e.g., acute or chronic \nhepatitis B infection):\nHCP who do not perform exposure-prone \ninvasive procedures \nNo restriction unless linked \nepidemiologically to transmission of \nhepatitis B virus infection\nStandard precautions always should be observed\nHCP who perform exposure-prone \ninvasive procedures\nThese HCP should not perform \nexposure-prone invasive procedures \nuntil they have sought counsel",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_328",
        "document_id": "rr6007",
        "text": "These HCP should not perform \nexposure-prone invasive procedures \nuntil they have sought counsel \nfrom an expert review panel, which \nshould review and recommend the \nprocedures the worker can perform, \ntaking into account the specific \nprocedure as well as the skill and \ntechnique of the worker \nPer recommendation of expert panel\nUpper respiratory infections\nHCP in contact with persons at high risk for \ncomplications of influenza\u2020\nExclude from duty\nUntil afebrile \u226524 hours (without the use of fever-reducing medicines \nsuch as acetaminophen). Those with ongoing respiratory symptoms \nshould be considered for evaluation by occupational health to \ndetermine appropriateness of contact with patients. If returning to \ncare for patients in a protective environment (e.g., hematopoietic",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_329",
        "document_id": "rr6007",
        "text": "care for patients in a protective environment (e.g., hematopoietic \nstem cell transplant patients), consider for temporary reassignment \nor exclusion from work for 7 days from symptom onset or until the \nresolution of symptoms, whichever is longer. \nThose who develop acute respiratory symptoms without fever should \nbe considered for evaluation by occupational health to determine \nappropriateness of contact with patients and can be allowed to \nwork unless caring for patients in a protective environment; these \npersonnel should be considered for temporary reassignment \nor exclusion from work for 7 days from symptom onset or until \nthe resolution of all noncough symptoms, whichever is longer. If \nsymptoms such as cough and sneezing are still present, HCP should",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_330",
        "document_id": "rr6007",
        "text": "symptoms such as cough and sneezing are still present, HCP should \nwear a facemask during patient care activities. The importance of \nperforming frequent hand hygiene (especially before and after each \npatient contact) should be reinforced.\nMeasles\nActive\nExclude from duty\n4 days after rash appears\nPostexposure (HCP without presumptive \nevidence of measles immunity)\nExclude from duty\n5 days after first exposure through 21 days after last exposure and/or \n4 days after the rash appears\nMumps\nActive\nExclude from duty\n5 days after onset of parotitis\nPostexposure (HCP without presumptive \nevidence of mumps immunity)\nExclude from duty\n12 days after first exposure through 25 days after last exposure or 5 \ndays after onset of parotitis\nPertussis\nActive\nExclude from duty",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_331",
        "document_id": "rr6007",
        "text": "days after onset of parotitis\nPertussis\nActive\nExclude from duty\nBeginning of catarrhal stage through third week after onset of \nparoxysms or until 5 days after start of effective antimicrobial therapy\nPostexposure\nSymptomatic personnel\nExclude from duty\n5 days after start of effective antimicrobial therapy\nAsymptomatic personnel \u2013 HCP likely to expose a \npatient at risk for severe pertussis\u00a7\nNo restriction from duty; on \nantimicrobial prophylactic therapy\nAsymptomatic personnel \u2013 other HCP\nNo restriction from duty; can receive \npostexposure prophylaxis or be \nmonitored for 21 days after pertussis \nexposure and treated at the onset of \nsigns and symptoms of pertussis\nSee table footnotes on page 44\nRecommendations and Reports\n44\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_332",
        "document_id": "rr6007",
        "text": "Recommendations and Reports\n44\t\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\nTABLE 5. (Continued) Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected \nwith certain vaccine-preventable diseases and conditions\nDisease/Condition \nWork restriction\nDuration\nRubella\nActive\nExclude from duty\n7 days after the rash appears\nPostexposure (personnel without evidence of \nrubella immunity)\nExclude from duty\n7 days after first exposure through 23 days after last exposure \nand/or 7 days after rash appears\nVaricella\nActive\nExclude from duty\nUntil all lesions dry and crust. If only lesions that do not crust \n(i.e., macules and papules), until no new lesions appear within a \n24-hour period\nPostexposure (HCP without evidence of varicella",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_333",
        "document_id": "rr6007",
        "text": "24-hour period\nPostexposure (HCP without evidence of varicella \nimmunity)\nExclude from duty unless receipt of \nthe second dose within 3-5 days after \nexposure\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nHerpes zoster\nLocalized in immunocompetent person\nCover lesions; restrict from care of \nhigh-risk patients\u00b6\nUntil all lesions dry and crust\nDisseminated or localized in immunocompromised \nperson until disseminated infection is ruled out \nExclude from duty\nUntil all lesions dry and crust",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_334",
        "document_id": "rr6007",
        "text": "person until disseminated infection is ruled out \nExclude from duty\nUntil all lesions dry and crust\nPostexposure (HCP without evidence of varicella \nimmunity)\nDisseminated zoster or localized zoster with \nuncontained/uncovered lesions\nExclude from duty unless receipt of \nthe second dose of varicella vaccine \nwithin 3\u20135 days after exposure\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nLocalized zoster with contained/covered lesions\nFor HCP with at least 1dose of \nvaricella vaccine, no work restrictions.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_335",
        "document_id": "rr6007",
        "text": "For HCP with at least 1dose of \nvaricella vaccine, no work restrictions. \nFor HCP with no doses of varicella \nvaccine, restrict from patient contact\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nAbbreviation: HBsAg = hepatitis B surface antigen.\nSources: Adapted from CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_336",
        "document_id": "rr6007",
        "text": "prone invasive procedures. MMWR 1991;40(No. RR-8); CDC. Guideline for isolation precautions in hospitals: recommendations of the Hospital Infection Control Practices \nAdvisory Committee (HICPAC) and the National Center for Infectious Diseases. Infect Control Hosp Epidemiol 1996;17:53\u201380; Williams WW. CDC guideline for infection \ncontrol in hospital personnel. Infect Control 1983;4(Suppl):326\u201349; CDC. Immunization of health-care workers: recommendations of the Advisory Committee on \nImmunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).\n*\tPersons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_337",
        "document_id": "rr6007",
        "text": "professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). \nSource: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/\ndefinition.html.\n\u2020\tIncludes children aged <5 years, adults aged \u226565 years, pregnant women, American Indians/Alaska Natives, persons aged <19 years who are receiving long-term \naspirin therapy, and persons with certain high-risk medical conditions (i.e., asthma, neurologic and neurodevelopmental conditions, chronic lung disease, heart",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_338",
        "document_id": "rr6007",
        "text": "disease, blood disorders, endocrine disorders, kidney disorders, liver disorders, metabolic disorders, weakened immune system due to disease or medication, and \nmorbid obesity). \n\u00a7\tIncludes hospitalized neonates and pregnant women.\n\u00b6\tIncludes patients who are susceptible to varicella and at increased risk for complications of varicella (i.e., neonates, pregnant women, and immunocompromised \npersons of any age).\nRecommendations and Reports\nMMWR\u2002 /\u2002 November 25, 2011\u2002 /\u2002 Vol. 60\u2002 /\u2002 No. 7\t\n45\nAdvisory Committee on Immunization Practices\nMembership List, February 2011\nChair: Carol Baker, MD, Baylor College of Medicine, Houston, Texas.\nExecutive Secretary: Larry Pickering, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_339",
        "document_id": "rr6007",
        "text": "Members: Lance Chilton, MD, University of New Mexico, Albuquerque, New Mexico; Paul Cieslak, MD, Oregon Public Health Division, Portland, Oregon; \nTamera Coyne-Beasley, MD, University of North Carolina, Chapel Hill, North Carolina; Jeffrey Duchin, MD, University of Washington, Seattle, Washington; \nKristen Ehresmann, MPH, Minnesota Department of Health, St Paul, Minnesota; Janet Englund, MD, University of Washington and Children\u2019s Hospital \nand Regional Medical Center, Seattle, Washington; Ren\u00e9e Jenkins, MD, Howard University School of Medicine, District of Columbia; Franklyn Judson, \nMD, University of Colorado Health Sciences Center, Denver, Colorado; Wendy Keitel, MD, Baylor College of Medicine, Houston, Texas; Michael Marcy,",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_340",
        "document_id": "rr6007",
        "text": "MD, UCLA Center for Vaccine Research, Torrance, California; Cody Meissner, MD, Tufts Medical Center, Boston, Massachusetts; Sara Rosenbaum, JD, \nGeorgetown University, District of Columbia; Mark Sawyer, MD, University of California at San Diego, California; Jonathan Temte, MD, University of \nWisconsin School of Medicine and Public Health, Madison, Wisconsin.\nEx Officio Members: James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Geoffrey S. Evans, MD, Health Resources and Services \nAdministration, Rockville, Maryland; Jesse Geibe, MD, Department of Defense, CDC, Atlanta, Georgia; Bruce Gellin, MD, National Vaccine Program \nOffice, District of Columba; Richard Gorman, MD, National Institutes of Health, Bethesda, Maryland; Linda Murphy, Centers for Medicare and Medicaid",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_341",
        "document_id": "rr6007",
        "text": "Services, Baltimore, Maryland; Norman Baylor, PhD, Food and Drug Administration, Bethesda, Maryland; Linda Kinsinger, MD, Department of Veterans \nAffairs, Durham, North Carolina.\nLiaison Representatives: American Academy of Family Physicians, Doug Campos-Outcalt, MD, Phoenix, Arizona; American Academy of Pediatrics, \nMichael Brady, MD, Ohio State University, Columbus, Ohio, David Kimberlin, MD, Birmingham, Alabama; American Academy of Physician Assistants, \nMarie-Mich\u00e8le L\u00e9ger, MPH, Alexandria, Virgina; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College \nof Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College of Physicians, Gregory Poland, MD, Rochester, Minnesota;",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_342",
        "document_id": "rr6007",
        "text": "American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; America\u2019s Health Insurance Plans, Mark Netoskie, MD, Houston, Texas; \nAmerican Medical Association, Litjen Tan, PhD, Chicago, Illinois; American Nurses Association, Katie Brewer, MSN, Silver Springs, Maryland; American \nOsteopathic Association, Stanley Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; \nAssociation of Immunization Managers, Kelly Moore, MD, Nashville, Tennessee; Association for Prevention Teaching and Research, W. Paul McKinney, \nMD, Louisville, Kentucky; Association of State and Territorial Health Officials, Jos\u00e9 Montero, MD, Concord, New Hampshire; Biotechnology Industry",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_343",
        "document_id": "rr6007",
        "text": "Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Joanne Langley, MD, Halifax, \nNova Scotia, Canada; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Department of Health, United Kingdom, David \nM. Salisbury, MD, London, United Kingdom; Healthcare Infection Control Practices Advisory Committee, Alexis Elward, MD, St Louis, Missouri; Infectious \nDiseases Society of America, Samuel L. Katz, MD, Durham, North Carolina; National Association of County and City Health Officials, Matthew Zahn, MD, \nLouisville, Kentucky; National Association of Pediatric Nurse Practitioners, Patricia Stinchfield, MPH, St Paul, Minnesota; National Foundation for Infectious",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_344",
        "document_id": "rr6007",
        "text": "Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Mexico, Vesta Richardson, MD, Mexico \nCity, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; National Vaccine Advisory Committee, Guthrie \nBirkhead, MD, Albany, New York; Pharmaceutical Research and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania, Peter Paradiso, PhD, \nCollegeville, Pennsylvania; Society for Adolescent Health and Medicine, Amy Middleman, MD, Houston, Texas; Society for Healthcare Epidemiology of \nAmerica, Harry Keyserling, MD, Atlanta, Georgia.\nImmunization of Health-Care Personnel Work Group",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_345",
        "document_id": "rr6007",
        "text": "America, Harry Keyserling, MD, Atlanta, Georgia.\nImmunization of Health-Care Personnel Work Group\nAbigail Shefer, MD, National Center for Immunization and Respiratory Diseases, William Atkinson, MD, National Center for Immunization and Respiratory \nDiseases, Jane Seward, MBBS, National Center for Immunization and Respiratory Diseases, Elizabeth Bolyard, MPH, National Center for Emerging Zoonotic \nInfectious Diseases, David Kuhar, MD, National Center for Emerging Zoonotic Infectious Diseases, Suchita Lorick, MD, National Center for Immunization \nand Respiratory Diseases, Gina Mootrey, DO, National Center for Immunization and Respiratory Diseases, CDC, Atlanta; Joseph Perz, DrPH, National Center",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_346",
        "document_id": "rr6007",
        "text": "for Emerging Zoonotic Infectious Diseases, CDC, Atlanta, Georgia; Paul Cieslak, MD, Public Health Division, Oregon Health Authority, Portland, Oregon; \nKristen Ehresmann, MPH, Minnesota Department of Health, St Paul, Minnesota; Alexis Elward, MD, Washington University School of Medicine, St Louis, \nMissouri; Harry Keyserling, MD, Emory University School of Medicine, Atlanta, Georgia; ACIP liaison representatives: Jean Haulman, MD, University of \nWashington, Seattle, Washington; Mark Russi, MD, American College of Occupational and Environmental Medicine, New Haven, Connecticut; David \nWeber, MD, University of North Carolina, Chapel Hill, North Carolina.\nU.S. Government Printing Office: 2012-523-043/21089 Region IV\u2003 ISSN: 1057-5987",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_347",
        "document_id": "rr6007",
        "text": "U.S. Government Printing Office: 2012-523-043/21089 Region IV\u2003 ISSN: 1057-5987\nThe Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free \nof charge in electronic format. To receive an electronic copy each week, visit MMWR\u2019s free subscription page at http://www.cdc.gov/mmwr/mmwrsubscribe.\nhtml. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; \ntelephone 202-512-1800.\nAddress all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 \nClifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov.",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6007_chunk_348",
        "document_id": "rr6007",
        "text": "Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. \nAll material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.\nUse of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.\nReferences to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations \nor their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses \nlisted in MMWR were current as of the date of publication.\nRecommendations and Reports",
        "metadata": {
            "year": "2011",
            "disease_type": "immunization",
            "source": "clinical_guideline"
        }
    }
]